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Abstract 
This thesis applies real options theory to case studies in health care. The aim is to 
establish the suitability of applying this technique, examine the implications of 
doing so, and outline methods through which real options analysis can be applied 
in practice. The concepts behind option valuation are established and current 
literature reviewed before introducing the theory of real options into decision 
making in health care. The first three case studies progress through the structure 
of financial options examining the call, put and compound options through 
application to a spectrum of decision problems faced by agents in health care. 
Firstly, watchful waiting is modelled as an option to defer therapeutic treatment 
using a call option framework. Secondly, the structure of the put option is used to 
model the option to defer removal of life support for patients in a coma. Thirdly, 
the strategy for technology approval adopted by the National Institute for 
Clinical Excellence is examined with appeal to compound option analysis. The 
fourth case study develops the work in two ways. The versatility of options 
analysis is developed by modelling underlying uncertainty with a combined 
Brownian motion / Poisson arrival evolutionary process, in preference to the 
single structures bsed in the previous case studies. Option premium is then 
shown to be a form of value of information relevant when information on 
uncertain variables can be observed through time. The usefulness of real options 
for analysing whether additional inform4tion is required is also considered. 
Within 6ach study the three defining characteristics of financial options; 
uncertainty, irreversibility and an ability to defer, are discussed and explicitly 
addressed. The applications have led to some questions being asked of existing 
economic evaluation methodology, particularly with respect to the three 
characteristics. These issues are addressed as they are encountered and 
summarised within the concluding chapter. 
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Chapter 1. Introduction 
1.1 The notion ofreal options analysis 
As individuals, most people will readily admit an enjoyment for having and 
making choices. We prefer to be in situations where we can make decisions, than 
situations where we are told what to do and how to do it. We value our options. 
Often we are even prepared to pay money in order to obtain more options. 
Individuals are not the only groups of people to appreciate options. Business 
managers also abide by the silent rule of 'keeping your options open'. To expand 
production, build new factories, abandon failing products and downsize, are all 
options that face owners and managers of today's firms. Health care 
professionals, whether clinicians, health economists, General Practitioners 
(GP's), National Health Service (NHS) managers, health psychologists, policy 
makers, or decision making bodies such as the National Institute for Clinical 
Excellence (NICE), also face options. These include when and how to allocate a 
budget, whether to build a new ward, options over which patients take priority, 
when to begin treatment, and which drugs are preferable for a given ailment. 
Options are continuously encountered, and actions taken today often prove to be 
ways of influencing options confronted tomorrow. Spending the majority of a 
bu dget early in the financial year reduces choices for spending later in the year, 
reducing future options. Current investment spending may alternatively provide 
positive side effects, creating options. Investment in a new laser creates the 
option to treat patients for a variety of problems including cervical cancer and 
glaucoma. Parting with the up-front costs necessary to build a hospital confers 
upon NHS managers the option to later expand the hospital creating, for instance, 
a dedicated eye unit or specialist transplant centre. 
Recently authors have begun to realise the importance of trying to value options. 
The ability to accurately place a value on owning options may help in assessing 
how much we might be willing to pay to gain options, or how much 
compensation we require if options must be given up. Dixit and Pindyck (Dixit 
and Pindyck, 1994) have devoted considerable effort to surveying options facing 
finns, and how these might be valued. So as to highlight the difference between 
having an option and a choice, a very precise definition of an option has 
developed. When a decision must be made under conditions of uncertainty, 
irreversibility, and timing flexibility, then according to Dixit and Pindyck, there 
is an option. 
Dixit and Pindyck are among a growing collection of authors who have 
recognised the similarities between this definition of every day options, and 
financial market options. The purchase of a financial options contract gives the 
owner the opportunity, or option, to perform a pre-specified stock transaction. 
Instead of options to invest, expand, defer and downsize, financial options are 
more restrictive, allowing only the purchase or sale of a pre-agreed quantity of a 
given stock, at a pre-arranged price. Buying the contract conveys the option. 
Options facing health care professionals are likely to be much more flexible than 
this, with a range of possible actions and differing payoffs to be received or paid 
when actions are undertaken (exercised). This similarity between financial 
options and current investments has lead authors to propose the use of financial 
option pricing techniques to value everyday options (Kester, 1984; Trigeorgis, 
1999). 
The analogy between financial options and commercial investments has gained 
increasing popularity among a variety of academics and is sufficiently 
widespread to have become a discipline in its own right; real options analysis 
(Amram and Kulatilaka, 1999). A real option is a proposed action that shares the 
characteristics of a financial option and that can be analysed by methods derived 
from financial option pricing techniques. This unites insights from finance with 
the peculiarities of everyday investments to create a dynamic decision making 
process applicable to a variety of decision problems. 
Brennan and Schwartz (Brennan and Schwartz E S, 1985) and McDonald and 
Seigel (McDonald and Seigel, 1985) were among the first to apply option pricing 
techniques to valuing real investments. Their analyses considered the depletion 
of natural resources and valuation of firms respectively. Since early applications 
such as these the potential of real options analysis has been increasingly realised. 
More diverse subject areas are appealing to this "new" view of investment theory 
(Metcalf and Rosenthal, 1995). 
Disciplines including environmental economics, private finance, and public 
sector economics have all embraced real options thinking. This has helped 
develop an understanding of issues such as optimal pollution control (Chao and 
Wilson, 1993), timber rotation (Plantinga, 1998), the handling of contagious 
diseases (Mahul and Gohin, 1999), and the benefits of research and development 
efforts (Pennings and Lint, 1997). Real options analysis has been able to explain 
observed phenomena that are inconsistent with existing decision techniques 
(Hasset and Metcalf, 1992), as well as aid handling of uncertainty (Sarker, 1999), 
enable incorporation of degrees of irreversibility (Tegene ct al., 1999), and 
simplify consideration of the waiting alternative (Ingersoll and Ross, 1992). 
Trigeorgis (Trigeorgis, 1999) and Cheung (Cheung, 1993) provide reviews of 
early applications of real options thinking. 
Health economics too may gain from considering these methods. The idea of 
applying financial techniques to health care is not new. O'Brien and Sculpher 
(O'Brien and Schulpher, 2000) suggested evaluating health technologies using 
portfolio theory. They examined the benefits of spreading funds over numerous 
projects to minimise the risk associated with budgetary allocations. The 
application of real options analysis to health care builds on such work. Section 2 
of this chapter establishes the motivation behind application of real options 
analysis to decision making in health care while section 3 establishes the research 
aims of this thesis. 
1.2 Motivations for applying real options analysis to decision making in health 
care 
There have been few previous attempts to integrate real options thinking into 
decision making within the field of health care. Health economists use valuation 
methods that have evolved from discounted cash flow (DCF) techniques 
advocated by Fisher almost a century ago (Fisher, 1907). Most common are 
variants of net present value (NPV), which state that a potential investment 
should be pursued if the present value of benefits is equal to, or exceeds, the 
present value of costs. Valuing health benefits can be difficult and more recently 
economic evaluation literature has begun to account for society's willingness to 
pay for improvements in health outcome (Gold et al., 1996; Sloan, 1996). 
Amendments have, however, carried forward some of the problems inherent in 
traditional techniques (table 1). It is such limitations in existing methodology and 
practice that motivate an appeal to real options analysis. Since these 
shortcomings have been discussed in detail elsewhere (Paddock et al., 1988; 
MacCallum, 1987; Trigeorgis, 1993; MacCallum, 1987) only a brief summary is 
presented here. 
Problems facing traditional analysis Advantages provided by real options 
analysis 
Now or never emphasis on decision making Dynamic decision making process that 
explicitly considers the merits of deferral 
Overlooking strategic reasons for investment Option valuation assesses opportunities 
created and destroyed by current actions and 
does not automatically reject a project with 
NPV<O 
Poor modelling of active management Real options analysis takes a flexible view of 
uncertainty that incorporates managements 
ability to respond to anticipated and 
unanticipated events 
Discounts rate issues Hedging leads to risk neutral valuation 
Implicit assumptions governing irreversibility Explicitly considers the degree of reversibility 
and impact on decision-making 
Table 1.1. Recognised problems facing decision techniques and how real options 
analysis mitigates these. 
Current techniques tend to analyse projects at a single point in time and usually 
make an immediate decision. Deferral is not commonly considered and rejected 
projects are rarclY reconsidered in the light of new information. Although 
increasing use of Bayesian analysis encourages re-estimation of project value, 
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particularly when trials are expected to reveal information, there remains a 
tendency to examine projects at specific, predetermined points in time. Real 
options analysis is a dynamic decision-making process that explicitly considers 
deferral and reviews the status of projects when new infon-nation is revealed over 
time. Examining costs and benefits of deferral allows recommendations about the 
timing of actions and future reviews, advising not just whetIler, but w1len 
immediate action is optimal. 
NPV methodology has been criticised for overlooking strategic reasons for 
investments (Hayes and Garvin, 1982). Rejecting projects with negative NPV 
fails to recognise potential strategic benefits, such as greater flexibility or 
leaming effects, which are not easily valued. These projects may retrospectively 
be beneficial causing potentially favourable ventures to be rejected outright with 
the strict NPV based decision (Trigeorgis, 1990). Pharmaceutical research and 
development projects often suffer low NPV estimates due to the infrequency 
with which individual projects develop into profit making ideas. New surgical 
techniques might initially not be cost-effective due to high failure rates, but 
leaming effects from continued practice may generate a cost-effective technique. 
Even projects deemed to have failed may contribute strategic value (McGrath, 
1999). Real options analysis has been proposed as a way to capture this value 
(Slater et al., 1998). 
NPV has also been accused of failing to account for the value of flexible and 
active management. Projects are analysed in period 0 using cash flow estimates 
given today's expectations to derive an optimal strategy. Decision trees combine 
sequential choices and events over numerous time periods enabling management 
strategies to respond to anticipated uncertainties. Detailed trees can be complex 
and computationally difficult to analyse, yet unanticipated events, to which 
managers will certainly react, are not modelled. Uncertainties in demand, 
running costs, technological developments, prices and disease progression mean 
projects rarely follow their expected path. Managers can respond by pursuing 
opportunities to expand, contract, abandon, or adjust the timing, input and output 
mixes, and progression rates of the project. 
Possible managerial actions are options that define the structure of real option 
valuation. Combining this insight with a dynamic view of uncertainty allows 
options analysis to incorporate the effects of both anticipated and unanticipated 
events. Managerial flexibility is then explicitly modelled (Trigeorgis, 1999; 
Copeland and Keenan, 1998; Slade, 1998). Different aspects of the value of 
flexibility have been referred to in the real options analysis literature including 
managerial flexibility premiums (Cheung, 1993), (Trigeorgis, 1999) and timing or 
deferral value (McDonald and Seigel, 1986). In each case a premium is 
calculated that represents the value of flexibility. It is important to note that the 
real options premium is not a risk premium' and exists even for risk-neutral 
decision makers (Smith and McCardle, 1998). Although authors chose to 
emphasise different types and aspects of flexibility they refer to the same 
premium. 
Traditional methods have sometimes made inappropriate adjustments for the 
timing of uncertain events with adhoc discount rates. Frequently a single 
discount rate is applied to an entire project, provoking debate over which is the 
most appropriate rate (Drummond et al., 1996). Within health care some 
researchers apply contrasting rates to costs and benefits. Smith and McCardle 
(Smith and McCardle, 1999) have argued that single rates are not suitable when 
complex projects encompass smaller staged investments whose risk structure is 
not the same as that of the overall project. In such circumstances varying rates 
may need to be applied according to the risk structure of sub-projects and 
correlation with the over all project. Real options analysis combines projects 
allowing risks to be hedged and a riskless position created that can be discounted 
using a risk-neutral rate (Coggins and Ramezani, 1998). This idea is at the centre 
of option pricing methodology (Jagle, 1999). 
NPV based studies also make implicit assumptions, particularly concerning 
irreversibility (Baldwin, 1982). When reversibility is assumed all projects with 
expected NPV>O are implemented immediately, as is currently the case. When 
projects have elements of irreversibility this forces decision makers to reflect 
1A premium paid by risk averse individuals to avoid a risky situation. 
carefully before implementation because once introduced, such projects cannot 
be costlessly altered. The inherent ability to reverse most projects via incurring 
abandonment charges makes assumptions of complete irreversibility or 
reversibility inappropriate. Real options analysis recognises irreversibility as an 
important characteristic and explicitly highlights sources describing both 
initiation of inactive projects and abandonment of failing active projects. 
Many practitioners believe that traditional techniques systematically undervalue 
some projects (Moyen et al., 1996) and managers appear to have acknowledged 
this through reluctance to consistently obey NPV signals (Nichols, 1994; Hanley, 
2001). This suggests decision makers may be attempting to overcome some of 
the problems described here and may be receptive to new tools that attempt to 
correct these deficiencies. Whilst real options analysis cannot solve all the 
problems discussed, these methods help to highlight the issues and may work 
towards mitigating some (Slater et al., 1998; Deaves and Krinsky, 1998). 
1.3 Setting out the research ahns 
Contrary to some belief, real options analysis is consistent with, and 
complements, existing evaluation methods (Smith and Nau, 1995; Smith and 
McCardle, 1998). Noticing this, Palmer and Smith (Palmer and Smith, 2000b) 
introduced the notion to decision making in health care. Their paper concentrates 
primarily on the ability of real options analysis to deal with uncertainties inherent 
in economic evaluation of health care technologies. The scope of real options 
extends potentially well beyond this. 
The primary purpose of this thesis is to contribute to existing research by 
exploring the application of real options theory to decision problems in health 
care. This is achieved by seeking to answer a number of research questions that 
fall into three categories; is it theoretically appropriate to apply real options 
thinking to health care? Can real options analysis improve decision making in 
health care? Is it feasible to apply real options analysis to health care problems in 
practice? The questions are set out below: 
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Is it theoretically appropriate to apply real options thinking to health care? 
ff Are the defining characteristics of real options problems present in health 
care projects? 
a Are the assumptions underlying real options analysis met in health care 
problems? 
a Where assumptions are not met can the methods and assumptions be suitably 
adjusted? 
Within the context of health care decision making, to what extent does real 
options analysis differ from existing methodology? 
" Does real options analysis lead to different conclusions? 
" Where different conclusions are reached, what implications does this have for 
decision making in health care? 
Can real options thinking be feasibly applied in practice? 
" Can the necessary variables be empirically estimated? 
" Are the conclusions meaningful? 
" Which areas are most suitable to analysis by real options? 
" Which areas are not conductive to real options analysis? 
In order to answer such questions, this thesis begins with a review of financial 
literature. This methodological and empirical appraisal discusses the theory 
behind option pricing and considers some valuation methods. Real options 
analysis is then introduced by demonstrating the analogy between exercising a 
financial option and initiating an investment project. The similarities and 
differences between the two are highlighted along with the variables required for 
valuation. Attempts to apply real options theory in practice are also discussed. 
Having introduced this new research tool chapter three considers how these ideas 
apply broadly within economic evaluation and health care decision making. An 
examination is made contrasting real options analysis and conventional cost- 
effectiveness techniques as ways of assessing value. Examples are drawn from 
throughout the health care sector. It is not the intention to contribute to the 
technical content of real options analysis but to examine existing methods and 
assess their applicability within health care. 
Chapters four through to seven each take a case study of interest. The fourth 
chapter considers watchful waiting as an option on therapeutic treatment and 
examines how the characteristics of the treatment decision align to a financial 
call option. A trinomial lattice framework provides the underlying structure for 
uncertainty in a hypothetical example. Contrastingly the concept of a put option 
is used in chapter five to look at the option to defer removal of life support for 
patients in a coma. This study uses a continuous Brownian motion model for 
uncertainty and discusses how options analysis can be used to advise both 
individual and group level treatment decisions. 
The call and put option ideas are combined in chapter six which examines the 
National Institute for Clinical Excellence's compound option to approve and later 
retract approval of health care technologies. Within this study issues surrounding 
irreversibility are explicitly addressed as the ability to alter either a decision itself 
or its ramifications are discussed. Finally chapter seven considers the option to 
gather additional evidence, drawing parallels between option valuation and value 
of information analysis. The option to gather observational trial evidence is 
modelled using a combined Brownian motion / Poisson arrival process. 
Each application considers whether the use of real options analysis alters our 
perspective of the area and whether there are implications for decision making. 
Chapter eight concludes by surnmarising the contributions made to the field of 
decision making in health care and discussing areas for further work. 
Chapter 2. Real options in a real world 
2.1 Financial options 
Z1.1 Introduction 
Real options analysis has evolved from financial option pricing theory as a 
potentially useful technique complementing traditional approaches to economic 
evaluation. Financial options analysis developed from the 1970s seminal work of 
Black, Scholes (Black and Scholes, 1973) and Merton (Merton, 1973). Today 
these techniques are used extensively to describe and price complex financial 
portfolios (Jarrow, 1999). Many authors summarise the basic properties of options 
and the theory behind their pricing. Brearly and Myers (Brearley and Myers, 
1992), and Wilmott, Howison and Dewynne (Wilmott et al., 1995) both provide 
comprehensive introductions whilst Hull (Hull, 1997) gives a more advanced 
review. Authors such as Haug (Haug, 1998) concentrate on the practice of option 
pricing with detailed financial methods and formulae. 
Real options analysis applies the financial theories to real projects that share the 
same characteristics as financial options. Within the framework of financial 
economics, options problems can be described in a clear, unambiguous manner. 
Relevant variables are specified within a written contract and usually concern 
publicly available information. Real world factors complicate these ideal financial 
circumstances. Although analogous, real options are harder to identify, describe, 
and analyse. Understanding financial options provides a basic underpinning from 
which to approach real option valuation. This chapter sets out the fundamentals of 
financial option pricing before formally introducing real options analysis. 
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21.2 Options have value 
Purchase of a financial options contract confers the right to perforin a specific 
future stock transaction. For instance a call option permits the holder to buy a 
fixed number of units of a given commodity (the underlying asset) at a specific 
price (exercise price), on or before a stated date (the exercise date). The owner has 
the right but not the obligation, to carry out the transaction. Whilst call options 
confer an entitlement to buy, put options confer a right to sell. Options also differ 
in their condition of exercise; options that may be exercised only on the exercise 
date are European options while those that may be exercised prior to this date are 
American options. 
Yv%ether an option is exercised depends on the exercise price (X) stated in the 
options contract, relative to the prevailing market price (S). Suppose an American 
call allows stock A to be purchased for 000. On the exercise date if the market 
price is E3 10 the option holder can exercise the option, buying at 000, and sell 
the stock on the market yielding a profit of EI 0. Exercise is optimal. If the market 
price were E250 the option holder will not want to exercise, preferring instead to 
purchase the stock from the market and allow the options contract to expire 
worthless. This gives a payoff of zero. The payoff, or intrinsic value, from 
optimally exercising the option is given by the maximum of the profit from 
exercising (S-X), or zero (equation 2.1). 
Intrinsic value (call) = max(S-X, 0) (EQN. 2.1) 
Options that are profitable to exercise (S-X>O) are known as being "in the 
money". The more profitable is an option the "deeper" into the money it is. 
Options that are currently unprofitable (S-X<O) are "out of the money" and should 
not be exercised, whilst "at the money" refers to options whose exercise price is 
equal to the current market price (S-X=O). 
II 
Alarket price Optimal action Intrinsic value 
E270 Allow option to expire fo 
E280 Allow option t expire LO 
E290 Aflow option to expire fo 
E300 Exercise EO 
E310 Exercise flo 
E320 Exercise E20 
E330 Exercise E30 
Table 2.1. Intrinsic value for an American call option on the exercise date with 
exercise (strike) price of E300. 
On the exercise date the market price might assume any value, each of which is 
associated with an optimal action. Table 2.1 gives intrinsic value for a plausible 
range of prevailing market prices. The option moves from being 'out of the 
money' to being 'in the money' at S=f3 00. An option will only be exercised when 
it is 'in the moncY', and so provides protection from losses. Figure 2.1 plots net 
benefit and intrinsic value, illustrating how the latter never falls below zero. 
Payoff from an American Call Option 
E40 
E30 
0 
E20 - 
0 F-1 0 
E 
0 F-0 - 13 E3 iB I. - 
_f: 10 - 
270 980---NQ-""ý300 , 11 n 390 30 
0 
>, -E20 - (9 
a. -F-30 
-F-40 
Stock Price 
--0- Net benefit E3 Intrinsic value 
Figure 2.1. Net benefit and intrinsic value ftorn an American call option with 
exercise price of; C300, on the exercise date. 
Put options operate just as call options but convey an opportunity to sell an asset 
in return for some fixed payment. A put option comes 'into the money' as market 
price falls below the exercise price leading to an intrinsic value [max(X-S, 0)] 
which mirrors that of the call option (equation 2.2). This similarity in structure 
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gives rise to the put-call parity and allows put options to be priced using 
information from the call option2. 
Intrinsic value (put) = max(X-S, 0) (EQN. 2.2) 
Purchase of a financial option creates choices that, as with real choices facing 
health care decision makers, have value. One of the sources of value is the ability 
to react to changing circumstances whilst the option is still held, and means that 
options have benefits in excess of their intrinsic value. To see this consider the 
same American option one week before the exercise date. Suppose the option is 
currently 'out of the money'. History informs the investor that prices are volatile 
and trend upward over time. Although the option is not currently profitable 
knowledge of the price evolution process suggests that profits may be realised in 
the future, making the option valuable even when intrinsic value is zero. Option 
value exceeds intrinsic value because the former accounts for future information 
that is not part of the intrinsic value calculation. Figure 2.2 shows hypothetical 
option values. 
Payoff from an American Call Option 
P 50 
- 
P 40 0 - 
ý F 30 R 
CL - 
0 E20 
E F 10 
- 0 F 0 13 E3 E3 , ý: - - 
4-- -F-10 310 320 30- 0 F 20 - - - 
F- 30 
-E40 
Stock Price 
0 Net benefit 9 Intrinsic Value -&- Option Vý_ýIue 
Figure 2.2. Graphical representation of option value, intrinsic value and net 
benefit from an American call option with exercise price E300. 
2A portfolio consisting of a put option and a stock has the same payoff as a call option (when the 
options have identical exercise prices) irrespective of the prevailing market price. To avoid riskless 
arbitrage the two, portfolios must have the same price. 
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To see this numerically consider a situation in which an NHS manager must 
decide whether to purchase a new piece of equipment. The equipment requires up 
front purchase and installation costs (C = E20,000) and yields monetary benefits 
net of running costs in each of the following three years. Benefits depend on 
demand and may be high (H = E8,500) or low (L = E2,000). These states of nature 
occur with respective probabilities q and (I -q). The equipment is then scrapped 
for a salvage value (A = E2,000). If the investment must be considered today, the 
decision maker has a choice. Expected annual monetary benefits are [qH+(I-q)L]. 
Assuming q=0.45 gives an annual steam of E4,925 (0.454500+0.55x2000). A 
discount rate of 5% gives: 
(qH+(I-q)L) (qH+(I-q)L) (qH+(I-q)L) A 
NB(I) = -C + (I+r) + (I+r)2 
+ 
(I+r)3 
+ 
(I + r)3 
= -4862 
The project is out of the money and would be rejected 3. Suppose, like a financial 
option, the decision could be delayed for one period during which infon-nation is 
revealed. If a newer technology arrives demand falls: 
NB(2) 
c+TLLL+A 
+7+i-- 
+ 12216 
IT r 1+7 +r r 
(I+r) +r (I +r)4 (I+r)4 
Should a new technology fail to arrive demand is high: 
-C HHHA NB(3) =-+- +-+-+- = 4641 (I+r) Tl+r; y (I+r)3 (I+r)4 (I + r)4 
Decision makers would choose not to purchase if demand was low (intrinsic value 
= f0), but to purchase if demand was high (intrinsic value = E4641). Option value 
is therefore given by 
NB* =Option Vahie = (OA5*4641)+(0.55*0) = E2088 
3 This now or never assessment of value is similar to intrinsic value under an option pricing 
approach. Intrinsic value has a minimum value of zero as the option will not be exercised if net 
benefit is less than zero. 
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Although waiting means postponing benefits, infon-nation is collected that 
potentially alters the adoption decision. In this case not only has the benefit of 
investment increased (NB(1)<NB*) by valuing the option to defer, but the 
possibility of deferral has changed the conclusion. Positive option value means the 
project is no longer rejected. 
Option value indicates the market price for which options should be bought and 
sold and is usually calculated over a range of values for the underlying asset 
(figure 2.2). An option priced higher is over-priced and will not be purchased. An 
option priced lower is under-priced and would not be offered for sale. E2088 
would be the market price for the option to defer purchase of equipment. Option 
value is bounded between intrinsic value and S, for a call option, or E, for a put 
option. 
Once option value and intrinsic value are known, option "premium", the 
difference between the two for any given stock value, can be calculated. Option 
premium gives the value associated with owning an option in preference to a now 
or never choice, or the value of being able to defer4. In the numerical example the 
project is out of the money making option premium is equal to option value 
(Option premium = E2088 -0= E2088). 
An option is always worth at least as much as an immediate choice (option 
premium ý! 0) because information gained during deferral is potentially useful. 
This is the case despite payoff being limited to intrinsic value if and when 
investment actually occurs (option premium = 0). Once the decision becomes an 
immediate choice, as is the case when exercise occurs, either no additional 
information is expected or the anticipated infon-nation holds no extra value. 
Option premium falls to zero and deferral holds no further benefits. 
Option value is influenced by numerous factors (table 2.2). Call options become 
profitable to exercise as stock price rises creating a positive relation between the 
4 This terminology is consistent Nvith Quigg (Quigg, 1993) and others, although Quigg discusses 
the premium as being relative to the total option value (option premium as a proportion of option 
value). Trigeorgis (Trigeorgis, 1999) refers to this same option premium as being a "time value". 
15 
price of the underlying asset and option value. The converse is true for put 
options. A longer maturity date (T) and time remaining to expiration (t) both serve 
to increase option value by extending the period for which the option is available 
and increasing the choices available to a decision maker. Uncertainty in the stock 
price (cy) also positively affects option value; as stock prices move with greater 
volatility, so the call (put) option holder benefits from more extreme upward 
(downward) price movements contributing to greater potential profits while losses 
are limited by the structure of intrinsic value. 
Variable Call option Put option 
Current value of stock (S) Positive Negative 
Maturity date (T) Positive Positive 
Time to expiration (t) Positive Positive 
Stock value uncertainty (a) Positive Positive 
Exercise price (X) Negative Positive [ýsk-free interest rate (r) Positive Negative 
Dividend (5) - Negative Positive 
Table 2.2. Spheres of influence on option value. 
The payoff structures underlying intrinsic value (equations 2.1 and 2.2) cause 
larger exercise prices (X) to have a negative impact on call option value, and a 
positive impact on put option value. The interest rate (r) impacts option value 
through the exercise price. The greater is the risk-free rate the more the exercise 
price is discounted over time generating a smaller present value. This is beneficial 
for the call but detrimental to the put option. 
Dividends cannot be earned until the stock itself is owned; the value of holding an 
option to purchase a stock is therefore reduced by dividend payments, increasing 
the incentive to exercise early. For a put option the incentive to exercise (sell the 
stock) is diminished because the value of possessing an option to sell, in 
preference to selling immediately, has risen. 
Options are beneficial to own because they preserve flexibility. Their value is 
related to factors specific to the option contract (T, t, X), as well as market-based 
influences (S, a, 6, r). Some pricing techniques used to establish the value of 
particular options are now examined. 
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21.3 Binomial option pricing techniques 
Calculating option values has historically proven difficult because demand for 
these assets is derived; depending on the price of the underlying asset. Despite 
this, in 1973, Black and Scholes (Black and Scholes, 1973) had an important 
insight that allowed the value of certain types of option to be ascertained; the 
assumption of no arbitrage opportunities meant that manufactured portfolios could 
be used to establish option value. This section illustrates these ideas numerically 
using a call option whose underlying volatility follows a highly simplified 
structure. Section 2.1.3 examines the Black and Scholes' model. 
Arbitrage opportunities exist when securities with equivalent risk and return 
structures are priced differently on the market. This allows trade that generates a 
risk-free profit. An arbitrage-free economy exists when all such opportunities are 
exhausted. If the risk and return structure of a security can be accurately 
described, then a composite portfolio may be constructed that exactly replicates 
this structure (the replicating portfolio). Shares of the underlying asset and a risk 
free asset can be combined to replicate the payoffs from an option5. Black and 
Scholes' insight was to recognise that since the option and the replicating 
portfolio share the same risk and return structure, within an arbitrage-free 
economy, they must also share the same price. Option pricing formulae use the 
replicating portfolio and no-arbitrage principles to specify a precise option value. 
The payoff of an option is correlated with the current market price of the 
underlying asset. Continuously evolving prices over the lifetime of an asset 
complicates option pricing by requiring changes in the replicating portfolio. To 
illustrate the principles of option pricing without encountering this complexity a 
call option that expires in one period and whose underlying asset follows a 
binomial distribution is discussed. Binomial pricing techniques, first developed by 
Cox, Ross and Rubinstein (Cox et al., 1979a) are among the most intuitive of 
methods available to price options due to their simplification of asset volatility. 
5 Alternatively a hedging portfolio could be created that combines shares and options to replicate a 
risk-free return. 
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Rather than asset prices evolving continuously, the binomial model restricts 
movement to upward or downward jumps of pre-specified distance and 
probability in each discrete period. 
Let the value of an underlying asset S, evolve according to a binomial distribution 
with probability q of increasing to S+, and probability (I -q) of decreasing to S- in 
the next period. 
q S+ 
I-q s- 
The value of a call option, C, written on this asset will move in a positively 
correlated way: 
q c+ < 
I-q C- 
An investor can borrow EB at the risk free rate to contribute towards buying N 
units of the underlying asset. This portfolio can be adjusted via changes in N and 
B to replicate the returns of the option in any future state of nature 6. Creating this 
portfolio occurs at a net out-of-pocket cost of N*S-B 7. Since the portfolio and 
option have the same risk and return structure they must have the same current 
price: 
C=(N*S-B) (EQN. 2.3) 
After one period the stock are sold and the loan repaid (both the principle B, and 
interest at rate r) giving a payoff of NS+-(I+r)B, or NS--(I+r)B, depending on the 
state of nature. The portfolio and option must also have the same future price: 
6 Alternatively a hedged portfolio could be created; sell short one call option and purchase N 
shares of the underlying asset. Capital gains / losses associated Nvith the stock are exactly offset by 
gains / losses of the option and return on the portfolio is riskless, NS-C=B. 
7 For a put option the replicating portfolio consists of selling shares of stock and lending at the 
risk-free rate, PýN*S+B. 
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q C+=N*S+-(I+r)*B 
C=N*S-B 
< 
I-q Cý-N*S- -(I+r)*B 
This gives two simultaneous equations [C+=NS+-(I+r)B and C-=NS--(I+r)B] that 
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can be solved to obtain N, the number of shares required to create the replicating 
portfolio. 
C+-C- =[NS+ -(I+r)B]-[NS--(I+r)BI 
C+ - C- = NS'- - NS- 
C+ - C- = N(S+ - S-) 
(EQN. 2.4) 
N C+-c- 
S+-s- 
N is given by the spread of future option values relative to the spread of future 
stock values. Rearranging either the upper or lower future value of the option 
gives the borrowing requirement, B, into which N can be substituted to give the 
requirement in terms of future values of the asset and option value: 
C-=NS--(I+r)B 
NS- - C- 
I+r 
B= 
S-C+ -s+c- 
(S+ -S-)(I+r) 
(EQN. 2.5) 
Finally substituting values for N and B (equations 2.4 and 2.5) into today's call 
price (equation 2.3) gives the current value of the call option 9. 
8 Known as the hedge ratio, or "delta" of the option. 
9 Solving for the current value of the call option. 
NS- -C- NS(I + r) - NS- + C- 
C+-C-[S(I+r)-S-]+C- 
C=NS- s+-s- 
I+r I+r I+r 
Define p= 
S(I+r)-S- 
s+-s- 
C= P(C+ -C-)+C- PC+ +(I-p)C- 
I+r I+r 
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C= PC+ +(I-P)C- 
I+r 
(EQN. 2.6) 
where p (interpreted as the risk neutral probability of a rise in stock pricelo) is 
given by: 
p 
(I+r)S-S- 
s+-s- 
(EQN. 2.7) 
Given ftiture values of the stock price (and thus future values of the call option) 
and a risk free interest rate, current call option value can be determined. Notice 
that the actual probability (q) of a rise in stock price, and investors' attitudes to 
risk, have no role in option pricing. Applying option valuation techniques is best 
illustrated with a numerical example. Suppose an asset whose current stock price 
is E90 follows a binomial distribution with probability 0.4 of rising to ;E 120 and 
0.6 of falling to E80. 
0.4 S+-120 
S=90 
< 
0.6 Sý80 
A call option specifies that the asset may be purchased with exercise price E 103 
next Period. The option will be exercised for a profit of f 17 if price rises and 
allowed to expire worthless if price falls. 
<q 
C- max(S+-103,0) = 17 
C- - max(S-- 103,0) =0 1-q 
10 In a risk-neutral world all assets earn the risk free rate. The expected return on a stock, where p 
is the probability of a price rise, is the risk-free rate: (I + r)S = pS+ + (I - p)S- . Rearranging; 
p= (S(I +r) - S-)I(S+ - S-), the weight applied to future rises in option pricing. 
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Incorporating this information into equations 2.6 and 2.7, with the assumption of a 
5% risk free interest rate, gives: 
p= 
(I+r)S-S- 
= 
1.05*90-80 
= 0.3625 s+-s- 120-80 
pC++(I-p)C- (0.3625*17)+(0.6375*0) C- = 5.8690 I+r 1.05 
The market price of E5.87 provides a single point on the option pricing line 
corresponding to current asset price. Deriving a complete option pricing line for a 
plausible range of stock prices requires a continuum of such calculations. 
Although this example is highly simplified and apparently unrepresentative of 
reality, the structure is quite useful and has, for instance, been developed to value 
multi-option investments (Trigeorgis, 1991), petroleum projects (Ekern, 1988) 
and a mine property (Kelly, 1998). Stock prices can only 'move' in one of three 
directions at any point in time; upward, downward or no change. Using a 
trinomial (figure 2.3) rather than binomial lattice, where the relative probabilities 
assigned to future prices reflect observed fluctuations, can improve the accuracy 
of the model. A stock price observed to rise more often than fall might have 0.6 
probability of rising and 0.2 for both remaining constant or falling during any 
given period. Childs and Triantis (Chi Ids and Triantis, 1999) have used a 
trinomial lattice to evaluate interacting research and development projects. 
Application of these methods has been further extended with a pentanornial lattice 
to assess the influence of product life cycles on the option to alter capacity 
(Bollen, 1999). 
p 
S+ 
sqs 
1-ýp-q s- 
Figure 2.3. A single period trinomial lattice 
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Some authors have introduced a tendency away from a symmetric structure to 
"tilting" lattices (Tian, 1999). In this case branches of the lattice are organised to 
create an upward bias to prices. For trinomial lattices unchanged movements 
become moderate upward movements and the remaining two branches create 
respectively greater and less extreme movements. Where stock prices are 
observed to fall over time the lattice may be biased downwards. 
The binomial example given is limited to a single period (n=l). Multi-nomial 
models are usually extended to many periods. A binomial lattice of 4 periods 
allows price to assume up to" 16 (2 4) values in the last period. An option that 
expires in one year modelled as a 12 period binomial lattice with each period 
representing one month allows up to 4096 (2 12) prices in the final period. 
Increasing the number of periods and reducing the time associated with each (eg. 
52 periods = one week per period) improves the reality of the model as prices 
evolve more quickly and take on a greater range of values. To price multi-period 
options valuation occurs the expiration date by summing possible 0=0,..., n) 
option values (multiplied by their relative probabilities) to find the expected 
ten-ninal option value. Backward induction and discounting are used to find 
current option value: 
n 
n! n-is E*p max(ziJd - E, O) 
j=o 
j! (n-j)! 
(EQN. 2.8) 
(1+ ry 
Where 11! Pj(j-P)n-j is probability that price will rise j times in n periods, j! (n - j)! 
each with risk neutral probability p, and max(ttid'iS - E, O) is the associated call 
value at expiration, taking account of the probability of up (u) and down jumps 
(d). Kamrad (Karnrad, 1995) has used multi period lattices to value manufacturing 
and mining production. 
11 Assuming lattice branches do not recombine. 
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Binomial models can be framed to approximate continuous models by creating 
infinitesimally short periods and simultaneously generating an infinitely large 
number of periods. Whilst multi-period call, put, American and European options 
can be modelled, complexity comes at a price. Sophisticated models can loose 
their transparency and may become difficult to handle with solutions requiring 
computer assistance. Programs in Excel or programming languages such as 
Fortran can be written to find option values and optimal exercise dates. Cox, Ross 
and Rubinstein (Cox et al., 1979b) have shown that when continuous time is 
approximated and specific values for u, d and p are chosen, as n -> 00, the discrete 
binomial formula above converges to the continuous-time Black and Scholes 
model. Yoshimoto (Yoshimoto and Shoji, 1998) for instance, uses a binomial 
approximation to find the optimal rotation age for a forest stand. The Black and 
Scholes formula is a continuous time model, attractive for its computational 
efficiency and direct relationship to the hedging ideology in pricing simple 
options. It is discussed in the following section. 
ZI. 4 Black and Scholes option pricing 
Black and Scholes created a mathematical fonnula to value options written on 
non-dividend paying assets whose prices follow a lognormal distribution. This 
fonnulation encompasses ideas that prices are continuous rather than discrete, do 
not fall below zero, and that lower and higher prices face a smaller probability of 
occurrence. Black and Scholes made s ome strong assumptions in addition to the 
arbitrage-free economy: 
Capital markets are perfect 
Short sales are permissible 
Securities are infinitely divisible 
Securities are continuously tradable 
Any amount may be borrowed or lent at the risk-free rate 
There are no transaction costs 
No dividends are payable 
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These assumptions allow the replicating portfolio principle to theoretically be 
applied accurately and continuously at no cost throughout the life of the option. 
The assumption of no dividends was made for simplicity and was later relaxed for 
known dividend payments (Black 1975) and for dividends expressed as a 
continuous compounded yield (Merton 1973). 
To value a European call option Black and Scholes considered the probability 
(given current price) that on the exercise date stock price exceeds the exercise 
price, prompting exercise to occur. Using arbitrage arguments a hedging portfolio 
(B=NS-C) is constructed, where C and S, are continuous variables. The model 
describes continuous application of the hedging portfolio; since S is constantly 
changing, N and B must be continuously adjusted to maintain equivalence 
between the hedging portfolio (NS-C) and risk free borrowing (B). Using Ito's 
Lemma for finding the derivative of non-smooth functions, Black and Scholes 
derived a partial differential equation (PDE) that must be satisfied by the value of 
the option: 
I 2S2Cff(S)+ SCr(S)_Ct(t) i cr r -rC =0 (EQN. 2.9) 
This is subject to an exercise condition, lower, and upper boundary. For a call 
option these are respectively; C=max(S-E, O), if S=O then C=O, and -C approaches S 
unity as S approaches infinity 12 . For a call with exercise price E, Black and 
Scholes showed option value to be: ' 
C(S, t, E) = SN(dl) - Ee-r'N(d2) 
where 
In(SIE) + (r -I cr 
2 
2 dl= 
cr-b- 
d2 =dI -a-lt- 
12 The European put option faces equivalent boundary conditions. 
(EQN. 2.10) 
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Cumulative standard normal distribution function 
Since dividends are assumed absent in the Black and Scholes' model, and an 
American option without dividends is never exercised early, the pricing of an 
American call is identical to a European call. The value of a European put may be 
ascertained either directly or via the put-call parity: 
P(S, t, E) = -SN(-dl)+ Ee-rtN(-d2) (EQN. 2.11) 
Valuation of an American put requires a further condition to check whether the 
discounted value of the option at any node is exceeded by the value from early 
exercise. For this there is then no closed-form solution given a finite time to 
maturity. Various numerical techniques can be used to obtain an approximation. 
The Black and Scholes formula can be used to confirin the nature of influences on 
option value discussed earlier (table 2.2). 
Some authors including Luchrman (Luehrman, 1998) have tabulated Black and 
Scholes option values. Analysts can use an adjusted volatility parameter ((: 7/4t) 
and stock price relative to the present value of the exercise price (S/(Ed-")) to 
consult tables presenting option value relative to stock price. Trigeorgis 
(Trigeorgis, 1999) provides option values for the adjusted volatility parameter 
between 0.05 and 1, and for the relative current asset price between 0.5 and 2.5. 
Despite the attractiveness of a comprehensive formula there exist some problems. 
'Long Tenn Capital Management' used the formula extensively to identify under- 
priced options and engage in profitable arbitrage. Success prevailed until a severe 
downturn in the US stock market meant that the cost of creating hedging 
portfolios exceeded the funds available, and the company collapsed. This example 
demonstrates how transaction costs assumed negligible in the model, can make 
continuous hedging difficult if not impossible to carry out, and that prices may not 
conform to the random walk specification underlying option pricing. Evidence 
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also exists that the formula carries some systematic biases in the pricing of call 
options. Bhattacharya (Bhattacharya, 1980) has demonstrated that although 
present, such biases are not generally operationally significant. The Black and 
Scholes' model remains a commonly used formula for pricing options. 
Several developments have extended the basic Black and Scholcs model. The 
Garman-Kohlhagen (Gannan and Kohlhagen, 1983) Model prices European 
options on foreign currency, Margrabe (Margarbe, 1978) developed a theoretical 
model for the right to exchange one asset for another - the exchange option, and 
Geske (Geske, 1979) created a model to price options on options - the compound 
option. This particular piece of work paved the way for pricing other kinds of 
option, including American call options on dividend paying stocks (Roll, 1977), 
and options on the maximum and minimum of two risky assets (Stulz, 1982). An 
important break through was pricing of options where the underlying asset price is 
subject to abrupt jumps (Merton, 1976). This was previously difficult due to the 
challenge of hedging such jumps, and proved important for pricing real options 
whose underlying assets may not be subject to continuous evolutionary processes. 
Progress in pricing financial options has eventually led to developments in pricing 
real options. Theories that have allowed financial analysts to price ever more 
complex combinations of assets, derivatives, interest rates and exchange rates 
have gradually transferred to pricing options to invest, abandon, exchange, and 
alter scale, that prevail in the real sector. 
2.2 Real Options 
ZZI Creating the analogy between financial and real options 
Real options analysis is based around the idea that some investment projects 
closely resemble financial options. Here the application of financial techniques to 
valuation of real options is explored. In particular this section examines the 
circumstances surrounding, characteristics underlying, and parameters appropriate 
for valuing different types of option. 
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A financial option is bought on a market and the owner must decide when, if at 
all, the option should be exercised subject to a fixed exercise date. Stock price 
uncertainty, payment of any dividends, and the exercise price and date influence 
optimal exercise. These factors encompass elements of uncertainty, irreversibility 
and an ability to defer. Variables are observed and monitored, and a decision rule, 
'exercisewhen keeping the option open (deferring) is no longer more valuable 
than killing the option (exercising immediately)', is adopted. If an investment 
opportunity is equivalent to a call option, initiating the investment can be thought 
of as 'exercising an option to invest'. Many of the characteristics underlying 
financial options also exist for 'real options' (table 2.3). 
Financial option Real option 
Acquiring option Purchased Purchased / conferred / created 
Factors affecting value Dividends, Exercise price, Interim payment, Investment cost, 
date time horizon 
Underlying uncertainty Stock price Net present value 
Source of irreversibility Once exercised the option Sunk costs, some actions and their 
no-longer exists implications cannot be altered, or 
are costly to alter 
Ability to defer Subject to exercise date Subject to endogenous and 
exogenous influences 
Table 2.3. Characteristics of financial and real options. 
An investor must decide at what point, if any, to initiate a project. On approval 
investment costs are incurred and the option to invest at a later date is killed. To 
help infonn the exercise decision a range of variables are observed including 
current asset price (if the project produces a commodity), or present value (if the 
project produces a service or similar untraded benefits). The costs and benefits of 
deferring are weighed and a decision rule is created: 'Invest when the benefits of 
keeping the option to invest alive no longer exceed the benefits gained from 
killing the option and commencing the investment'. In other words, invest when 
the present value of expected cash flows is sufficiently high relative to the 
investment cost. 
Financiers confront a fixed and known exercise date. Real projects may or may 
not face an explicit deadline although there is usually some implied time horizon 
and some deadlines may be stochastic. Investment deadlines might be imposed 
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internally by managers, or by investment opportunities naturally disappearing. 
Alternatively timing constraints may be due to external constraints such as patents 
or competitive forces. Since real options are unlikely to have a single fixed date 
on which to exercise, they are more akin to American rather than European 
options. Option pricing methods have also been adapted to value opportunities 
with no expiry date (McDonald and Seigel, 1986). 
Many real options do not have a fixed exercise price; investment costs may 
evolve. Sources of fluctuations may again be external (input prices), or internal 
(related to project scale). This poses little of a challenge to the analogy and can be 
accounted for graphically through either a shift or pivot in the intrinsic value 
curve. For instance, in the case of investment cost being positively related to 
project value intrinsic value will slope upward more steeply. Trigeorgis 
(Trigeorgis, 1999) describes a model with stochastic investment cost. 
Financial options are described in formal contracts where the structure of the 
problem is stated, and relevant variables clearly specified. The contract sets out 
unambiguously the tenns (exercise price and date etc) that bind relevant parties, 
ruling out debates concerning whether the option exists, who owns it, who has the 
right to exercise, or when the option expires. Financial outcomes such as price can 
be unquestioningly observed leading to a transparent exercise decision. 
The explicitness of financial options does not always transfer to the real sector. 
Since formal contracts do not exist, real options must be forcibly identified, are 
often harder to describe, and outcomes may be the subject of some debate. 
Important in defining and identifying real options therefore, are the characteristics 
underlying the decision problem. Option problems, whether real or financial, are 
characterised by uncertainty, irreversibility, and an ability to defer (figure 2.4). 
These factors, and the interactions between them, are central to identifying and 
understanding real options problems. Some authors emphasise one factor (usually 
uncertainty) over the others but for an option to exist all three must be present. 
Since real options are not expressed within formal contracts, examining a project 
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for these factors is a reliable way to recognise a real options problem and is used 
to explore the case studies presented in later chapters. 
With no ability to 
defer information 
cannot be improved. 
Choices are based on 
current information 
Ability to defer 
Commitment to 
irreversible 
actions delayed 
Uncertain variables 
observed, 
information gained 
Uncertainty In the absence of 
over outcomes uncertainty the optimal 
action and timing is 
known 
Debate over the 
optimal action 
I 
Possibility of making 
sub-optimal decisions 
Fully reversibili y 
renders uncertainty 
irrelevant; sub-optimal 
decisions can be altered 
Irreversibility 
Improved information 
1 0( may reduce the like ih od 
of sub-optimal decisions 
Irreversibility means poor 
decisions continue to incur 
sub-optimal outcomes, 
providing an incentive to delay 
Figure 2.4. Interactions between uncertainty, irreversibility and the ability to 
defer. 
Although discussion has centred upon the option to invest as being analogous to 
the call option real options analysis encompasses more than just investment 
projects. A firm might consider options to expand, temporarily close, reopen, 
permanently close, or switch inputs and outputs. In the real options literature 
growth options, abandonment options, options to exit and switching options have 
been used to assess these circumstances. Compound options may also exist in the 
real sector. For instance current research and development provides an option on 
product development which in turn provides the option to market, and expand or 
abandon production depending on market conditions. The following section 
considers the pricing of real options. 
ZZ2 Pricing real options 
Pricing real options requires identification and estimation of variables previously 
recogniged as influencing option value. Table 2.4 summarises these variables, 
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their interpretation from a real options perspective, and comments on their 
measurement. The precise variables required to value an option depend on the 
model used, but follow this general fon-nat. 
Call option Real option Source and measurement 
Spot price (S) Present value of Estimated cash flow given current expectations 
expected cash flows of the future. Evolves with the realisation of 
M uncertain events and interim cash flows. 
Variance in Variance in Volatility caused by numerous sources of 
stock value expected value over uncertainty including prices, disease 
(CY 2) time (a) progression, effectiveness of a therapy. 
Exercise price Investment cost (I) Estimate of upfront development costs, may 
W vary over time. 
Time to Time until Timing constraints imposed either internally or 
expiration (T) investment externally including government, progress of 
opportunity patient, availability of funds, competitive 
disappears (T) pressures, expiry of patents, political pressures. 
May be stochastic. 
Risk-free Risk-free interest Observed 
interest rate (r) rate (r) 
Dividend (5) Payout rate (5) Periodic cash flows resulting from the project or 
denied / paid while deferring. For instance costs 
incurred whilst deferring 
Table 2.4. Variables required for real option valuation. 
The assumptions underlying real option valuation are similar to those for financial 
options but with some additions. Early real options applications used contingent 
claims valuations methodology that transfers hedging arguments to the real sector. 
Assumptions that the underlying source of uncertainty was tradable and that a 
well-developed derivatives market exists ensure hedging can be carried out. The 
majority of applications therefore concerned projects where a tradable commodity 
was produced such as mining of natural resources (Brennan and Schwartz E S, 
1985; Paddock et al., 1988). 
Whilst the original aim was to value traded assets the models can equally well be 
applied to projects whose underlying source of uncertainty is not traded 
(Benaroch and Kauffinan, 1999). Applications have increasingly moved in this 
direction with analysis of research and development (Angelis, 2000) and 
environmental investment decisions (Cortazar et al., 1998). In these cases the 
assumptions of contingent claims are inappropriate (Slade, 1998) and dynamic 
programming techniques are used, which examine the stopping and continuation 
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value of an option and consider a decision maker's willingness to hold the option 
until the following period. 
McDonald and Seigel (McDonald and Seigel, 1986) developed a basic model of 
real option pricing addressing the issue of when to pay a sunk cost I, in exchange 
for a project of value, V. This represents an optimal stopping problem for the 
decision maker. He / she must choose when to exercise (stop) the option in return 
for a flow of uncertain benefits. In their model the value of the investment V, 
evolves according to a geometric Brownian motion. 
dV= a Vdt+aVdz (EQN. 2.12) 
The underlying random variable V changes each period dt with some drift a 
subject to a known and constant variance a2. Brownian motion is a Markov 
process; future values of the diffusion process depend only on the current value. 
The term dz is an increment from a Weiner process such that the probability 
distribution of a change in any time interval is independent of any other time 
interval, and has changes that are normally distributed with variance growing 
linearly with the time horizon. 
The optimal stopping problem maximises the value of the investment opportunity, 
F(V). Investment at time t provides payoff Vt - I, where I is the investment cost. 
The decision maker maximises the expected present value of investment at time t, 
subject to the evolution of V: 
F(V) =max c[(V, - I)e-Pt ] (EQN. 2.13) 
Where - is the expectations operator, t is the future time (currently unknown) 
when the investment is made, and p is the discount rate. To obtain a finite 
investment date the constraint ct <p is imposed. Without such a constraint the 
value of the investment project would grow more quickly than it is discounted 
over time. Larger t would always increase project value creating an incentive for 
continuous deferral. An optimal exercise date would not exist. The difference p- 
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a is defined as 8, the payout rate 13 . The payout rate causes a project to grow at a 
slower rate than the market discount rate and is akin to a dividend (table 2.4). 
The most lucid case exists when a=0. With this assumption the value of the 
project at time t is given by V(t) = Vo e" (where V(O) =Vo). If investment occurs 
at timec, the value of the investment oPportunity becomes: 
F(V) = (Ve" -I)e-l' (EQN. 2.14) 
Equation 2.13 considers the future unknown value achieved when investment 
occurs and discounts back. Equation 2.14 incorporates the current known project 
value, asserts a growth rate of (xt, until investment occurs atr, and discounts back. 
Maximisation over time requires that the first derivative be set to zero and the 
second derivative be negative: 
dF(V) 
-(p - a)Ve-(p-a) r+ pje-pr =0 (EQN. 2.15) dr 
V -(p-a)r This corresponds to equating the marginal benefit (a e) and marginal cost 
(p(Ve-('-')' + IeP')) from waiting and leads to the optimal exercise date T*: 
1p 
r*=max -log 
la 11 
(EQN. 2.16) 
If c* is 0 the optimal exercise date is now. Positive values of r* indicate how far 
into the future one should wait before investing. Forc*=3 the investment should 
be undertaken three periods from the current time period. 
With no uncertainty if a : 0, V(t) will remain constant or fall as time elapses. The 
optimal strategy becomes adopt immediately if V21 and never adopt otherwise. 
When O< a<p immediate investment is optimal only whenu*=O. From equation 
2.16 this requires that V exceeds some threshold level V* where: 
13 Some times referred to in real options literature as a convenience yield. 
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V*= 10 I>I 
p-a 
(EQN. 2.17) 
Sincep>a, P>1, and V* necessarily exceeds 1. Forvalues of V ý: V*, 
p-a 
I. log[ P, 1 is less than zero. -c*=O and immediate investment is optimal. For 
a (p-a)V 
V<V*, a positive deferral period exists because I log[ P, ]>O. Relative growth 
a (p-a) 
(&'T) and discounting (e-PT) cause expected present value to increase over time so 
that in some future period V will sufficiently exceed I (V*>I), leading to 
investment. The value of the investment opportunity in this case is found by 
substituting the optimal timing T* (equation 2.16) into the value of the investment 
opportunity (equation 2.14): 
F(V) = [aII(p - a)l(p - a)VIpI] 
pla (EQN. 2.18) 
Table 2.5 surnmarises these explicit decision rules and option value for different 
assumptions concerning project growth and intrinsic value. 
Assumption Intrinsic value Action Option value, F(V) 
a0 If V<I Never invest 0 
a :0 if VI Invest immediately V-1 
O< a<p if V V* Invest inunediately V-I 
O< a<p if V< V* Defer [aI / (p - a)j(p - a) VIpI] 
pl' 
Table 2.5. Decision rules from real options analysis when (7--0. 
When no growth is expected (a-<O) option value is equal to intrinsic value 
[max(V-1,0)], otherwise option value exceeds this leading to a positive option 
premium [F(V)-max(V-1,0)]. Larger expected growth generates greater option 
value, and option premium, creating a stronger incentive to defer. Figure 2.5 plots 
option value for different levels of a showing this relationship whilst reinforcing 
the similarity between real and financial option value. The decision threshold V* 
is shown as the first value of V (above V=1=1) at which option value equals 
intrinsic value or equivalently when option premium falls to zero. 
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Option value 
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Figure 2.5. Option value for four levels of project growth (a--O, 0.2,0.4) where 
1=1, and cF--O. 
The decision thresholds and functions for option value derived above relate to the 
case of no uncertainty. Figure 2.5 therefore illustrates that option value can exceed 
intrinsic value even in the absence of uncertainty demonstrating that option 
premium is not a risk premium. Most projects do have some degree of 
uncertainty. 
The solution to the theoretical case where cr >0 follows a logic similar to the 
reduced case. A Bellman equation encompasses information about the stopping 
value (intrinsic value) and the continuation value (future value) of a real option, 
asserting that over any time interval prior to investment total expected return is 
equal to expected capital appreciation. The optimal action maximises the sum of 
these two components. When u>0, dynamic programming techniques use this 
concept to solve the stopping problem defined by exercise of an option. Dixit and 
Pindyck (Dixit and Pindyck, 1994) demonstrate the use of Ito's Lemma 14 to 
expand the Bellman equation and derive a second order partial differential 
equation (PDE) that must be satisfied by the value of the investment opportunity, 
14 A mathematical tool for computing the derivative of non-continuous random functions 
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F(V). This is the stochastic equivalent to equation 2.15 which maximises in the 
deterministic case: 
I 2V2 
ya F"(V) +a VF'(V) - pF(V) =0 (EQN. 2.19) 
F'(V) and F"(V) represent the first and second derivatives of F(V) with respect to 
V. By satisfying the PDE, F(V) conforms to the intuitive constraint that the value 
of the investment opportunity must equal the maximum of the continuation or 
stopping value. A set of Boundary conditions must also be satisfied that limit F(V) 
and identify the solution V*. 
F(O) =0 Absorbing barrier 
F(V*) =V *-I Value matching condition (EQN. 2.20) 
F'(V*) =I Smooth pasting condition 
The absorbing barrier provides a lower boundary on F(V), stating that should 
project value fall to zero, the investment opportunity will be worth nothing. Both 
will remain worthless due to the stochastic process governing V. The value 
matching condition holds at V*, equating the value of the investment opportunity 
with the value of immediate action V-1. The free boundary, V*, and the region of 
V for which the PDE is valid, are endogenous and as yet unknown, and are 
identified using the smooth-pasting condition. At V* the two arguments of the 
Bellman equation not only equate but meet tangentially. If this were not the case 
then over some small waiting period, either the stopping payoff or the 
continuation payoff would rise more rapidly and immediate exercise would not be 
optimal, an improvement in payoff would be possible by exercising at a different 
time point. 
Finding F(V) requires solving the PDE subject to the boundary conditions. To 
comply with the absorbing barrier F(V) takes the form: 
F(V) =A V-6 (EQN. 2.21) 
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where fl is the known constant: 
fl = -1 -alU 
2+ V[alu 2_ 1]2 +2p /a 2 >I (EQN. 2.22) 
Substituting the first derivative of F(V), arranged for A into the value matching 
condition to find V* and putting this back in to the solution for A gives V* and A 
in terms of P and I alone: 
v*=-p--I (EQN. 2.23) 
A= (V*_, )I(V*), O = (p_j), 
O-11(p. 8j, 6-1) (EQN. 2.24) 
The value of the investment opportunity and the optimal investment rule are 
provided by equations 2.21 and 2.23 respectively. These solutions are equivalent 
to equations 2.17 and 2.18 in the deterministic case and along with equations 2.22 
and 2.24 provide sufficient information for decision makers to make informed 
choices within a real options framework. The presence of uncertainty means the 
timing threshold t* cannot be solved for directly in the stochastic case leading to 
some debate over project timing. 
Since p>(x and P>1, both the deterministic and stochastic solutions for V* involve 
a multiplier attached to I that exceeds 1. In both cases therefore, the optimal 
investment threshold V* exceeds the cost of the investment, 1, leading to a 
decision threshold that conflicts with traditional decision-making (V=I). Since V* 
necessarily exceeds 1, real options analysis always supports deferral when NPV 
based techniques recommend immediate action. 
McDonald and Seigel (McDonald and Seigel, 1986) describe a real option that is 
available in perpetuity and achieve closed form intuitive results. Since many real 
options have timing constraints and other complications such as staged 
developments and capabilities to contract and expand the project in response to 
market conditions, methodology has progressed to incorporate these factors. As 
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project descriptions become increasingly complex closed form analytical solutions 
may be unattainable and numerical methods are required. As authors consider 
broader applications alternative models including lattices that incorporate 
investment deadlines have become popular. Authors have extended and enhanced 
the primary works exploring a range of options based techniques that encompass 
varying levels of sophistication. The following section discusses some 
applications of real options theory. 
2.2.3 Review o the application of real options of 
Applications of real options analysis have developed in terms of depth (addressing 
more complex problems), breadth (focussing on wider types of problem including 
options to abandon and switch) and scope (increasing the variety of fields to 
which real options is applied). This review considers all aspects paying particular 
attention to the last since this thesis falls into the category of increasing scope. 
Early applications of real options theory centred on problems with a single source 
of traded uncertainty and significant upfront costs. This helped emphasise the 
similarity between financial and real options and meant that investments in 
resource extraction industries were especially prominent because a commodity is 
sold. For instance, Tourinho (Tourinho, 1979) considered depletion of natural 
resources while Paddock et al. (Paddock ct al., 1988) focussed on petroleum 
reserves. This theme has continued into recent applications with Frimpong 
(Frimpong and Whiting, 1997) and Cortazar (Cortazar and Casassus, 1998) 
looking at the value of an existing mine and expansion respectively, and Imai 
(Imai and Nakajima, 2000) performing options analysis of an oil refinery project. 
Significantly, many early applications focus on valuing projects in isolation and 
treating options independently. Real life investments are rarely this simple, often 
involving exercising a string of connected options or simultaneously exercising 
interacting, or compound, options. As early as 1989, Dixit (Dixit, 1989) tackled 
joint consideration of firms' entry and exit decisions. Hypothetical examples were 
used to explore the relationship between price thresholds triggering entry and exit. 
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Dixit highlighted the wide appeal of the results; "ranging from foreign trade to job 
search ... witness the great reluctance of university 
deans to approve new faculty 
positions in departments that experience a surge of students. " 
Trigeorgis performed several analyses using compound options. In 1991 
(Trigeorgis, 1991) a log transfonned binomial numerical analysis, capable of 
modelling option interactions, demonstrated results consistent with previous 
attempts to value American abandonment options by Myers and Majd (Myers and 
Majd, 1990). Later work looked at interactions between options for multi-option 
investments (Trigeorgis, 1993) and examining leases with complex options built 
in (Trigeorgis, 1996). More recent work in this area includes sequential ordering 
of interrelated projects (Childs et al., 1998), interdependencies between toll road 
infrastructure projects (Rose, 1998), optimal timing and spread of phased rollout 
projects (Pennings and Lint, 2000), and sequentially staged investments (MaJd 
and Pindyck, 1987). 
Methodological improvements in the depth of real options analysis, including 
pricing compound interacting options and projects based on multiple sources of 
uncertainty, permitted the breadth of real options applications to develop. 
Investment opportunities came to be considered as strategic growth options 
(Kester, 1984; Kulatilaka and Perotti, 1998). In particular Hevert (Hevert et al., 
1998) considered the impact of interest rates on the value of growth options. 
Perhaps more importantly projects other than investments gained increasing 
attention. Margarbe's (Margarbe, 1978) financial work on options to exchange 
assets encouraged work on options to switch inputs and outputs. Options to 
contact/expand production, timing options (Farzin et al., 1998), options to scrap 
(Moretto, 1996a), or abandon (Pennings and Lint, 2000; Myers and Majd, 1990), 
and options to temporarily and permanently shut down (McDonald and Seigel, 
1985) have all been the subject of analysis. 
Whilst early applications maintained the solid analogy to finance, increasing 
breadth promoted the similarities between finance and projects from wider fields 
where uncertainty, irreversibility and an ability to defer are present. Applications 
have become particularly prominent in envirom-nental sectors where the 
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characteristics are especially evident. Uncertainty can be associated with prices of 
naturally occurring resources such as wood, in which case irreversibility may be 
the time and cost to replace a forest stand and the ability to defer the decision to 
harvest might be infinite. Authors examine specialised themes including climate 
policy (Conrad, 1997a; Plantinga, 1998), forest management (Thorsen, 1999), 
strategic development of agricultural land (Tegene et al., 1999) and crop 
management (Khanna et al., 2000). 
Hasset (Hasset and Metcalf, 1992) and Chao and Wilson (Chao and Wilson, 1993) 
develop pollution concerns. The former takes the individual's perspective with 
regards to purchasing energy saving appliances while the latter assumes the 
perspective of a firm purchasing emission allowances. Both conclude that waiting 
generates improved information that provides an incentive to defer irreversible 
investments. This creates inertia against environmentally friendly efforts both at 
the individual and firm level. 
Environmental policy has been examined by Kocagil (Kocagil and Eduardo, 
1996), who looked at the impact of new environmental standards on the mining 
industry, and Conrad (Conrad, 1997a), who considered a government's option to 
introduce policies to slow global warming. Both use hypothetical examples to 
analyse policies of pollution abatement. Conrad uses Brownian motion to model 
mean temperature drift and volatility to serve as the underlying source of 
uncertainty. The author uses two evolutionary processes to represent 
environmental impact before and after implementation of preventative policies. A 
trigger temperature for adoption of policies was found to be 15.54 'C. Given 
current forecasts the authors suggest this is unlikely to be reached within two 
decades of the analysis being carried out. In this instance real options analysis 
recommended deferring action to slow global warming. 
Conrad has also contributed to real options applications within the field of forest 
management. Albers (Albers, 1996) had previously considered the option to 
develop tracts of tropic rainforest, identifying elements of uncertainty (future 
forest value), irreversibility (the loss associated with deforestation) and the ability 
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to defer (waiting before commencing development). Conrad's contribution 
(Conrad, 1997b) assesses the relative benefits of preserving a stand of old-growth 
coast redwood, and abandoning the forest in favour of selling the wood. The 
amenity value of the forest as a function of visit rates is modelled as the 
underlying source of uncertainty with timber prices assumed constant. Conrad 
solves for a trigger amenity value required to justify preservation. 
Forestry has received considerable attention. Plantinga (Plantinga, 1998) 
investigated optimal time to harvest, Yoshimoto (Yoshimoto and Shoji, 1998), 
optimal rotation age, and Thorsen (Thorsen, 1999), establishment of new forest 
stands. Such analyses typically use future stand values or wood prices as the 
underlying source of uncertainty and highlight an irreversible investment (sunk 
cost and loss of the forest). Whilst Plantinga favours Brownian motion to describe 
uncertainty in future stand values Yoshimoto prefers a binomial approximation to 
model future wood prices. Thorsen looks at implications of policies to influence 
investor behaviour, and concludes not only that subsidies to induce afforestation 
must increase, but that the extent of the increase depends on the nature of the 
subsidy. Analyses such as this suggest potential ramifications for policy design in 
other areas including health care. 
Whilst most applications of real options analysis fall within broad categories such 
as resource extraction, forestry related, and technology adoption there have been 
an increasing number of novel applications. Burda (Burda, 1995) applies option 
pricing techniques to assess individuals' decisions to migrate. Uncertainty is 
discussed in the context of income in the home and new countries, with migration 
involving unrecoverable costs that can be postponed almost indefinitely. This 
work may have implications for the wider labour market, in particular mobility of 
workers in sectors such as nursing. Grenadier (Grenadier, 1995) uses options 
theory to value lease contracts incorporating options to renew and cancel leases 
with payments contingent on asset use. Saphores (Saphores, 2000) considers 
optimal introduction of measures to curb pest populations, and Mahul (Mahul and 
Gohin, 1999) similarly looks at optimal timing of animal disease control policies. 
Review of such applications prompts potential applications within the health care 
arena, in this case control of contagious disease and immunisation programmes. 
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The majority of applications are of a theoretical nature with numerical analysis 
often based on hypothetical figures to illustrate important concepts and maintain 
transparency, although some authors (Thorsen, 1999) have used historical prices 
and observed volatility to calculate optimal thresholds. Whilst real options 
analysis has spread widely in some areas in recent decades, the limited scope and 
lack of empirical applications are arguably due to the mathematical complexity of 
many real options models. Several articles and books, for instance Luehrman 
(Luehnnan, 1998) and Copeland and Antikarov (Copeland and Antikarov, 2001), 
have pursued non-technical explanations and discussion aimed at applying real 
options theory in practice, to help over come this problem. 
This thesis aims to expand the scope of real options by applying the technique to 
several decision making problems encountered within health care. No attempt is 
made to contribute to the mathematical content of real options analysis; instead 
existing models are used within case studies to illustrate the analogy between 
financial and health care options, and to demonstrate some key results and 
implications for decision making of using the real options approach. Chapter 4 
examines the watchful waiting decision, chapter 5 analyses the option to defer 
removal of life support technology for comatose patients, chapter 6 considers the 
National Institute for Clinical Excellence's option to approve new and existing 
technologies, and chapter 7 looks at option value as a value of deferred 
information in the context of using clinical trials to gather addition evidence. Prior 
to this some alternative notions of option value are discussed in order to clarify 
the definition of option value used within this thesis. 
ZZ 4 Alternative notions of option value 
Discussion thus far has centred on a specific interpretation of option value; the 
value of projects characterised by uncertainty, irreversibility and an ability to 
defer, as ascertained using financial option pricing techniques. This notion of 
option value might be referred to as a 'production type' option value since 
production related activities are usually the subject of interest. In parallel with this 
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two schools of thought concerning what shall be termed 'consumption type' 
options have developed. One school makes reference to option value, the other to 
quasi-option value. 
Weisbrod (Weisbrod, 1964) initiated a debate when he considered that individuals 
might be willing to pay a price for assured access to an environmental resource. In 
particular he referred to consumers who have an option to visit Utah's Wasatch 
mountain range. He argued that when there is uncertainty over their future 
demand and exogenous future supply of the natural resource, consumers place a 
value on owning the option to visit in future and are willing to pay to preserve this 
option. Weisbrod raised the issue that if no fon-nal mechanism exists to charge 
potential users for this benefit, their option values would not be incorporated into 
private decision making concerning the future of the resource. 
Weisbrod's ideas lead to some confusion with different interpretations of his work 
developing into two contrasting schools of thought. Cicchetti and Freeman 
(Cicchetti and Freeman, 1971) believed option value related to the relationship 
between maximum willingness to pay for an option and expected value of 
ownership. If option price is the individual's maximum willing to pay for an 
option guaranteeing the right to consume future benefits, then option value is the 
difference between this and the expected value of consumer surplus derived from 
actually consuming the benefits. If this is true consumer surplus underestimates 
economic benefits. Cicchetti and Freeman argued that option value exists 
predominantly as a result of risk averse behaviour and is limited to positive 
values. 
Schmalensee (Schmalensee, 1972) used a similar framework to Cicchetti and 
Freeman to derive a more general result concluding that option value might be 
positive or negative depending on the characteristics of the problem and 
individual preferences. Since Schmalemsee was not optimistic about accurate 
measurement of preferences he advised option value be assumed zero for applied 
studies. Bohm (Bohm, 1975) reinforced conclusions concerning the sign of option 
value but in so doing challenged Schmalemsee's risk aversion assumption and 
recommendation for applied work. Subsequent work has contributed to both 
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arguments with numerous authors seeking to explain and reconcile the apparently 
conflicting results (Bishop, 1982; Anderson, 198 1). There now appears consensus 
that option value can be positive or negative depending on the preferences and 
assumptions underlying uncertain variables (Freeman, 1984). 
Meanwhile Henry (Henry, 1974), and Arrow and Fisher (Arrow and Fisher, 
1974), simultaneously developed an alternative interpretation of Weisbrod's work. 
Their quasi-option value focussed on irreversibility. When a project is irreversible 
(for instance results in irreversible destruction of an ecosystem or requires 
irrecoverable investments), waiting for information prior to making a commitment 
may be valuable. These authors argued that independently of risk aversion, cost 
benefit analysis that omits this value of information is biased against 
environmental preservation. 
Conrad (Conrad, 1980) believed that quasi-option value was equivalent to the 
expected value of perfect information when deferral reveals complete infon-nation, 
and the expected value of information when deferral reveals only partial 
information. Hanemann (Hanemann, 1989) later pursued this line of thinking 
arguing that option value was distinct from, but bounded by the unconditional 
value of information. In Hanemann's opinion quasi-option value existed 
conditional on no irreversible action being undertaken and therefore was a 
conditional value of information. 
This school of thought developed with inclusion of information functions to 
model information arrival through time (Batabyal, 1997), and challenges to the 
assumption of total irreversibility via inclusion of an 'irreversibility cost' (Zhao 
and Zilberman, 1999). Efforts to measure quasi-option value include Greenley 
(Greenley et al., 198 1) who used contingent valuation to assess option value for 
water quality and recreation on the South Platte River, and Smith (Smith et al., 
1983) who measured willingness to pay for water pollution control. Both 
concluded that option value was significant accounting for 40% of reported 
consumer surplus (Greenley) and 50% of stated willingness to pay bids (Smith). 
Ha-Duong (Fla-Doung, 1998) considers climate policy choices, defining option 
value to be variation in expected value of future information between two 
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strategies of aggressive and moderate emissions abatement. Option value was 
shown to be positive and around 50% of the cost of abatement. 
Hanemann (Hanemann, 1984) made an important contribution to the field when 
he showed that the two interpretations, option value and quasi-option value could 
be reconciled. Hanemann demonstrates that the Arrow-Fisher-Henry (AFH) 
quasi-option value can be measured in two ways and that the Schmalensee-Bohm. 
(SB) option value represents the difference between these measures. He suggests 
the reason for the difference is that the two interpretations deal with different 
aspects of decision-making under uncertainty. AFH is concerned with dynamic, 
temporal resolution of uncertainty whilst SB is a static measure. This is consistent 
with Smith (Smith, 1983) who had previously suggested "the apparently 
contradictory conclusions of several earlier studies are largely due to a reflection 
of differences in these studies' characterisation of the behavioural decision 
process". 
Fisher (Fisher, 1997) later provides commentary that forges links between these 
consumption based option values and financial option value, using simple 
versions of the two models to demonstrate equivalence. 'Consumption' and 
'production' type option value both involve decision making under uncertainty 
requiring knowledge of underlying sources of uncertainty, information gained 
through time, and details of the exercise decision. Differences seem to be a matter 
of perspective, underlying assumptions and valuation methods. Most importantly 
production type options use valuation methods derived from financial option 
pricing to establish value. It is these techniques and their applicability to health 
care that fan-n the basis of this thesis. 
A final perspective of option value has arisen from consideration of future choices 
and the impact of current decision making on availability of choices. Rosenhead 
(Rosenhead, 1992) recommends that decision makers should select alternatives 
today in order to optimise the choices available in ftiture periods. Whilst this is 
similar in nature to considering deferral in real options techniques, Rosenhead 
does not propose financial option pricing techniques as a way to establish value. 
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Chapter 3. Real options in health care. 
3.1 Introduction 
Most current research in health economics fails to acknowledge the option like 
characteristics of many health care related decisions (table 3.1). For instance 
pharmaceutical companies have options to research, clinically test, and develop 
new compounds, hospital budget holders have options to invest in new equipment, 
or increase the prevalence of existing equipment. The decision to exercise such 
options is surrounded by uncertainty, and requires irreversible commitment in 
terrns of time, money, exposure to risk and confronting potentially costly side 
effects. There is also the possibility of deferral, although in some cases this may 
be limited. 
Decision maker Option Type 
Patient 0 Option to purchase private health insurance 0 Invest 
0 Option to comply with prescribed drugs 0 Abandon/continue 
0 Option to defer surgery 0 Defer 
Managers 0 Option to alter hospital capacity, ward size 40 Expand/contract 
GP 0 Option to prescribe medication Invest 
0 Option to switch medication Switch 
Childbearing mother 9 Option to have a caesarean Switch 
0 Option over anaesthetic Switch 
National Institute for 0 Option to approve a drug, procedure, device Invest / switch 
Clinical Excellence 
Pharmaceutical 0 Option to research, market test and release investlexpand/ 
company now compounds contract/abandon 
Policy makers 0 Option to initiate waiting list reduction Invest 
measures, campaign to increase supply of 
nurses 
Clinical trial 0 Option to alter the size of study arms or Switch/extend/ 
manager length of trial contract 
Table 3.1. Options in health care. 
Consider a patient facing surgical amputation for a foot ulcer. The option to 
amputate is owned by the physician in consultation with the patient. Uncertainty 
exists over progression of the untreated ulcer. If self-healing occurs amputation is 
unnecessary, if rapid deterioration occurs amputation is essential to reduce 
spreading. Amputation is not guaranteed to successfully halt ulcer growth leading 
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to additional uncertainty surrounding post-surgery progression. Adverse side 
effects from surgery and the patient's ability to cope with post surgery disabilities 
are further sources of uncertainty. Amputation has health (infection, risks from 
general anaesthetic) and mobility (relearning basic mobility) costs for the 
individual as well as financial costs that provide sources of irreversibility. 
Deferral provides information on spread or rate of healing. In the event that self- 
healing occurs amputation is avoided. If this is not the case immediate surgery 
may have reduced (though perhaps not eliminated) the likelihood of spreading, 
and may have reduced the severity of amputation compared to amputation 
following deferral. The consultant has an option on immediate surgery akin to a 
financial call option. 
Real options are embedded throughout the health care sector. Accounting for 
option like characteristics can have implications for decision making and as a 
result affect the optimal allocation of resources. This chapter examines the three 
defining characteristics and establishes their importance for decision making 
within the health care context. This helps demonstrate the equivalence between 
financial options and real health care options and justifies the application of 
option pricing models to supplement existing economic evaluation methodology. 
Sections 3.2 considers existing decision making techniques. Section 3.3 examines 
the role of uncertainty (section 3.3.1), irreversibility (section 3.3.2) and the ability 
to defer (section 3.3.3) in health care 4ecision-making problems. Section 3.4 
compares the valuation methods underlying classical economic evaluation in 
health care and real options analysis. This section demonstrates that when projects 
are compared like for like the two methodologies give the same assessment of 
value. This means that it is differences in the assumptions governing valuation 
that cause the contra9ting results and conclusions of real option valuation. Section 
3.5 brings these aspects together. 
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3.2 Economic evaluation in health care 
Potentially unlimited demand for health care services, limited supply of resources 
and the lack of market prices as a method of allocation mean that other 
mechanisms are required to distribute health care funds among competing uses. 
Optimal allocation of resources requires comparison of projects either against 
some exogenously stated criterion or against alternative projects. For a single 
project, having assumed a specific perspective, possibly that of society or the 
National Health Service, and identified a study time horizon, economic evaluation 
examines costs and benefits. Analysis by net present value (NPV) allows projects 
of unequal length, or those with high start up costs in contrast to prolonged 
running costs to be compared. A project is implemented if the present value of 
benefits exceeds costs (equation 3.1) or equivalently if NPV exceeds zero 
(equation 3.2). B, and Ct are respectively periodic monetary benefits and costs; r is 
an appropriate discount rate. 
T Bt 
>T Ct (EQN. 3.1) 
T Bt T 
NPV =z-_E 
ct 
>0 (EQN. 3.2) 
, =, (I+r)' =, (I+r)t 
Future costs and benefits however, are rarely certain and the handling of 
uncertainty has attracted much attention in economic evaluation literature (Briggs 
and Gray, 1999). First order uncertainty concerning the probability that a given 
event will occur, such as whether an individual will become infected with a 
contagious disease, or whether a drug is effective, is typically incorporated using 
expected values. A treatment that may be very effective, with benefits of El 50, 
moderately effective, with benefits of E 100, or barely effective with benefits of 
M, with respective probabilities 0.2,0.5, and 0.3, has an expected benefit of f: 92 
[0.2(l50)+0.5(l00)+0.3(40)]. Having obtained expected NPV sensitivity analysis 
is frequently used to assess the effects of changes in base case parameter values 
on the outcome of interest. Two-way sensitivity analysis demonstrates interactions 
by altering inputs simultaneously. 
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Second order uncertainty exists when there is uncertainty not only over the 
outcome of an event but also the probability associated with each potential 
outcome. The probability of developing a disease and costs of factor inputs may 
be subject to second order uncertainty. Probability distributions can be assigned to 
variables using Monte Carlo Simulation (Doubilet et al., 1985) that lead to a 
related distribution surrounding the outcome measure. Expected value for the 
project under consideration will depend on the distributions chosen to represent 
uncertainty, and whether pessimistic, optimistic, expected or median base case 
values are used. 
Methods for handling uncertainty may help the understanding of a project and 
improve the extent to which a model reflects reality but do not necessarily help in 
decision making. Uncertainty may result in an inability to demonstrate statistical 
significance meaning that an analysis fails to show a difference (greater than that 
expected by chance) between two alternatives. In addition there are no guidelines 
for choosing between projects of contrasting risk and return structures such as 
where a greater point estimate is associated with a larger confidence interval that 
contains lower possible outcomes. Claxton (Claxton, 1999) has argued in favour 
of using expected values only for decision making, and reserving estimates of 
uncertainty to help establish priorities for research and the reduction of 
uncertainty. 
Although cost-benefit methodology works in principle, few health-care related 
benefits accrue in monetary form. This has led to different types of economic 
evaluation each with contrasting aims; cost minimisation, cost- 
effectiveness/utility, and net- benefit analyses. Cost minimisation examines 
projects of equivalent outcome selecting the alternative with minimum resource 
use. This is most useful when outcomes are comparable. 
Cost-effectiveness analysis examines costs per unit of a specific outcome measure 
such as the number of adverse outcomes avoided or number of successful 
outcomes. Cost-utility analysis enables broader comparisons to be made. 
Outcomes are described in units such as life years saved, quality adjusted life year 
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gained, and disability years avoided that account for quality as well as quantity of 
life affected by a given treatment. Cost utility calculates the cost per unit of 
outcome and also marginal cost per unit of additional outcome in order to derive 
an incremental cost-effectiveness ratio (ICER) (equation 3.3). Dominated 
alternatives that cost more and provide fewer benefits, and extendedly dominated 
alternatives (dominated by some combination of other actions) are removed from 
consideration. The remaining therapies can be ranked with greater benefit being 
available at increased cost (see (Karlsson and Johannesson, 1996)). 
ICER =. 
Ca - Cb 
_ 
AC 
Ba - Bb AB 
(EQN. 3.3) 
Choosing between the alternatives requires, whether implicitly or explicitly, some 
valuation of society's willingness to pay for an additional unit of health benefit 
(k). Alternatives are selected in order up to and including the regime with the 
largest ICER compatible with this willingness to pay (equation 3.4). Goeree 
(Goeree et at., 1999) uses this evaluation methodology to assess cost effectiveness 
of strategies to treat Gastro-oesophageal reflux disease. Authors have suggested 
obtaining willingness to pay valuations from court payout decisions, previously 
implemented programmes (league tables), and conjoint analysis (O'Brien et al., 
1998; O'Brien and Gaffii, 1996) studies. 
ICERa ý' 
Ca -Cb <A 
Ba -Bb 
(EQN. 3.4) 
Some drawbacks exist within the cost utility framework. Negative, 0 and 
undefined ratios pose potentially large problems. For instance negative ratios may 
result from either a cost or benefit reduction, which have opposing implications 
for decision making. Costs and benefits must be accurately specified within ratios 
as the impact of misplacing a value as the numerator or denominator can be large. 
Cost-benefit analysis values health outcomes in monetary units to calculate net 
benefit. Society's willingness to pay for a health outcome (k) is explicitly used to 
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convert ratios into net benefits's, which can be expressed either in monetary units 
16 (equation 3.5) or in units of effectiveness (equation 3.6) . Programmes are chosen 
in order of incremental net benefit subject to budgetary constraints. 
A (B,, - Bb) - (ca - Cb) ýý 0 
(B,, 
- Bb) - -11 
(Ca 
- CbYý 0 
(EQN. 3.5) 
(EQN. 3.6) 
Advantages of the net benefit approach include avoidance of problems associated 
with ratios, easier calculation of confidence intervals and the ability to compare 
outcomes from a broader spectrum of projects. Outcomes expressed in monetary 
units can be compared to any program where outcomes can similarly be assigned 
monetary value. This is particularly useful for governments responsible for 
decision making over a range of departments including health and education. 
There has been extensive work in recent years to explore the advantages of a net 
benefit approach (Stinnett and Mullahy, 1998) including demonstrating 
equivalence with cost-effectiveness ratios (Phelps and Mushlin, 1991). Advances 
in this field include construction of cost-effectiveness acceptability curves that 
plot the probability of a project being cost-effective for a range of estimates for 
willingness to pay. This in turn has prompted discussion of the consequences of 
making wrong decisions, and the value of acquiring further information. 
Drummond has summarised both methods for economic evaluation and 
implementation of these methods in practice (Drummond et al., 1997; Drummond 
and McGuire, 2001). 
Within the general framework for economic evaluation and decision making in 
health care there is much to debate. This thesis concentrates on aspects relevant to 
real options analysis taking the structure as given 17 . Real options analysis requires 
15 A cost-benefit analysis in the true sense would use the willingness to pay of gainers and losers 
from a project, whilst the net benefit approach typically uses a single societal willingness to pay. 
16 Given as either net monetary benefit or net health benefit. 
17 Some health economics literature uses the terminology 'financial option appraisal' to refer to 
monetary valuation and comparison of treatment alternatives, for instance Batra (Batra, 2001). 
This is not the same as the real options theory presented within this thesis. Similarly Bala (Bala et 
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a monetary valuation of projects and is therefore applied within, and comparable 
to, the net benefit approach. The remainder of this chapter looks at the treatment 
of uncertainty, irreversibility and the ability to defer within traditional methods 
and considers how real options analysis might contribute to the ways in which 
they are handled. 
3.3 The defiyzinz characteristics ofdecision makinz 
3.3.1 Uncertainty 
This section looks at uncertainty in financial markets and contrasts this to 
uncertainty in health care decision making. Smith (Smith, 1983) provides a 
systematic framework from which to examine uncertainty, arguing that three 
questions should be considered; 
(1) What is the source of the uncertainty? 
(2) How is the uncertainty in decision making ultimately resolved? 
(3) Does decision making permit progressive learning to incorporate new 
information that may resolve some of the uncertainty? 
These questions can be developed to provide a complete characterisation and 
understanding of uncertain variables; 
(1) What sources of uncertainty are relevant to the current decision? 
(1.1) Who is affected by uncertainty and thus who's perspective important? 
(2) Can uncertainty be resolved at all? 
(2.1) Is uncertainty resolved naturally overtime? 
(2.2) Must uncertainty be actively resolved? 
(2.3) Are costs incurred in observing new information? 
(2.4) Can the uncertainty ever be fully resolved? 
al., 1999) has referred to a patient's (consumption type) option value from having treatments 
available to them. These benefits were estimated empirically and do not necessarily equate to 
financial option value. 
51 
(3) Can new information be incorporated into the decision model? 
(3.1) Does irreversibility prevent actions being altered to account for new 
infonnation? 
(3.2) Can information be incorporated at some cost? 
(3.3) Can barriers to incorporating information be reduced via further 
decision making and the creation of flexibility? 
In finance an option has a single source of uncertainty (price process, interest rate, 
exchange rate). For a call option current knowledge and ftiture expectations 
governed by an evolutionary price process influence the owner's incentive to 
exercise. As prices evolve they reveal information that is freely available each 
period. Perfect infon-nation is available each period when price is revealed. 
Despite this tomorrows price remains uncertain; uncertainty is never fully 
resolved. Where price history is believed to influence future prices, random walks 
with drift have been used to characterise uncertainty. In this case new information 
is continually being incorporated into the model and used to alter predictions for 
the future. When no drift is used history is judged to be irrelevant, information 
may affect the current exercise decision but is not used to predict future prices. 
While exercise is deferred new information can be costlessly incorporated into the 
decision-making process, following exercise, irreversibility prevents this. 
Whilst answers to the questions for fitiancial options are reasonably 
straightforward this is not necessarily the case for real projects. Health care 
decisions cover a broad range of investment and disinvestment opportunities with 
multiple sources of uncertainty often relevant to a single decision problem 18 . 
Relevant sources include financial based prices (of inputs such as disposables or 
labour) and costing data (capital overheads, bed costs), and physical based disease 
progression (growth of cancer, spread of contagious disease), responses to 
treatment, and risk reductions. Projects whose value is sensitive to price variables 
are most likely to reflect simple financial options. Where multiple sources are 
present Monte Carlo simulation can be used to combine uncertainties as inputs 
18 Options with multiple sources of uncertainty are termed Rainbow options 
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into a single output such as net benefit. Copeland and Antikarov (Copeland and 
Antikarov, 2001) demonstrate the use of Monte Carlo simulation within real 
options analysis. 
Prices and costs in the real sector behave much like prices in the financial sector 
evolving over time with new information widely available. Disease incidence, 
prevalence and status within an individual also evolve through time with current 
values observable and future values unknown. By contrast however, costs may be 
incurred when observing information relevant to health care decisions. Expensive 
patient tests, population surveys, and studies of resource use may be required to 
observe detailed information. Other sources of uncertainty such as safety, efficacy 
and cost-effectiveness may require specific actions such as clinical trials to 
improve information. 
In most instances as with financial price variation, uncertainty is never fully 
resolved, although real sources of uncertainty may be correlated through time. A 
patient who has deteriorated continuously throughout the previous 10 periods is 
increasingly less likely to begin recovery in the following period. For coma 
patients there is a strong link between time spent in a coma and the likelihood and 
degree of recovery (Council on Scientific affairs and council on Ethical and 
judicial affairs, 1990). 
Information arrival can be incorporated into real options models in many ways. A 
stochastic Markov process such as Brownian motion might be relevant when 
changes in a variable are continuous, independent and normally distributed with 
mean zero and variance increasing linearly with the time interval. When the lower 
limit of the variable is zero, such as with prices or health status, using the 
logarithm (as in the Black and Scholes formula) may be appropriate. When 
history is believed important, a more generalised Wiener process with non-zero 
drift and alternative volatility parameter may be suitable. A Poisson specification 
is appropriate when information is expected to arrive at discrete, though uncertain 
points in time. Modelling information arrival will depend on what is known, or 
believed to be true of the evolutionary process. 
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Health care decisions can involve irreversibility that limits the ability to 
incorporate new information. Altering plans in response to information can be 
costly and some actions themselves cannot be reversed (such as amputation) 
rendering additional information, when available, effectively worthless. 
Responses to uncertainty and information evolution therefore depend on the 
degree of irreversibility characterising a decision. 
3.3.2 Irreversibility 
While irreversibility is inherent in exercise of a financial option, continuous 
deferral maintains a position of flexibility that allows new information to 
influence decision making. Once exercise occurs it cannot be reversed, even if 
poorer than anticipated outcomes result. The ability or inability to improve good, 
and mitigate poor outcomes can be used to define the extent of irreversibility. The 
less costly are such actions the lower the degree of irreversibility. In financial 
markets further shares, options and futures might be bought and sold in an attempt 
to mitigate losses. 
Several sources of irreversibility affect the attractiveness of real projects 
(Gershbach, 1997). Investment under uncertainty literature focuses on an inability 
to recuperate some or all sunk costs (Dixit and Pindyck, 1994), and the degree of 
difficulty in restoring a previous state. altered by some decision has also been 
discussed (Fanai and Bum, 1997). Manipulation of anticipated and unanticipated 
outcomes (Fanai and Bum, 1997) and the associated cost (Zhao and Zilberman, 
1999) is emphasised in literature that considers irreversibility as a selection 
criterion for projects. Actions in health care can fall into all three categories. 
Sunk costs are incurred in capital investments, patient surgery, and research and 
development but are particularly relevant to infrastructure decisions including 
development of a new hospital or ward. This form of irreversibility is most 
significant when benefits do not accrue until the entire investment is complete, 
such as following surgery. This type of irreversibility is commonly encountered. 
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Having been initiated most project strategies can be altered (at some cost) to 
influence outcomes. Unanticipated changes in demand could prompt disposal or 
purchase of technologies, unpopular policy decisions can be altered at some 
political cost and altering a patient's drug regime may induce withdrawal effects 
or new side effects that then impose costs. These strategy alteration costs create 
inertia against changing the initial decision policy, even when the original plan 
reveals lower than expected rates of return. 
Finally some actions themselves are physically irreversible. This kind of 
irreversibility is most prominent in environmental sectors (Viscusi, 1988) where, 
for example, destruction of the ozone layer cannot be reversed. Within health care 
the decision to terminate care for a patient whose life is preserved solely through 
life support technology is irreversible. This source of irreversibility also relates to 
aids sufferers where the receipt of current treatment regimes diminishes the 
benefits or in some cases precludes the use of future technologies with greater 
potential to improve well-being. Decisions to surgically amputate also face 
irreversibility. This form of irreversibility can also exist'when a decision is 
deferred. For instance deferring treatment may allow a disease to have some 
irreversible impact and deferring approval of an efficacious treatment may permit 
existing patients to be managed suboptimally. 
The degree of irreversibility encountered in a health related decision increases 
with sunk costs, strategy alteration costs and the inability to physically reverse 
actions. Any scrap value gained when technologies are decommissioned or 
projects abandoned, reduces irreversibility. Despite these clear sources of 
irreversibility there is little explicit discussion of irreversibility in the majority of 
health economic evaluations. Real options techniques can contribute to existing 
methodology by encouraging explicit discussion of irreversibility as well as 
providing a means of analysis. Basic real options models assume complete 
irreversibility in the sense that projects have upfront costs that cannot be 
recuperated and no ability to reverse is included. This is appropriate for modelling 
options such as the removal of life support. Exploring and modelling future 
options created or by the exercise decision incorporates degrees of irreversibility. 
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3.3.3 Deferral 
When a decision is surrounded by uncertainty, and there is some degree of 
irreversibility, deferral becomes a relevant alternative to immediate action. In 
practice existing decision-making techniques employ a now or never framework; 
projects with positive NPV are accepted, and rejected projects are not necessarily 
reconsidered in light of new information. Real options analysis provides a 
framework within which deferral can be assessed and compared with immediate 
action. The similarities between deferral of financial and real projects, and 
incorporating deferral are considered here. 
Discussion of the ability to defer must encompass the length of deferral (and the 
extent to which this is understood / known by relevant parties), information 
potentially available from deferral, and the costs associated with observing this 
information. The maximum deferral period is stated explicitly for financial 
options by the exercise date and is fixed at the time of purchase. For American 
options exercise may occur any time prior to the exercise date so the remaining 
deferral period is always known with certainty. Information in the form of prices 
are revealed freely each period and can be incorporated into decision making until 
such time as exercise occurs. 
The deferral period for real investments can take a number of forms including 
indefinite postponement, limited periodic postponement (waiting x periods), or 
waiting subject to additional analysis being completed or specific information 
becoming available. The option to remove life support may be deferred almost 
indefinitely whilst a patient awaiting transplant surgery faces a limited deferral 
period. Deferral might be limited by factors such as budget constraints. Funding 
for a project may only be guaranteed for a year, or leasing arrangements may 
constrict time available. The end of an NHS financial year signifies an exercise 
date. Negative attitudes to deferral of health improvement measures, expressed for 
instance as complaints about waiting lists may generate shorter exercise dates, 
despite longer deferral being potentially beneficial for some patients. 
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Health care options are likely to have stochastic exercise dates. For instance a 
patient might receive watchful waiting; a regime whereby some (usually invasive) 
treatment is deferred pending information on disease status. Watchful waiting is 
only relevant either before the disease enters some irreversible state (or has some 
irreversible impact), or the patient becomes unfit for surgery (or is believed to no 
longer benefit), or the patient dies from alternative causes. Given differing disease 
progression both within and between individuals, the ability to defer will change 
over time for a given patient, and vary between patients. Contrasting beliefs about 
disease progression may even create different perceptions of the ability to defer 
for a given patient at a given point in time. 
Although deferring financial options reveals freely observable price infon-nation 
deferral itself can have a cost. An investor will always defer exercise of a non- 
dividend paying stock because information is available at no cost. When 
dividends are payable deferring exercise delays receipt of dividend payments 
imposing a cost on deferral. The investor must weigh the relative costs and 
benefits from deferral to make a decision. 
Multiple sources of uncertainty underlying real options means deferral can reveal 
broader types of information. Prices (drugs, devices), demand and supply 
. conditions, disease prevalence and incidence, and individual disease status might 
all be monitored. Information relevant to health care decision making is unlikely 
to be freely observable. For patient-leyel decisions monitoring disease progression 
may involve costly tests, such as magnetic resonance imaging, that provide an 
incentive for early exercise. Costs incurred in deferral and observing information 
must be weighed against the benefits (delay investment cost, improved 
information) in order to assess the desirability of deferring action. When the cost 
of deferral exceeds the benefits exercise is optimal. 
Deferral is introduced into decision tree structures by including a waiting 
alternative branch at the trunk of the tree. Cost-effectiveness of deferral is 
calculated by comparing discounted expected costs and benefits of deferral 
(option value) to those of immediate action (net benefit), (figure 3.1). 
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1-4 
--LN! Bý] 
Deferred Ac-, 
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Option Value 1.4 1 ROA I 
Figure 3.1. Comparing immediate action and deferred action. 
When deferral is introduced there must exist some way for information to improve 
during the period of waiting; otherwise there is no incentive to defer. This is 
achieved by modelling events such as price changes or disease progression 
following the decision to defer and prior to the following decision node. In this 
way revisions are made to the available information set and can influence the 
decision of interest. Real options analysis therefore allows decisions to be 
conditioned not only on today's information but also anticipation of tomorrow's 
infonnation and infonnation that may be revealed in every future period for which 
deferral is a possibility. 
3.4 Comparison of valuation methods 
Whilst real options analysis makes explicit the treatment of uncertainty, 
irreversibility and the ability to defer within economic evaluation, the principles 
underlying valuation remain consistent with those of traditional methodology. As 
such, it is differences in the way the three factors are perceived and modelled that 
generate conflicting results and conclusions. In the very unlikely case that a real 
options approach and traditional economic evaluation lead a project to be 
compared like for like, identical assessments of value are obtained. Chapter 2 
section 1.1 illustrated how net present value techniques can be used to estimate 
option value when deferral is modelled fully. This example assumed a very simple 
structure for uncertainty. When uncertainty, and therefore risk, is dealt with 
appropriately in net present value the two methods again give consistent results. 
This can be seen through the use of a simple numerical example. 
Section 1.2 in chapter 2 valued an option whose payoffs were related to the price 
of a stock. Uncertainty was modcllcd using a binomial structure that allowed 
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future payoffs to rise or fall with respective probabilities q=0.4 and (I -q)=0.6. 
Exercise of the option was assumed irreversible and there was an ability to defer 
exercise for one period. Figures 3.2 and 3.3 re-illustrate this problem, where C is 
the value of the option and S is the value of the underlying stock. 
0.4 S+-120 
S=90 
< 
0.6 Sý80 
Figure 3.2. Hypothetical asset underlying a call option 
<q 
I-q 
C'- max (S-'-103,0) = 17 
Cý max(S--103,0) =0 
Figure 3.3. Hypothetical call option 
Suppose this option relates to a decision faced by the National Institute for 
Clinical Excellence who have an option to approve a drug for treatment of 
Alzheimers disease. Real options analysis suggests that a portfolio is created that 
combines the option and the stock such that the payoffs from the portfolio are 
equal irrespective of whether stock price and option value increase or decrease 
over time-This ýreviously enabled current option price to be estimated using 
equations 2.6 and 2.7. 
(I+r)S-S- 1.05*90-80 
P= 
ST-S- 
= 120-80 = 
0.3625 
PC+ +(I-p)C- (0.3625*17)+(0.6375*0) I- == r% RAQn 
I+r 1.05 
These equations valued the project using a risk-neutral probability that a positive 
outcome would result, and so discounted payoffs at the risk-free rate establishing 
option value of E5.87. Conventional valuation techniques would have valued the 
same project using the actual probability of a positive outcome and discounted at 
a risk-adjusted rate. This reflects the implicit risk that the decision maker must 
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face and so will be greater than the risk-free rate. The risk-adjusted rate of return 
(rA) for the option can be calculated by estimating the return on a portfolio with an 
equivalent risk and return structure. A portfolio can be created using a risk free 
investment (B) and N shares of the underlying stock to recreate the payoffs of the 
option (NS-B). The current and expected future payoff from this portfolio, and the 
actual probability of a positive event occurring, can be combined to estimate the 
expected return on the portfolio and so the return on the option (equation 3.7)19. 
I+r A q(NS+-B(I+r))+((I-q)(NS--B(I+r))) 
(NS-B) 
I+r A 
(0.4*(0.425*120-1.05*32.38))+(0.6*(0.425*80-1.05*32.38)) 
= 1.159 (0.425*90)-32.38 
(EQN. 3.7) 
Calculating option value using actual probabilities and a risk-adjusted rate gives 
an identical value for the option: 
qC++(I-q)C- (0.4*17)+(0.6*0) c=A=5.8690 
I+r 1.159 
Net present value methods value a risky project and so require a risk-adjusted 
discount rate. Different aspects of the same project can face contrasting risks, 
necessitating multiple discount rates within a single project. If the appropriate 
risk-adjusted rates of return were known a priori the two valuation methods would 
have resulted in identical assessments of value for the option faced by NICE. 
Real options analysis values a riskless project by using the principle of hedging to 
ensure that the payoffs from holding a portfolio (that incorporates the option) are 
the same in any future state of the world. When valuing such a project the risk- 
neutral discount rate is appropriate. If all risks within a project are hedged in this 
way the risk-neutral discount rate can be used to discount costs and outcomes 
19 Calculation of the number of shares required (N) and amount of risk free borrowing (B) arc 
given in chapter 2 section 1.2. 
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relevant to the entire project. This also allows the project to be valued without 
appeal to subjective assessments of, and preferences towards, risk. 
In order to create the portfolio used to replicate option payoffs and generate a risk- 
free return some other investment, portfolio of investments or financial instrument 
must be identified that offsets the risk and return structure of the investment 
opportunity of interest. Although seemingly difficult this task should be put into 
context; within a large public health care system where a variety of investment 
projects at both patient and system level are undertaken each year each with 
contrasting risk exposures, there exist vast possibilities for creating portfolios. 
Booth for instance (Booth and Walsh, 2001) has examined hedging payoffs from 
rental income in the housing market. Perhaps a greater issue is that real options 
analysis requires an efficient market for risk (to allow hedging). However, for net 
present value analysis to be carried out accurately the same assumption is required 
to enable calculation of risk-adjusted rates of return. 
This section has illustrated some important aspects of real option valuation 
relating to the treatment of risk. Whilst these issues are very relevant to the 
practice of economic evaluation, the focus of this thesis lies elsewhere, in the 
approach to valuation that a real options analysis encourages. This includes the 
approach to recognising, understanding and appreciating the importance of 
uncertainty, irreversibility and the ability to defer, and explicit modelling of these 
factors. 
The example presented in this section has demonstrated that when projects are 
compared like for like option pricing and traditional techniques provide the same 
assessment of value for an investment opportunity. Any discrepancy in value 
therefore reflects differences in the way the project is described and modelled 
under the two approaches. Real options analysis adopts a dynamic structure for 
uncertainty, explicitly identifies types and degrees of irreversibility, and 
rigorously analyses deferral. It is these attitudes towards some of the key drivers 
of value that generate differences in valuations obtained within a real options 
framework and a conventional economic evaluation. 
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The case studies presented within the remainder of this thesis explore situations 
where options analysis might be applied within economic evaluation of health 
related decisions and show that some very different conclusions can be reached. 
3.5 Conclusions 
Many economic agents operating within the field of health care face choices that 
are akin to options. Since such decisions share the defining characteristics of 
financial options; uncertainty, irreversibility, and an ability to defer, it seems 
appropriate to use financial option pricing techniques as a valuation method. Real 
options analysis can be applied within the existing net benefit framework. The 
contrasting ways in which real options analysis perceives and models uncertainty, 
irreversibility and the ability to defer generate differences between the results and 
conclusions of the two approaches. 
The challenge facing health economists is to identify real options in health care; 
an arena where formal option contracts do not exist. Having rccognised problems 
whose analysis may be improved through explicit consideration of the three 
underlying factors a ffirther challenge is to adapt existing option pricing models to 
account for peculiarities defining the health related decisions. The remainder of 
this thesis assesses four potential applications; the option to defer immediate 
therapeutic treatment, the decision to defer removal of life support, the option to 
approve technologies and treatments for use on the NHS, and the collection of 
trial data to improve information. 
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Chapter 4. Should we wait and see? The real 
options approach to watchful waiting. 
4.1 Introduction 
Within clinical areas where disease progression is slow and conventional therapies 
do not dramatically extend either quantity or quality of life, watchful waiting may 
be a relevant treatment alternative. Watchful waiting describes a patient 
management strategy in which immediate curative treatment is not given. Instead 
the patient undergoes a period of close observation in which periodic check ups 
permit illness progression to be monitored. Given this ability to defer, if 
uncertainty and irreversibility also characterise the decision to begin treatment, 
real options analysis may justifiably be used to assess such patient management 
strategies. 
This chapter considers the methodological and practical suitability of applying 
real options analysis to a decision-making problem in which deferral is already 
considered a relevant alternative. Having discussed watchful waiting in section 2, 
section 3 explores how deferral is currently incorporated into decision making and 
the contribution of real options analysis. Section 4 sets out watchful waiting as an 
coption to treat', examining the characteristics of the decision problem and 
parameters required for valuation. Section 5 provides a hypothetical example 
assessing watchful waiting as a treatment alternative for patients with abdominal 
aortic aneurysms, and explores the implications and consequences of employing 
real options analysis. Concluding remarks and broader implications are the subject 
of section 6. 
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4.2 Matchfid waitincr as a treatment alternative 
During watchful waiting2O patients undergo assessments that provide information 
valuable for the final treatment decision. Watchful waiting is an active strategy 
implying a conditional treatment decision, not a policy in which an ailment is left 
to deteriorate unchecked, or where a placebo therapy is given, and should be 
distinguished from time spent on a waiting list. Uncertainty over outcome, 
associated risks (complications, infections, side effects), and high financial costs 
of immediate treatment all provide motivations for deferral. Deferring allows data 
on population, sub-group, and individual cost-effectiveness to be collected from 
on-going trials, or monitoring disease progression. These sources of information 
contribute to making the decision of when to commence immediate treatment for 
a defined (group of) patient(s). When deferral reveals that treatment is 
unnecessary, perhaps due to self-healing, the potential adverse effects of 
immediate action are avoided. 
The growing quantity of studies in this area, including economic evaluations, 
testifies to the increasing recognition that deferring aggressive therapy can be an 
appropriate, and in some cases, cost-effective treatment alternative (Chodak, 
1994; Steinberg et al., 1998). To assess deferral Johansson (Johansson, 1994) 
followed 233 patients with early stage prostate cancer between March 1977 and 
February 1984. Patients younger than 75 were randomised to deferred treatment 
or radiation therapy. Risk of progression and death was found to be high in grade 
III compared to grades 11 and I tumours, suggesting watchful waiting may be most 
appropriate for patients in the latter groups. 
More recently Warner and Whitmore (Warner J and Whitmore Jnr W F, 1994) 
analysed 75 of 4000 prostatic cancer registrations who were managed expectantly 
for at least one year following diagnosis. In the majority of patients, local 
progression preceded distant metastasis, leading the authors to conclude that 
"short periods of observation may be permissible if such prove useful in 
estimating tumour growth rates". 
20 Also referred to as intelligent watchfiil waiting (Horowitz, 2000) and expectant management 
(Zhao and Ming, 1998). 
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Decision making for patients with prostatic cancer is not alone in drawing 
attention to the deferral alternative. Early therapy versus watchful waiting has 
previously been assessed for glue ear (Maw et al., 1999; Bennett et al., 1998), 
small abdominal aortic aneurysms (Katz and Cronenwett, 1994) (Valentine et al., 
2000), mild chronic hepatitis C (Wong and Koff, 2000), solitary pulmonary 
nodules (Dictlein M. et al., 2000), and acute bacterial rhinosinusitus (American 
Academy of Family Physicians, 2001). Conclusions vary according to illness, 
severity, patient age, methods of observation used in the waiting period, and 
compliance (Wong and Koff, 2000). Deferral has also been considered for 
hormone therapy (Anderson, 198 1). 
Whynes (Whynes, 1995) developed a framework for identifying optimal times of 
transfer between watchful waiting programmes and intervention. This study looks 
specifically at watchful waiting that terminates due to spontaneous medical 
improvement rather than situations in which medical deterioration provokes 
aggressive therapy. Structuring the decision to swap treatments as a cost 
minimisation problem, Whynes identifies that increases in the probability of 
recurrence after auto-resolution, the probability of remaining unresolved, and the 
cost of a watchful waiting programme relative to immediate therapy, reduce 
optimal times of transfer, effectively curtailing the deferral period. 
When assessing cost-effectiveness of watchful waiting, current decision 
technologies have not generally acknowledged that deferring preserves the option 
to commence immediate treatment in future should the disease begin to 
deteriorate significantly. In failing to account for this source of value, existing 
decision criterion may arrive at mistaken conclusions with regards the 
attractiveness of watchful waiting. The following section considers deferral in 
decision making. 
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4.3 Incornoratine, deferral into decision makin 
When diseases progress quickly patients may suffer detrimental long-term effects 
or become unfit for surgery making deferral an inappropriate course of action. The 
decision maker must evaluate whether watchful waiting is a cost-effective 
alternative, and when immediate treatment should start for a given individual (or 
group of individuals) with identified risk factors. Mechanisms used to assess 
deferral in decision making are therefore important. 
Wong et al (Wong and Koff, 2000) considered cost-effectiveness of watchful 
waiting versus immediate therapy for mild chronic hepatitis C. Using clinical trial 
data and data from published sources the authors considered the relative merits 
over a twenty-year period of biopsy every three years compared to immediate 
antiviral therapy. Those patients randomised to watchful waiting were 
subsequently treated with combination therapy (ribavirin and interferon) for 24 
weeks if biopsy revealed cirrhosis or moderate hepatitis. Markov simulation was 
used to estimate prognosis beyond the capacity of the trial. With a 5% discount 
rate for costs and survival, the incremental cost-effectiveness ratio for immediate 
therapy was $13,500, and had extended dominance over watchful waiting. In this 
instance high repeated costs ($1,033) of observing infian-flation (biopsy detecting 
the clinical state of the liver), and the inability of this therapy to prevent future 
hepatitis C, meant deferral was not optimal for patients with baseline 
characteristics. 
The waiting alternative has been evaluated using decision tree analysis. 
Introducing deferral requires including a branch in addition to branches 
representing immediate treatments (figure 4.1). When watchful waiting is chosen 
observed disease progression can influence the treatment decision. Costs and 
benefits associated with watchful waiting are likely to differ from those associated 
with immediate therapy causing expected cost-effectiveness of the strategies to 
differ. 
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Intrinsic 
value 
Spectrum of 
Immediate-4, outcomes 
treatment following 
treatment 
Rapid disease 
progression Immediate 
Watchful 
Slow progression treatment 
waiting 
No progression 
Option Spontaneous Watchful AO 
value improvement waiting 
Figure 4.1. Decision tree for a single immediate action that can be implemented 
now or deferred. 
Dietlein et al (Dietlein M. et al., 2000) used this style of analysis to assess cost- 
effectiveness of varying treatments for management of solitary pulmonary 
nodules. Watchful waiting was compared to transthoracic needle biopsy, 
exploratory surgery, and positron emission tomography. When 100% nodule 
growth was observed by computer tomography (CT) during an observation 
period, the patient was referred for immediate exploratory surgery. Observation 
continued for two years with regular CT checks. Mean values for variables used in 
the analysis were obtained from medical literature. At baseline values the 
alternatives involving immediate action lead to improved health outcomes at a 
higher cost. When the probability of malignancy was small (0.1-0.7) even the 
most cost-effective immediate therapy had an ICER that exceeded the stated 
willingness to pay for a life year saved (50 000 EUR). For this range of 
probabilities watchful waiting was declared the preferred strategy. 
Despite the attractiveness of this intuitive and logical approach some drawbacks 
exist. Williams (Williams, 1997) illustrates both the beauty and limitations of 
decision trees through describing a reasonably complex technology adoption 
problem. Although not a watchful waiting study Williams' work demonstrates 
some of the generic problems associated with modelling deferral. 
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When multiple treatments are available, each of which might be deferred, the 
complexity far exceeds that of the stylised example in figure 4.1. A single deferral 
alternative can create a continuum of outcomes from evolving variables. 
Following initial deferral, immediate action or further deferral may occur; the 
basic structure of the decision tree is repeated. Each opportunity to defer causes a 
geometric increase in the number of branches, whether occurring from different 
deferred treatments or multiple opportunities to defer the same treatment. This 
complexity is immediately apparent in Williams' work. Williams' 'buy now' tree 
contains 55 possible outcomes. Introducing deferral in each of the four periods 
generates an additional 90 outcomes. 
When a decision problem encompasses numerous uncertain variables such as 
disease progression, fitness to treat, and costs of treatment, deferral may reveal 
information on each. This complexity affects the transparency of decision models 
complicating both analysis and interpretation of results. Such 'bushyness' has 
been reduced using state transition models, such as Markov modelling, to 
summarise uncertain variables. These models use transition probabilities to 
determine movements between disease states over consecutive time cycles. 
Although useful in simulating events that recur over time, and so potentially 
appropriate for considering deferral, Markov modelling is not commonly used for 
this purpose. 
In Williams' hypothetical example the initial problem description is relatively 
simple with no uncertainty in demand or benefit to patients, and only four periods. 
Despite the simplifying assumptions there is sufficient complexity to prompt 
questions concerning what is leamt over time and the motivation for deferral. 
Answers are not apparent in Williams' work yet these are essential questions that 
must be understood and answered if deferral analysis is to provide useful 
conclusions. Through explicitly considering deferral and its interaction with 
uncertainty and irreversibility, real options analysis provokes answers to questions 
such as these. It is predominantly evolution of information on disease progression, 
the uncertainty surrounding treatment, and potential irreversibility of treatment 
side-effects that makes watchful waiting a viable treatment alternative. 
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Finally, existing methodology commonly models a current (static) perception of 
uncertainty defined by a probability distribution over outcomes. Real options 
analysis considers of how this perception changes during deferral. For instance, 
the mean of a distribution of interest, such as growth rate of an aneurysm may 
increase through time2l. In terms of decision trees, uncertain events have a family 
of distributions; each member represents uncertainty in a given time period. Real 
options analysis thereby models a dynamic perception of uncertainty. Despite this 
apparent added complexity, real options analysis sits well within the decision tree 
framework. Immediate action is assessed according to standard techniques and 
summarised by expected net benefit. Deferral is assessed using real options 
analysis that estimates option value. The two valuations are compared and the 
action with greatest value is the preferred strategy. 
4.4 Matchfid waiting as an option on treatment 
4.4.1 The real optionsproblem 
Deferring the decision to actively treat a patient is akin to an American call 
option; exercise can be deferred for some period of time and involves paying 
some 'cost' in return for a stream of benefits. Demonstrating the analogy between 
financial options and the option to treat requires consideration of the 
characteristics defining the two decision problems, and parameters necessary for 
valuation. Here we concentrate on the option to defer treatment for abdominal 
aortic aneurysms (AAA's). 
Optimal treatment for patients presenting with AAA's involves surgical repair of 
those likely to rupture and shorten life expectancy, whilst avoiding unnecessary 
surgery in patients who would otherwise die of unrelated causes Katz (Katz et al., 
1992). Currently, for aneurysms smaller than 5cm the risk of rupture is relatively 
low causing some debate about whether immediate elective repair is necessary 
(Katz and Cronenwett, 1994). This fuels arguments in favour of watchftil waiting. 
21 Basic real options models assume a constant variance, although changing variance may be 
incorporated using numerical methods. 
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Clinicians must decide on a treatment management strategy for presenting patients 
who can be treated immediately or be managed with watchful waiting (figure 4.2). 
Survive 
surgery and 
Immediate after care 
elective -40 
repair Do not survive 
- surgery 
- Growth Immediate 
elective 
Watchful repair 
waiting No growth -11 
program 
Watchful 
Reduction-, - waiting 
program 
Figure 4.2. Management of a patient presenting with an abdominal aortic 
aneurysm. 
To receive the benefits of deferred stock purchase decision-making bodies such as 
individuals or firms, must first purchase an option. Real options such as the option 
to defer treatment are rarely purchased on a market, instead they are usually 
C onferred to patients and clinicians through previous actions. In the case of 
watchful waiting the treatment option may be conferred via early screening, which 
identifies potential problems before they become self-evident. Although the 
methods of obtaining financial and real options differ, once owned, the 
similarities become apparent (table 4.1). 
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Financial Real option to defer immediate treatment of 
option abdominal aortic aneurysms 
Decision maker Owner of option Clinician in conjunction with patient and family 
Source of option Purchased Conferred endogenously through previous investment 
in screening technology and surgical development, 
and exogenously via gradual disease progression and 
early presentation by individual 
Dominant source of Stock price Underlying disease progression; rate of growth in 
uncertainty aneurysm 
Information gained Changesin Absolute growth / shrinkage, and rate of change 
by deferral stock price 
Source of Exercise price Cost of surgical reparation, associated risks and their 
irreversibility costs. Patient becoming unfit for surgery 
Ability to defer Limited by Will vary between diseases and patients. Limited by 
exercise date aneurysm growth and factors rendering the patient 
unfit for surgery. Influenced by treatments available. 
Table 4.1. Characteristics defining the option to defer treatment for abdominal 
aortic aneurysms. 
A financial investor must decide on what date, prior to the option expiring, 
exercise is optimal. Waiting allows information gathering on stock price 
uncertainty but also defers the benefits of owning stock, such as capital 
appreciation and dividends. The clinician must decide when commencing surgical 
repair is optimal. Immediate action is more costly than deferral and brings risk of 
operative mortality (primarily cardiac risk). Uncertainty over aneurysm growth 
generates uncertainty over whether immediate surgery is always necessary. 
Waiting allows information gathering on severity of disease but defers potential 
benefits of immediate treatment including improved health status. Deferral may 
be cheaper, but is associated with risk of rupture and death both of which are 
positively related to aneurysm size and growth rate. Some patients may become 
medically unfit for surgery during a deferral period. 
The three defining characteristics of financial options are present in the option to 
defer treatment. The ability to defer is inherent to the problem, and as with a 
financial option, is limited. The exercise date cannot, however, be agreed when 
the decision problem is first considered; the point at which an option to defer 
treatment no longer exists is stochastic, influenced by factors such as the growth 
rate of the aneurysm and the patient becoming unfit for surgery. 
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Financial and health care options both have sources of uncertainty. On deferring 
exercise of a financial option, the price of the underlying asset is observed. Real 
options usually have multiple sources of uncertainty. For watchful waiting, in 
addition to uncertainty over aneurysm growth, uncertainty may exist over a 
patient's ability to respond, fight back, and cope, in addition to unrelated health 
problems occurring. These sources of uncertainty combine to create a state of 
well-being that evolves over time. Clinicians observe information on disease 
progression and well-being each period. Disease specific measures such as growth 
rate of a tumour or aneurysm, and prostate specific antigen levels, or generic 
scales such as blood pressure, self-rated quality of life or expected remaining 
QALYs, may be used to measure well-being. 
Despite knowing historical price variation, the random walk evolution of stock 
prices means that financiers can never predict future prices. Although this is true 
in essence for real options more emphasis is usually placed on historical 
observations as current and historic values are more likely to be predictors. With 
health care options, particularly deferred treatment, the passing of time increases 
available information upon which a decision to exercise is conditioned. A 
clinician may observe a relatively large aneurysm that would normally undergo 
immediate repair. Following a period of deferral, the absence of diameter growth 
may alter the clinician's recommendation. Observed rapid growth of a small 
aneurysm may likewise alter a prior opinion to defer treatment. 
Financial options are irreversible in the sense that exercise involves paying the 
exercise price. Watchful waiting defers some treatment, usually surgery, which 
involves extensive sunk costs in the fon-n of bed costs, surgeon and anaesthetist 
costs, and the cost of disposables. Immediate action also involves physical sources 
of irreversibility such as side effects of surgery. Deferral of treatment for localised 
prostate cancers for instance, defers the possible irreversible effects of impotence 
and incontinence, not to mention risk of infection, or worse; death. Deferring 
amputation likewise provides an example of irreversibility. Where the deferred 
treatment is medical rather than surgical commencing some drug regimes may 
create irreversibility due to withdrawal effects. Unlike the financial case deferral 
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can involve irreversibilities for health care related options. When watchful waiting 
leads the patient to be come unfit for surgery, deferral has had irreversible effects. 
While similarities between financial options and the option to defer treatment 
exist, applying option-pricing techniques to health care requires identifying 
variables that relate to the parameters used in financial fonnulae (table 4.2). The 
parameters actually used in an application will depend on the pricing method 
chosen but are closely related to those given. 
Parameter Financial Real option to defer immediate treatment 
option of abdominal aortic aneurysms 
Current value of source Spot price (S) Current estimated expected benefit from 
of uncertainty surgical repair 
Estimate of uncertainty Variance in Uncertainty surrounding expected benefit of 
stock value (cy') surgical repair over time 
Cost of exercising option Exercise price Cost of surgical repair (anaesthetics, 
M antiseptics, disposables, bed costs, surgeon 
costs). Will remain fairly constant over life of 
option 
Date before which Exercise date Date when aneurysm ruptures or patient 
option must be exercised (T) becomes unfit for surgical repair 
Cost associated with Dividend (5) Costs of tests used to gather information. 
deferral Uncertainty, worry and pain for the patient 
Table 4.2. Parameters used in financial option pricing techniques and their 
counterparts for the option to defer treatment for abdominal aortic aneurysms. 
Stock price provides the source of uncertainty underlying the majority of financial 
options. Spot price and associated volatility give the relevant information for 
pricing fon-nulae. Shares have value, prices, because they confer a future stream of 
benefits. Price therefore effectively represents the current value of these streams. 
The analogy in health care is the present value of a project that, once initiated, 
confers a stream of cash flows. For the option to defer treatment, the present 
benefit from surgical repair and associated volatility through time (as disease 
progresses) must be estimated. 
The sunk cost of surgical repair represents the cost of exercising the treatment 
option, and the exercise date is found by estimating the date when the aneurysm 
will rupture or the patient will become otherwise unfit for surgery. 
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Dividends are paid to stockholders but are not received by holders of options. 
Deferring exercise of a call option delays receipt of dividends creating an implicit 
cost to deferral. Deferring exercise of a treatment option can involve more explicit 
costs; specifically the cost of observing patient infon-nation. Observing aneurysm 
progression involves detailed tests and scans such as ultrasound with significant 
costs. These costs are assumed absent in financial models where prices can be 
observed freely, but can be incorporated into option pricing as implicit dividends. 
The similarities in structure between holding and exercising financial and health 
options and the ability to approximate financial variables suggests that health care 
decision problems such as the deferred treatment option are amenable to real 
options analysis. The following section considers a hypothetical numerical 
example. 
4.4.2 Numerical example 
Clinicians must choose management strategies for patients who present with an 
aneurysm and are suitable for either immediate elective repair or watchful 
waiting. The decision to beginning immediate treatment is conditional upon the 
clinicians information on aneurysm size and expected growth, and given by 
results from scans, and observations taken during deferral. 
An aneurysm is assumed to be able to grow, remain constant, or reduce in size 
with the same probabilities and to the same extent during each deferral period. 
A patient who improves during the first period and deteriorates the following 
period faces the same outcome as if they remained unchanged for two consecutive 
periods. The patient is monitored at regular intervals, with ultrasound or computed 
tomography scanning used to supply information on aneurysm size and growth 
rate. Immediate surgical repair is carried out when the diameter of the aneurysm 
reaches some threshold size 22 . 
22 Katz 1994 uses 6 monthly observations and a treatment triggering threshold of 5cm. 
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A model based on real world data would estimate the health benefit of immediate 
surgery using knowledge of the cur-rent si2e and growth of the aneurysm, risk of 
ruPture, risk of becoming unfit for surgery, and surgical risk. Monte Carlo 
simulation could be used to combine these sources of uncertainty into a measure 
of well-being, and convert well-being into net benefit using society's willingness 
to pay for a unit of health outcome (figure 4.3). Since the sources of uncertainty 
evolve, monetary benefit also evolves revealing information through time, just as 
a price variable. For the purposes of the example expected benefit is assumed to 
be $20,000. 
Sources of uncertaitýnýty 
Period I 
r, ý, Period 2 
WeU-being from surgery 
Aneurysm size Period 3 
Risk of rupture 
Surgical risk 
Well being 
Willingness to pay 
I Monetary benefit I 
Monetary 
benefit t 
surge 
Figure 4.3. Combining sources of uncertainty to derive evolving net benefit from 
surgery. 
Monetary benefit is assumed to follow a trinomial distribution dominated by the 
trinomial structure of aneurysm growth in each period. Joining trinomial periods 
in a repetitive, expanding manner creates a lattice representing progress of the 
patient over successive periods. As biomedical state is truly a continuous variable 
parameters are chosen to approximate a continuous time diffusion process. 
Following Trigeorgis (Trigeorgis, 1991) the total deferral period (T) is divided 
into N intervals of length dt such that T=N*dt. As dt tends to zero the trinomial 
converges to a continuous distribution. Trigeorgis demonstrated estimation of 
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binomial state and time variables to guarantee stability of the discrete time 
approximation. 
Immediate treatment is assumed to be deferrable for up to one year (T=1 )23 . The 
patient then becomes unfit for surgery and the option to treat expires. 
Observations are made on a monthly basis (N=12). The incremental cost of each 
monitoring session involving abdominal ultrasonography, above the cost 
associated with a physician visit, is assumed to be $261 24 . In contrast to the 
analogous stock dividend, this cost is assumed to be independent of evolving 
monetary benefits. 
The current cost of elective AAA surgery including disposables, clinician time, 
and bed costs is assumed to be $24,020 (Katz and Cronenwett, 1994). Although 
currently not cost-effective (net benefit = $20,000424,020=44,020), net benefit 
fails to account for the option to treat at some point in the future, when treatment 
may have become cost-effective. Framing the problem as an option to defer 
treatment, $20,000 is the current estimate of the uncertain variable and $24,020 is 
the exercise price. An annual riskless discount rate of 6% is used. A volatility 
parameter dictates the evolutionary process of expected benefits from surgery. 
25% volatility results in a trinomial structure with approximately a 0.25 
probability of rising or falling by 10%, and 0.5 probability of remaining 
unchanged (figure 4.4). 
23 In practice the length of the ability to defer is stochastic. The use of a constant is a simplifying 
assumption that facilitates analysis but does not affect the principle results. 
24 Cost estimates based on figures presented in Katz (Katz and Cronenwett, 1994). 
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Period I 
01. L2 6 Sj-ý-Increase 10% 
so 
0.5 Sjý=Rernain unchanged 
0.24 SIýDecrease 10% 
Figure 4.4. Recombining trinomial lattice showing the evolution of net benefit. 
Fortran code (see appendix) based on an algorithm by Haug (Haug, 1998) and 
adjusted for observation costs is used to project monetary benefits through time 
until the exercise date. After each deferred month a decision node permits 
immediate treatment to commence. This allows exercise at any point up to one 
year from the time of initial deferral. Final period option values are calculated and 
backward induction applied to compare deferral with immediate action in the 
penultimate period and thus calculate option value for this period. The code 
moves recursively through the trinomial lattice, deriving option values for each 
period until the present is reached. Current option value is then compared to the 
expected benefit of immediate action. * 
4.4.3 Results 
Given the base case parameter estimates (table 4.3) the current value of the option 
to defer immediate treatment is $954, despite negative net benefit (-$4020). If 
these estimates were true in practice for an individual, deferral would be the 
appropriate strategy. In practice a patient with negative net benefit would be 
assigned to a watchful waiting regime rather than 'rejected' outright (as with a 
77 
Period 2 Period 3 Period 4 
proposed investment project). Negative net benefit would therefore confirm the 
conclusion that immediate action is not appropriate. 
Parameter Base case value 
Time to expiration (in years) (T) I 
Number of periods (N) 12 
Riskless rate (r) 0.06 
Current expected benefit (S) $20,000 
Treatment cost (X) $24,020 
Volatility parameter (V) 25% 
Observation cost (F) $261 
Table 4.3. Base case parameters for the option to defer treatment for abdominal 
aortic aneurysms. 
ExPected benefit from immediate action differs over time for a given individual, 
and between individuals. Table 4.4 gives option value and net benefit for a 
plausible range of expected benefits. Examining the range permits direct 
comparison of the decision rules resulting from the two methodologies. 
Expected Benefit Option Value Net Benefit 
15,000 75.37 -9020 
16,000 143.6 -8020 
17,000 269.18 -7020 
18,000 418.06 -6020 
19,000 674.79 -5020 
20,000 954.22 A020 
21,000 1358.31 -3020 
22,000 1770.42 -2020 
23,000 2336.08 -1020 
24,000 2901.75 -20 
25,000 3575.83 980 
26,000 4292.29 1980 
27,000 5025 2980 
28,000 5861 3980 
29,000 6698 4980 
30,000 7557 5980 
31,000 8474 6980 
32,000 1 9392 1 7980 
Table 4.4. Option value and net benefit for a range of expected benefits for the 
option to defer treatment for abdominal aortic aneurysms. 
Net benefit analysis presents a dichotomous decision rule to accept or reject 
immediate treatment, identified by the level of benefits where net benefit equals 
zero. In this case patients with monetary benefit in excess of $24,020 receive 
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immediate treatment. Those patients, failing to meet this criterion either join a 
watchful waiting program or receive no ftirther attention, though no distinction is 
made 25 , and no optimal deferral time is suggested. Two patients with little clinical 
difference where one just meets the criterion and the other falls slightly below can 
receive opposing management strategies. Real options analysis presents a 
trichotomous decision structure: immediate action, watchful waiting or no action. 
Patients on the borderline are still managed differently but their strategies are 
likely to be more compatible. 
The contrasting decision structures mean there are four regions of possible 
conflict or agreement, over the range of expected benefits, between real options 
and net benefit decision making (figure 4.5); Below expected benefit of $17,000 
(region 1) both techniques reject immediate treatment. Real options denies 
admission to a watchful waiting because the option to wait is worth so little, and 
net benefit analysis does not distinguish those on deferral and those refused 
further treatment. Between $17,000 and $24,020 (region 2) option value exceeds 
zero supporting deferral. While net benefit rejects immediate treatment there is no 
formal criterion to recommend the waiting program. After $24,020 (region3) net 
benefit becomes positive recommending immediate treatment whilst option 
valuation conservatively continues to support deferral. Finally above $28,500 
(region 4), when the marginal benefit from the two outcome measures becomes 
equal, both methodologies advise immediate treatment. 
The regions of most interest are those where real options analysis potentially 
alters the preferred treatment strategy. In regions I and 2 options analysis 
differentiates patients who would benefit from deferral and those for whom 
deferral holds no long-term benefit. Traditional techniques, with their 
dichotomous decision structure cannot make this distinction. This causes potential 
differences in the way patients are treated. A patient placed on a waiting scheme 
by traditional decision-making might be more cost-effectively managed with no 
further treatment (or observation) if the benefit to surgical repair in the future is 
very small. 
25 If the analysis concerned a treatment decision in which deferral is not routinely considered or 
waiting programs are not in place the patient would receive no further treatment. 
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Figure 4.5. Graphical representation of option value and net benefit for a range of 
expected benefits for the option to defer treatment for abdominal aortic 
aneurysms. 
Patients falling into region 3 would receive immediate surgery according to net 
benefit but enter deferral if option value is used. If some of these patients progress 
to no longer need repair, the patients themselves are spared unnecessary surgery, 
and fewer people await surgery in the long run reducing pressure on waiting list. 
For these conclusions to hold, clinical measures must be able to accurately 
describe patients in terms of their benefit from immediate treatment and the way 
this variable evolves through time. This ensures only suitable patients undergo 
watchful waiting. In addition the period of time between watchful waiting ending 
and actually receiving treatment must be short. If this is not the case, the option to 
treat may expire whilst the patient queues for immediate treatment. 
Changes in parameter values affect option value and the desirability of deferral 
(table 4.5). Bivariate sensitivity analysis is used to explore the impact of T and N 
since a longer time to expiration is usually associated with more observational 
periods. N is increased in-line with T to keep the deferral period (dt) at one 
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month 26 . As the time to expiration increases from six months (T=0.5, N=6) to two 
and a half years (T=2.5, N=30) option value increases for a given level of 
monetary benefits. A longer time to expiration allows expected benefits to evolve 
for an extended period, permitting self-healing or deterioration to become more 
pronounced over the life of the option. The positively skewed payoff structure of 
options prevents poorer payoffs being realised (choosing not to treat patients in 
which self-healing occurs) and the positive payoffs ( from treating very ill 
patients) increase option value. 
Timing between stages of a disease is crucial if watchful waiting is to be 
considered a relevant treatment alternative. When diseases progress quickly 
patients remain suitable for watchful waiting for a very short period of time. 
Observations must be frequent to detect the optimal timing of treatment prior to 
the option becoming unavailable. Diseases with slower progression make more 
suitable watchful waiting candidates since observations can be less frequent, 
without risk of losing the option. Exploring different times to expiration for a 
given patient, to find the expiration date at which immediate action becomes 
optimal, can give an indication of the optimal deferral period. For instance, if the 
expected time to expiration is two years, and analysis for 6 months suggests 
deferral is optimal but analysis for one year recommends immediate action, then a 
clinician can reasonably comfortably defer treatment for 7/8 months. Perhaps in 
the early periods observation can even occur less frequently. 
Time to Number Option Discount Option Volatility Option 
expiration of time value rate value value 
(years) periods 
0.5 6 333.5 0.02 748.7 0.1 76.8 
1 12 954.2 0.04 847.1 0.15 305.1 
1.5 18 1566.8 0.06 954.2 0.2 625.3 
2 24 2151.8 0.08 1070.3 0.25 954.2 
2.5 30 
1 
2709.4 
1 
0.1 
1 
1195.6 
1 
0.3 
1 
1353.8 
Table 4.5. Sensitivity analysis for the option to defer treatment for abdominal 
aortic aneurysms. Base case values displayed in bold. 
26 Changing N or T alone influences the degree to which the model approximates the continuous 
evolutionary process. 
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Univariate analysis is used to assess the effect of the discount rate and volatility. 
The costs involved in surgery are incurred at some point in the future. The 
discount rate therefore has a positive impact on current option value. 
Volatility has a positive impact for reasons similar to the time to expiration; 
greater volatility allows more extreme movements in monetary benefit of which 
the positively skewed valuation system takes advantage. Figure 4.6 shows the 
impact on option value of increasing volatility from 15% to 25%. Altering 
volatility in this way causes the upward and downward movements in monetary 
benefit each period to increase from 6% to 10%, and causes the whole option 
valuation curve to shift vertically. 
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Figure 4.6. Effect of volatility on option value for a range of expected benefits for 
the option to defer treatment for abdominal aortic aneurysms. 
Superimposing net benefit would indicate that regions 2 and 3 (optimal deferral, 
formal watchful waiting scheme, according to real options analysis) together 
account for a greater range of monetary benefits. The point at which option value 
exceed zero occurs at a lower monetary benefit and the point atwhich deferral is 
suspended in favour of immediate treatment occurs at a greater monetary benefit. 
Potentially more patients therefore face the possibility of altered management 
strategies as a result of using option valuation. This has implications for the length 
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of waiting lists for treatment, and the numbers of patients recommended for 
watchful waiting. 
The responses to model parameters described here are consistent with predictions 
based on behaviour in financial models. 
4.5 Conclusions 
Wong et al's study of watchful waiting versus immediate therapy for mild chronic 
hepatitis C uses standard techniques to calculate cost per QALY and concludes 
that watchful waiting is not optimal. Incorporating the option value of deferral 
may lead to waiting being cost-effective in some cases where it is not currently. 
Failing to accurately account for option value may result in sub-optimal treatment 
decisions. This chapter has attempted to correct this potential deficiency by 
applying real options analysis to an area where deferral is already considered a 
relevant treatment alternative. 
The similarity between financial options and the option to defer treatment are 
apparent at an intuitive level; uncertainty, irreversibility and the ability to defer 
characterise both forms of option. This chapter has shown how the real options 
model can also incorporate factors specific to the watchful waiting decision. For 
instance the speed of disease progression enters through changes in the volatility 
parameter, the costs of aggressive therapy are stated explicitly in the exercise 
price, and observation costs incurred during the waiting period are considered as 
an implicit dividend. 
Within this application, some challenges to the analogy were encountered. 
Initially, simple financial options have a single source of uncertainty. The value of 
the option to defer treatment is influenced by disease progression, currently 
available treatments, risk of rupture and surgical risk. Closer examination of 
financial markets reveals options written on more than one asset suggesting that 
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multiple sources of uncertainty are not so uncommon 27 . The use of Monte Carlo 
simulation that is increasingly used within health care evaluations means this 
problem is more apparent than real. The simulations allow sources of uncertainty 
to be combined as inputs into a single output whose uncertainty underlies the 
payoff of the option. 
A further strain to the analogy is the ability of the exercise price, surgery costs, to 
vary. Financial option contracts clearly state terms of exercise including the 
predetermined exercise price. Although surgical costs are not likely to be highly 
volatile they are unlikely to remain constant over a prolonged period. This issue 
has been addressed by Trigeorgis (Trigeorgis, 1999) who finds closed forin 
solutions for options with stochastic exercise prices following continuous 
diffusion processes. The trinomial technique employed here can be altered to 
account for treatment costs varying over time. This would involve assigning an 
evolving distribution akin to that for expected benefit. The complexity of the 
model would be greatly increased. 
Data collection issues pose a problem to the application of real options analysis in 
practice. Currently data on disease progression, particularly aneurysm growth, is 
collected with a static perspective so net benefit estimates supply information on 
cost-effectiveness for the current period and do not take a dynamic view of 
uncertain parameters. In explicitly recognising uncertainty, irreversibility and the 
ability to defer, real options analysis asks about their precise influences on the 
decision. This requires a projection of uncertainty into the future that in turn 
requires regular, periodic measurements of uncertain variables today. Clinical 
trials monitor data periodically but intervals tend to be uneven, extending as the 
trial progresses (eg. I month, 3 month, 6 month observation points). Ideally 
adoption of real options methodology requires existing practice be altered to meet 
28 these data requirements . Some authors, for instance Capozza (Capozza and Li, 
2001) have tested theoretical models with empirical data, this would also be 
required for the true applicability of real options analysis to be ascertained. 
27 Such option have been called Rainbow options in the real options literature (Copeland and 
Antikarov, 2001). 
28 Few applications of real options theory progress to empirical analysis predominantly because of 
data requirements. 
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Here a trinomial option pricing approach has been used to value the watchful 
waiting alternative. Choice of valuation technique can be important in 
detennining the extent to which a model represents the decision problem of 
interest. Although advances continually arise in financial option pricing there can 
be some delay in making techniques suitable for real options analysis. Many 
option pricing techniques involve complex differential equations with no closed- 
form solutions, making the use of numerical techniques and programming 
inevitable. This can potentially lead to problems for the transparency of analyses 
and generates a trade off between simplifying the real option to suit basic 
valuation techniques and accepting detailed financial valuations that strain the 
analogy. As a result there are few real options applications that use empirical data 
and detailed valuation techniques to assess prominent decisions. Multinomial 
methods have proven popular because they represent a compromise between 
technical accuracy and transparency. 
The multi-nomial methods presented here might be used to address several 
decision problems within health care. Any decision that can potentially be 
deferred, whether treatment of an individual, developing and releasing a new 
pharmaceutical, or considering a society wide initiative to promote a vaccination 
programme, can theoretically be analysed using real options theory. The 
versatility of the multi-nomial structure, incorporating many time periods and the 
ability to manipulate the probability and extent of upward and downward 
movements in uncertain variables, means this type of model can support a wide 
variety of applications. 
The aim of this exploratory study was to attempt to establish a methodological 
and conceptual justification for the use of real options analysis within an area of 
health care where deferral is already considered relevant. This chapter has used 
standard techniques to demonstrate that real options analysis may be applied to 
health care decision making, and to fail to do so may introduce bias into 
evaluations where deferral is potentially viable. Future applications of real options 
analysis to deferred treatment may demonstrate that watchful waiting is beneficial 
in areas where consensus views waiting as detrimental, or where watchful waiting 
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has previously not been considered. In particular the period of deferral between 
regular screening sessions such as with cervical smear, and the optimal timing of 
release from hospital to care in the community might be analysed. 
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Chapter 5. The option to preserve life for patients 
in a coma 
5.1 Introduction 
Initiating life support for comatose patients creates an option to defer removal of 
that support akin to an American put option. This confers the chance of later 
recovery. Exercising the option and withdrawing life support technology 
eliminates future treatment possibilities and the patient's opportunity to regain 
consciousness. The current option has implications for later available options and 
decisions. Option valuation provides a framework to evaluate options available 
to decision makers at a given point and their impact for future decision making. 
Rosenhead (Rosenhead, 1992) has highlighted the importance of strategically 
managing options, emphasising the use of robustness analysis to examine 
beneficial and detrimental opportunities. Amram and Kulatilaka (Amram and 
Kulatilaka, 1999) refer to the 'discipline' of real options when discussing the 
relationship between the set of options currently available and those available, or 
potentially available, in the future. For instance, a pharmaceutical company 
researching treatments for cancer creates options to produce and market 
successful compounds. This in turn generates an option to expand or contract 
production depending on revealed market conditions. 
While health care evaluations report expected economic return as a measure of 
desirability, evaluating cost and benefits for the purpose of creating and 
destroying options is not usually considered. This chapter applies real options 
theory to the option to remove life support, an area where deferral, an important 
source of maintaining options, is not explicitly considered. The ability to alter 
and manipulate future option sets is shown to be an important source of value. 
Section 2 considers creation and destruction of options in health care, drawing on 
examples from throughout the sector and narrowing to focus on the option to 
defer removal of support. Section 3 reviews the financial put option and the real 
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options theory equivalent; the abandonment option. Section 4 models removal of 
life support as a perpetual abandonment option. A hypothetical example is 
presented. Section 5 concludes. 
5.2 Creating and destroving options in health care 
At any point in time a decision maker has a number of choices. For instance, a 
National Health Service manager must choose how much of a budget to allocate 
to each speciality, an intensive care team must decide whether to dedicate 
equipment to an existing or new patient. Such option sets might be significantly 
affected by current actions. For instance if 75% of a spending budget is 
consumed within the first 3 months of the financial year then severe limitations 
are imposed for the remaining months. Initial spending has reduced the available 
options set. 
Research and development efforts provide clear examples of creating future 
options in health care. Clinical trials and cost-effectiveness analyses may 
demonstrate that a new treatment is equally effective as current therapies, 
increasing the number of treatments available for a given ailment. Development 
of new technologies and extending use of existing technologies enables detection 
of new disease areas and better understanding of, and treatments for, known 
disease areas. Incurring costs to improve knowledge and understanding today 
unlocks options available for treating illnesses in future. This mirrors the way 
purchase of an option today confers the choice to defer exercise tomorrow. 
Some ventures have a less evident impact on options. Early investment in 
pioneer technologies brings the option to upgrade cheaply and adapt more 
quickly as newer and better versions emerge, or switch to similar technologies 
once staff receive initial training (Grenadier and Weiss, 1977; Moretto, 1996b). 
Previous research and experience in new surgical techniques gradually enables 
patients to choose between invasive and less invasive modes of treatment such as 
medical or surgical management; kidney dialysis or kidney transplant. These 
88 
choices have only developed through sequential decisions taken within the health 
care industry that have periodically extended available options. 
Whilst these are examples of option creation, the same events can often be the 
source of destroying options. Investments requiring upfront expenditure prevent 
funds being allocated elsewhere, reducing the options available. Consumption of 
one drug may preclude use of another, such as treatments for aids. The decision 
to amputate a limb may limit the life choices available to a patient. Since acting 
now destroys options, deferring action is an important way to maintain options. 
For instance, deferring purchase of a technology preserves the option to do so 
later and perhaps confers an option to invest in a newer. improved model. 
Consider the option to defer removal of life support. Coma may arise following a 
variety of insults to the brain. Physical injury, nutritional deficiency, poisoning, 
stroke and the effects of degenerative diseases may all result in cognitive loss. In 
this state the body retains only the ability to perform vegetative functions and 
cannot survive without sufficient nutritional and bodily support. With help such 
as simple feeding, nutrition, bathing, ventilation and circulatory assistance 
(Singer and Grant, 1999) patients may live for months or years (Council on 
Scientific affairs and council on Ethical and judicial affairs, 1990). For some 
patients the only semblance of life may be sleep-awake cycles, for others, 
sporadic responses to internal and external stimulus may occur and manifest 
themselves in displays of emotion, such as smiling and crying. 
Despite current cognitive loss there is a possibility that afler some uncertain 
period of time the patient will spontaneously improve sufficiently to regain 
consciousness and some degree of normal life. Practice has revealed however, 
that patients may remain severely disabled and enjoy only a low quality of life. 
In some cases, given the limited prognosis (The Multi-Society Task Force on 
PVS, 1994) of the patient and continuing high resource costs, (Kauftnan and 
Lipton, 1992) decision makers may choose to tenninate life support and allow 
the patient to die. The ethical issues inherent in end-of-life decision making 
contribute to the debate over whether and when to withdraw treatment (Meisel et 
at., 1999). 
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Incurring the financial expense necessary to initiate life support is analogous to 
purchasing a perpetual option to defer removal of support, and preserve life until 
the option is exercised. The option is purchased if the expected value of 
ownership exceeds the price, which in this case includes the costs of introducing 
the patient to the intensive care unit, linking them to support technology and 
associated nursing care. Once bought, the option to remove care can be deferred 
almost indefinitely. Exercising the option and ending treatment destroys the 
option to recover removing all the patient's future lifetime options, and destroys 
the option to remove support at a later date should the patient fail to improve. 
Deferring removal preserves the option to withdraw life-sustaining technologies 
prolonging the patient's opportunity to spontaneously recover. 
Conventional decision theory would, in principle, calculate cost-effectiveness of 
treatment withdrawal using expected discounted cost and benefits (Chalfin et al., 
1995). The benefits to withdrawing treatment are resource savings, and the costs 
are potential Quality Adjusted Life Years (QALYs) forgone. Previous economic 
analyses in this area, however, have concentrated primarily on cost (Sailly, 
1994). In addition, existing analyses consider the attractiveness of an immediate, 
now or never, action. To the author's knowledge the ability to wait before 
removing life support, the information potentially conferred, and the option 
preserved have not been explicitly addressed. 
An initial examination of the withdrawal decision suggests there are similarities 
with an American put. Option pricing techniques that value the option to defer 
removing support and associated maintenance, rather than destruction, of future 
options, may help in understanding and analysing this decision problem. Since 
deferral is a relevant alternative for intensive care patients, particularly when 
information about recovery is lacking, (Council on Scientific affairs and council 
on Ethical and judicial affairs, 1990) option analysis seems an especially relevant 
valuation tool. 
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5.3 Real option theories ofabandownent 
Whilst an option to defer immediate treatment delays initiating a project with 
uncertain future outcomes, the option to defer removal of life support brings an 
end to an ongoing project. Removing life support efforts takes an active project 
and terminates the uncertain benefit flows, periodic QALYs gained and 
discounted future potential QALYs, in favour of an inactive status; allowing the 
patient to die. Real options analysis refers to the termination of active projects, 
which are analogous to put options, as abandonment options. This section 
reviews the financial and real theories relevant to pricing the option to remove 
life support. 
Put options are options to sell, rising in value as stock price falls. Exercise occurs 
when current market stock price falls below the contracted exercise price, and a 
payoff equal to the difference between the two is received, making intrinsic value 
a mirror image of the equivalent call option. Akin to call options, by allowing the 
holder to exercise only when stock price falls, the option provides protection 
from losses. Even when an option is not currently profitable, knowledge of the 
volatile price evolution process reassures investors that profits may be made at 
some future date. While the option is still held there exist choices and a chance to 
benefit from price falls that no longer exists once the option is exercised. For 
these reasons the put option has value in excess of intrinsic value, making the 
option valuable to the holder even when intrinsic value is zero (figure 5.1). 
A put option must be bought on a market. Abandonment options exist only once 
an investment has been made; a project is initiated by incurring set up costs that 
act as the purchase price of the option. While the put option is held, the owner is 
entitled to a stream of dividend benefits associated with stock ownership. The 
owner of a real project realises a stream of payoffs that last only as long as the 
project is in operation. Options convey a right with no associated obligation, and 
in tune with this, the owner of the investment programme has the right to 
abandon his investment should the payoffs prove less than desirable. 
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Figure 5.1. Intrinsic value and option value for a perpetual American put option 
with exercise price E300. 
On exercise the put owner receives a single payoff (exercise price) and stops 
receiving both capital gains and dividends. When profits fall below some 
threshold level, exercise of the option to terminate the project occurs. 
Abandonment involves sale of assets in return for a single lump sum payoff 
(scrap or abandonment value) and an end to the stream of payoffs associated with 
ownership. Losses are then limited to any fixed costs associated with abandoning 
the project creating a kinked payoff structure akin to intrinsic value. 
Numerous authors have recognised the similarities between put options and 
abandonment of real projects. McDonanld and Siegel (McDonald and Seigel, 
1985) provide one of the earliest attempts to value firms with an option to shut 
down, examining the impact of variable output price on the value of the option. 
More recently Berger (Berger et al., 1996) considered valuation of generic 
abandonment options and Alvarez (Alvarez, 1999) analysed optimal exit of firms 
facing demand uncertainty. In this study exit is recommended only when the 
value of future productive options is less than the value of irreversibly exercising 
the exit option. Alvarez notes that this may lead to continued production when 
net cash flows are negative. At a micro level Moretto (Moretto, 1996a) examines 
individuals' car scrapping decisions illustrating how irreversibility and 
uncertainty combine to lengthen the period of ownership, increasing deferral. 
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The majority of abandonment option applications either value a firm currently 
possessing abandonment options, or consider a micro level decision of whether 
or not to abandon a single project. The latter category usually attempts to identify 
some abandonment threshold beyond which the project should be terminated. For 
instance Conrad (Conrad, 1997b) identifies the cut wood price threshold beyond 
which an old-growth forest, currently used for amenity value, should be 
abandoned and the resulting wood sold off. Similarly Myers and MaJd (Myers 
and Majd, 1990) determine option values and optimal abandonment schedules 
for generic projects. These authors also explore the impact of deterministic and 
stochastic scrap values. This seems an appropriate stance from which to 
investigate the option to defer removal of life support technology. 
5.4 The option to defer removal of life support 
5.4.1 The real optionsproblem 
Initiation and termination of life support technology respectively create and 
destroy the option to preserve life. Termination of support may become a viable 
choice if the possibility of the patient regaining consciousness is very small or if 
severe disability would result. The decision to abandon life support efforts may 
be made immediately or deferred (figure 5.2). Immediate removal of support 
efforts kills the option to remove support at a later date should the patient fail to 
improve. Deferral maintains this option. Comparing the values associated with 
each of the two decisions therefore identifies the incremental value of deferral 
(option premium), and so the value associated with owning and maintaining the 
current option. 
Option to 
remove life 
support 
Innnediate action; 
withdraw support 
Deferral; maintain 
the option to 
remove support 
Receive / pay 
immediate exercise 
price 
Receive some quality 
of life each period 
Figure 5.2. The option to defer removal of life support 
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As with the option to defer immediate treatment, for the application of real 
options analysis to be justified in practice, the characteristics of the option to 
remove support must identify with the characteristics of the put option (table 
5.1). In this unusual instance the option owner, the decision maker, is not the 
party directly affected by the source of uncertainty, the patient. The decision to 
exercise is taken by the intensive care unit doctor in discussion with the patient's 
family, and in the interests of the unconscious patient. 
Financial Real option to defer removal of 
option life support 
Decision maker Owner of Clinician in conjunction with 
option patient's relations 
Source of option Purchased Conferred through the starting 
and continuing life support 
Dominant source of Stock price Underlying biomedical state of 
uncertainty the patient 
Information gained Changesin Individual level information on 
through deferral stock price well-being, te of change 
Source of Exercise Death of patient, costs involved 
irreversibility price in termination of support 
Ability to defer Limited by Limited only by the patient 
exercise date naturally dying or regaining 
consciousness 
Table 5.1. Characteristics defining the option to defer removal of life support. 
Having been conferred through starting life support the value of the removal 
option depends on sources of uncertainty that evolve whilst exercise is deferred. 
The dominant source of uncertainty is the vegetative patient's well-being 
measured by their biomedical state and converted into QALYs. Deferring 
removal provides QALY benefits for the patient whilst still unconscious 
(dividend type payouts) as well as potential future QALYs in the event of 
recovery. These are transformed to monetary benefits using an estimate of 
society's willingness to pay for a unit of health outcome, for input into a real 
options model. 
Further sources of uncertainty include: relatives gaining some non-monetary 
rewards while removal of support is deferred (although an element of certainty 
and perhaps relief may also be gained when immediate action is pursued); the 
lack of clarity concerning predictions of recovery and, in the face of recovery, 
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quality of life regained; disagreement between health care professionals as to 
whether a patient is emerging from a vegetative state due to lack of tests to detect 
patient inner awareness (Hollerback et al., 1995); the emergence of technological 
advances that may induce improvement; and the value from transplanted organs. 
Whilst all these factors are relevant, to focus on the structure of the decision, 
elements of uncertainty about recovery and the value of organ transplantation 
form the core of the analysis. This enables a stylised example to be created that 
resembles the financial put option whilst maintaining sufficient simplicity to 
allow transparent interpretation of the model. The evolution of a composite 
variable defines the uncertainty underlying the decision problem. With this in 
mind information is gained each period about the patient's continuously drifting 
biomedical state and associated possibility for future recovery. This information 
may be measured using the Glasgow Coma Score (GCS), and would need to be 
converted into monetary terms. The data would then feed into the final exercise 
decision. 
Irreversibility is particularly prominent in this example, not only are costs 
incurred in the event of removing support but ultimately once supporting 
machines and care are removed, and loss of life confinned, a life is lost. Dixit 
and Pindyck (Dixit and Pindyck, 1994) suggest that an abandonment option is 
"realistic if a live project has some tangible or intangible capital that disappears 
quickly if a project in not kept in operation. " This is particularly true of a 
patient's life lost when preservation efforts are discontinued. 
Finally, deferral is inherent in the decision to remove support. Deferral maintains 
the option for later abandom-nent whilst allowing continued monitoring and 
reassessment. In practice life support is often continued for many months and 
sometimes even years. Although discussion of the option to initiate life support 
may seem attractive, the inability to defer this decision makes a real options 
approach inappropriate. The option to invest in life saving technology as a way to 
create options to treat future seriously ill patients might, however, be discussed. 
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Application of real options theory requires similarities in valuation parameters as 
well as decision structure. Whilst the parameters required to value a particular 
option are highly dependent on the valuation technique used, generic variables 
can be discussed (table 5.2). 
Variables describing uncertainty, the current estimate and volatility are given by 
the expected benefit from preserving life (dictated by uncertain QALYs), and 
associated volatility through time. When assessments of comatose patients are 
made, classification is usually via scores such as the Glasgow Coma Score 
(GCS), Glasgow Outcome Scale (GOS), the Acute Physiology, Age, and Chronic 
Health Evaluation (APACHE) Il and III and the Simplified Acute Physiology 
Score (SAPS). The Glasgow Outcome Scale, for instance, identifies five 
categories of outcome; good recovery, moderate disability, severe disability, 
vegetative and dead. Whilst scores give a reasonable indication of well-being 
including information on motor functioning, verbal response, eye opening and 
pupilliary light reflex, they do not provide accurate quality of life assessments. 
This currently hinders the application of option pricing techniques. 
Parameters Financial Real option to defer removal of life 
option support 
Current value of Spot price (S) Current expected benefit from 
source of uncertainty preservin life 
Estimate of Variance in Uncertainty surrounding expected 
uncertainty stock value (cr') benefit over time 
Immediate cost/benefit Exercise price Immediate monetary benefit / cost 
of exercising option M associated with removing support. Eg. 
Benefit of transplantable organs 
Date before which the Exercise date Date, %vhen patient dies naturally and 
option must be (T) option to remove support is no longer 
exercised available 
Benefit associated Dividend (D) Expected benefit from QALYs gained 
with deferral each period net of periodic costs 
Table 5.2. Parameters commonly used in financial option pricing and their 
counterparts for the option to defer removal of life support. 
Degree of detail in case studies of comatose and vegetative patients is a barrier to 
estimating uncertainty. Of those observational studies examining well-being, 
occurrences of death and regaining consciousness are relatively well 
documented. Whilst some studies provide information on survival, degree of 
recovery, and death, the timing of events is often lacking (Kaplan 1999). Bastos 
96 
and Bricolo (Bastos PG et al., 1993) for instance, provide one-year final 
outcomes. Some studies aggregate outcomes combining death with vegetative 
state, or vegetative state with survival (Facco E et al., 1998) making 
reinterpretation of data impossible. 
Studies providing sufficiently detailed information tend to concentrate on the 
first month of coma. For instance Bassetti (Bassetti et al., 1996) considers 
patients who remained comatose for more than 6 hours following cardiac arrest. 
Of 60 patients 13 (27%) died within the first 3 days and 31 (65%) died the 
following month. Of the 12 patients who regained consciousness (20%), the only 
details given are that 11 awoke in the first week. This lack of detail poses severe 
problems for a real options analysis that requires periodic estimates of well- 
being. 
A put option realises value on exercise. The option to defer removal of support 
may provide value from exercise through donation of suitable organs such as 
heart, lungs, kidneys, livers and corneas that aid recovery of other patients. Costs 
may, however, be incurred in removal of support, such as the cost of additional 
physician support. The balance of these influences will determine whether the 
final exercise price is a cost or benefit. Although a cost paid on exercise does not 
align completely to the financial model, the structure of the decision remains the 
same; if payoffs from continuing the project are sufficiently poor, then paying 
some cost to end the project becomes worthwhile. This may be the case in many 
real options applications. 
A patient's natural death or spontaneous recovery determine the exercise date for 
the removal option. While financial options generally have a given exercise date, 
valuation as a perpetual option, as is most appropriate in this case, is not unusual 
for real options. If a patient was older, impact of the time to maturity might be 
explored using a finite binomial / trinomial approximation. 
Finally, in contrast to the call option, deferring exercise of a put option is 
associated with receipt of dividends. Preserving life has dividends in the fonn of 
QALYs gained each period for which the patient remains alive. Maintaining life 
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through external support, however, involves use of high technology machines, 
beds, continuous nursing care, drugs and nourishment. Estimates of cost per bed 
day, for instance, range between flOOO-F-I 800 (Singer and Grant, 1999). Such 
costs should be offset against positive interim payments. 
5.4.2 The model 
Since well-being of patients can improve, remain unchanged, or deteriorate each 
period, trinomial valuation initially seems appropriate. Several factors make this 
specification unsuitable in practice. Patients remaining vegetative are often 
assessed according to a probability of death score (Cho et al., 1995). This is 
informed by observed data such as the patient's response to pain (Somosonary 
Evoked Potentials (SEPS)), spontaneous breathing, Glasgow Coma Score (GCS), 
Acute Physiology, Age, and Chronic Health Evaluation (APACHE 111) system 
probability of death, and in some cases blood glucose levels. Most commonly, 
assessments are made on entry to, and exit from, the intensive care unit. Despite 
the varsity of assessments, data on vegetative state patients is not yet sufficiently 
detailed, in terms of frequency, to infann a trinomial model. The probability of 
moving between states in any given time period and absolute changes in well- 
being cannot currently be estimated with sufficient confidence for inclusion in a 
model. 
Given these difficulties, and the effectively perpetual nature of the option, a 
geometric Brownian motion infinite horizon model is used. In this process, the 
underlying random variable Q, the expected benefit gained from deferral and life 
preservation, changes continuously each period dt with some drift, a, subject to a 
known and constant variance, cý; 
dQ= a Qdt+ a Qdz (EQN. 5.1) 
This process assumes that the current value of the project is known and that 
future values are log-normally distributed with variance growing linearly with 
the time horizon. The parameter dz is a Weiner process, a random variable drawn 
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from a normal distribution with mean zero and variance A Figure 5.3 
demonstrates the relationship between Brownian motion and the discrete 
multinornial process by illustrating the evolution of expected benefit. 
Expected 
benefit 
Time 
Figure 5.3. The evolution of expected benefit determining (x and (y for the 
Weiner process. 
Myers and Majd (Myers and MaJd, 1990) use this specification to solve a general 
abandonment problem employing methodology initially used by Merton 
(Merton, 1973) to find a partial differential equation (PDE) for abandonment 
value. This formulation has also been used by Conrad (Conrad, 1997b) to value 
the option to preserve old-growth forest. Brownian motion is predominantly used 
in applications where the underlying source of uncertainty is a commodity price 
that can be reasonably modelled with a log normal distribution. Expected benefit 
is restricted to positive values since death represents the lowest benefit to 
29 
preserving life, at a value of zero . In addition, the majority of patients face a 
relatively low benefit to survival and fewer patients face a fair to good prognosis. 
Brownian motion therefore seems appropriate. 
Brownian motion requires specification of (x and cy in place of probabilities and 
degrees of up and down movements. If the probability of regaining 
consciousness dominates expected benefit, the latter may drift downwards as 
time spent unconscious elapses, resulting is a negative value for (X. Both the trend 
and variance are assumed known with certainty although sensitivity analysis may 
be used to demonstrate the impact of different parameter values. 
29 Vaulation studies have actually shown that some health states can be considered Nvorse than 
death. For simplicity it is assumed that death is a boundary state with a utility value of zero. 
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Whilst the infinite horizon Wiener process is commonly used in real options 
applications it is one of many possible specifications for underlying uncertainty. 
For instance a Poisson jump may more accurately represent the probability of 
spontaneously regaining consciousness. Although expected benefit may be 
subject to discontinuous jumps resulting from sudden changes in biomedical 
state, the current fon-nulation is chosen for the way the continuous Weiner 
process mimics a patient's continuously drifting biomedical state. 
The value of the removal opportunity, V(Q), consist of two elements, entitlement 
to expected benefit from continued life and the option to remove support should 
the patient's prognosis, and so expected benefit, fall to very low levels. Whilst 
the option is still available net cash flows are received each period [ (Q - Qdt 
equal to the difference between expected benefit of remaining alive (Q) and the 
cost of maintaining support (C). While expected benefit follows the evolutionary 
process, the daily cost of patient related care in an intensive case unit is assumed 
to be fixed at E592 (Kemna, 1993). 
The value of the removal or disinvestment opportunity must satisfy a partial 
differential equation (equivalent to Equation 2.19 for the investment opportunity) 
that Dixit and Pindyck (Dixit and Pindyck, 1994) show to be; 
I 2Q2V" 
-T a (Q)+aQV (Q)-rV(Q)+Q-C=O (EQN 5.2) 
Dixit and Pindyck illustrate that the general solution is: 
V(Q) = B, Q'I + B2 Q72 + QIS - Clr (EQN 5.3) 
The discount rate for costs and benefits are given respectively by r and 5. The 
last two terms of equation 5.3 give the value of pursuing life support efforts 
forever, irrespective of the health status. The first two terms value the option to 
remove support at some point in the future. The likelihood of removal becomes 
extremely small as Q tends to infinity suggesting the value of the removal option 
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should approach zero as Q becomes large. To achieve this B, is set to zero 
leaving: 
V(Q) ý B2 QY2 + Q18 - Clr (EQN. 5.4) 
Where B2 is a constant yet to be detennined and y2 is given by: 
y2 =-L-alu 
2- V[aler 2_ 
-i ]2 +2g1U2 <O (EQN. 5.5) 2 
Dixit and Pindyck use this formulation as part of a combined fin-n entry and exit 
decision strategy identifying complementary entry and exit price thresholds. Here 
the exit decision is the focus of attention and appropriate exit boundary 
conditions are derived to ensure a solution exists (equations 5.6-5.8). These limit 
the value of the option to withdraw support, and link the values and derivatives 
of deferring removal and immediate removal, when immediate withdrawal 
occurs. 
Absorbing barrier: V(Q = OD) = (EQN. 5.6) 
Fahte matching condition: V(QL) =E- (Q1S - CIO (EQN. 5.7) 
Smooth pasting condition: T7'(QL) ý1 (EQN. 5.8) 
The option to remove support exists while the patient remains alive. When the 
patient resumes consciousness the option to remove support is no longer relevant 
and becomes worthless. The absorbing barrier (equation 5.6) states that the value 
of the removal opportunity falls to zero as expected benefit from deferral 
becomes infinitely large. 
Intuitively, whilst expected benefit remains above some threshold (QL), removal 
is deferred and the option preserved. When expected benefit falls below this 
threshold removal becomes optimal. The value of the removal opportunity V(Q) 
is valid only above this lower expected benefit threshold. At the removal 
threshold society pays / receives the lump-sum quantity, E, (assumed to be a 
receipt of El 0,000) to terminate the periodic cashflows (Q - Qdt. The value 
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matching condition (equation 5.7) ensures the value of the option and immediate 
action are equal at the abandomnent threshold QL. 
Whilst the value matching condition identifies a feasible set of thresholds, the 
smooth pasting condition (equation 5.8) identifies the optimal decision point by 
ensuring the marginal value of deferring and removing are equal. 
Applying the smooth pasting condition to the value of the removal option V(Q_) 
and rearranging gives B2: 
B2 =('-S-I)I(YQY-') 
Substituting this into the value matching condition yields: 
B2 Qr + QIJ - Clr =E- (QIJ - C1r) 
Q7 + Q18 - Clr =E- (Q1S - C1r) YQY-l 
(EQN. 5.9) 
(EQN. 5.10) 
(EQN. 5.11) 
Solving yields the optimal threshold QL, the lowest value of expected benefit 
consistent with the patient receiving continued support: 
QL =(E+ 
2C )( 
5Y2 
r5 -1+2Y2 
(EQN. 5.12) 
QL may be used to find B2 at the decision threshold, B2(L)- QL and B2(L) are used to 
find the value of the removal option V(Q) given in equation 5.4: 
V(Q) = B2 QY2 + QIS - Clr (EQN. 5.4) 
Sensitivity analysis can be used to explore the effect of changing base case 
parameter estimates. 
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5.4.3 Results 
For the base case scenario, expected benefits are assumed to drift downwards at 
2% per year (a---0.02) with a constant volatility of 15% ((3--0.15). Periodic costs 
of ; E592 per day and upfront benefits to ending support of E10,000 are used. 
Costs are discounted at 6% and benefits at 2% in accordance with economic 
evaluation practice. A period of one month is used to illustrate the model (table 
5.3). 
Parameter Basecase 
parameter values 
(monthly) 
Drift in expected benefit (ct) -0.0106 
Variance in expected benefit (a) 0.0125 
Discount rate for costs (r) 0.0116 
Discount rate for benefits (5) 0.0106 
Periodic costs of maintaining support (C) E16,576 
Benefits from ending life support (E) f 10,000 
Table 5.3. Base case parameter values for the option to defer removal of life 
support. 
An Excel spreadsheet is used to calculate the optimal threshold (QL), the value of 
the removal option [V(Q)], and the net benefit of immediate removal 
[E- (Q18 - C1r) ]. For base case parameter values the optimal removal threshold 
occurs when expected benefits reach f 10,120 (QL=f 10,120). For any given 
patient currently receiving support, when their monthly expected benefit from 
preserved life falls below f 10,120, life prospects have become so poor that 
removing support is optimal. A patienfabove this threshold should have removal 
of support deferred. 
Figure 5.4 shows option value and net benefit over a range of expected benefits 
encompassing the threshold QL. A patient to the left of the decision threshold 
would have support removed immediately, and a patient to the right would 
receive continued support. For an investment option there is an implicit 
assumption that the project is not active, suggesting the threshold has yet to be 
reached but that project value is rising to induce action. This renders deferral 
relevant below the threshold. For the cur-rent case the opposite implicit 
assumption exists; that the 'project' is active and expected value is yet to fall 
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sufficiently to induce action. Therefore, in this instance deferral is relevant above 
the threshold and the decision maker looks for decreasing expected benefits 
through time to trigger action. 
The option to defer removal of life support 
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Figure 5.4. Option value and net benefit for the option to defer removal of life 
support. 
The value of a financial put option tends towards zero as stock price increases. 
This is not evident in this real option. The value of the option to defer removal 
comprises option value and the value of continuing support infinitely (equation 
5.3). As expected benefit increases the latter component dominates causing 
option value to rise again. In practice there would exist an upper threshold such 
that a patient with expected benefits exceeding the trigger would regain 
consciousness and the upper portion where option value begins to rise would 
become invalid. 
Real options analysis suggests that removal of life support should be deferred 
until the expected value from preserving life falls below QL =E 10,120. If the 
decision to remove support is considered as a now or never decision, 
characteristic of existing decision techniques, removal occurs when the payoff 
from removal (E) equals the value from continued support ( Q18 - C1r). Net 
benefit is given by E- (Q1S - C1r) and the level of benefits where net benefit 
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equals zero identifies the removal threshold. Rearranging for this level of 
expected benefits Q. ) gives: 
QL* =J(E+ 
c 
r 
(EQN. 5.13) 
With traditional techniques that do not account for the value of maintaining the 
removal option, immediate abandonment would occur when expected benefit 
falls below El 5,253 per month (Qpý = EI 5,253). 
Consistent with existing applications of real options analysis the two decision 
thresholds do not coincide. For the option to defer removal of life support the 
real options decision threshold is below that of traditional decision making. For a 
given patient, standard cost-effectiveness analysis would recommend treatment 
withdrawal more readily than real options analysis. Real options analysis 
therefore allows the well-being of the patient to deteriorate further before 
treatment withdrawal is recommended, theoretically ensuring that the patient is 
supported for longer in intensive care. 
Real options analysis has provided a more conservative criterion. This 
conclusion suggests there may exist large deviations in the amount of time for 
which life preservation efforts are sustained when the two decision rules are 
compared. Palmer and Smith's work (Palmer and Smith, 2000a) confirms that for 
reasonable parameter values applied to an option to invest in a new health 
technology, the two decision criteria can differ substantially, reinforcing this 
conclusion. 
In addition patients with expected benefit between the two thresholds would be 
treated differently under the two methodologies. A patient with an expected 
benefit of E12,000 would have their care removed in conventional decision 
making but would receive continued support under a real options approach. If 
budgetary allocations in this area are based on historical patterns, this result 
suggests that an insufficient quantity of resources may be allocated to intensive 
care units for patients to be treated optimally. If current treatment decisions are 
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actually determined by the availability of resources, which may be the case in 
some trusts, then there may exist some scope for optimal reallocation of 
resources. 
The value of maintaining a flexible position (keeping the option to remove 
support in preference to taking immediate action and losing the option) is given 
by the difference in value between deferring and acting immediately. This 
incremental value of deferring, or option premium, captures the value of 
maintaining rather than destroying future available options, and so places a value 
on flexibility. The optimal threshold QL can also be identified as the first value of 
expected benefit at which this option premium falls to zero. Where the options 
premium is positive (above QL), possessing future choices is more valuable than 
immediate action and deferring removal is appropriate. Where the option 
premium is equal to zero (below QL) possessing future options holds no extra 
value and immediate removal is appropriate. The decision thresholds for real 
options and net benefit analyses differ precisely because of this ability to account 
for future options. 
5.4.3 Sensitivity analysis 
For a given patient the value of the option to defer removal of support is 
determined by their characteristics, which influence parameter estimates. 
Individual patients with different risk factors will have different option values 
that alter the relative attractiveness of maintaining their life support, and 
preserving their recovery option. For instance patient age is an important 
predictor of coma outcome since very young and very old patients historically 
face greater risk of failing to regain consciousness, when compared to middle age 
persons (Coggins and Ramezani, 1998). Age may affect the evolution of well- 
being, causing expected benefit to deteriorate more quickly in the very old and 
very young. Figure 5.5 shows option value for a middle aged person (CC-0.02) 
compared to an older person (a=-0.04). 
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Reducing the drift in expected benefits increases option value for the removal 
opportunity. This gives the seemingly perverse result that a middle aged person 
deteriorating less slowly will have a higher removal threshold; optimal removal 
of support occurs at a higher threshold than for the older person (middle aged QL 
= El 0,120, older person QL = E9,930). 
Option value for older and middle aged patients 
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Figure 5.5. Option value for middle versus older aged patients 
To understand this, consider the put option. When stock price falls more quickly 
potentially greater profits are made, the option is worth more, and exercise 
occurs more readily. With the option to defer removal of support a patient 
deteriorating quicker releases their organ donation sooner, presents a smaller 
resource commitment over the duration of deferral (because they are expected to 
die more quickly), and most importantly following deferral for such a patient 
exercise will require sacrificing fewer expected benefits. These influences exert a 
positive influence on option value causing exercise to occur less readily. Older 
patients are therefore likely to receive more prolonged support. 
Although the older patient receives care until a lower threshold is reached, in 
practice the speedier deterioration may cause the threshold to be reached sooner 
and support to be continued for a shorter period of time. This conclusion is 
consistent with Sarkar (Sarker, 1999) who argued that although trigger thresholds 
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for investment options are more conservative using real options analysis 
investment often occurs sooner. In addition older persons may start from a lower 
initial level of expected benefit and may therefore be closer to their removal 
threshold. 
The cause of the coma; traumatic, non-traumatic or degenerative disease, has 
also been identified as an important indicator of outcome (The Multi-Society 
Task Force on PVS, 1994). Patients entering the state due to a degenerative 
disease will face less uncertainty over their outcome. This difference in 
uncertainty means a trauma patient (perhaps a--O. 15) has a different decision 
threshold to a patient suffering neurological problems (perhaps cy--0.05). 
Increased uncertainty means the monetary benefit of deferring removal 
deteriorates in a more volatile way, increasing the possibility of future 
improvement. This generates greater option value causing a lower removal 
threshold. The trauma patient will have removal of support deferred for a longer 
period of time if equal average rates of deterioration (cc) between the patients are 
assumed. 
Attitudes towards time preference impact on option value because deferring and 
keeping opportunities available in future is a key part of real options analysis. 
Discounting costs and benefits at a greater rate, placing less value on future 
outcomes, affects both the value of immediate removal and the value of deferred 
action. Since future outcomes have less weight option value is diminished 
creating pressure for the optimal threshold to increase, and prompting treatment 
withdrawal to occur more readily. The value of immediate action meanwhile is 
enhanced because the present value of QALYs sacrificed when support is 
removed falls, causing the decision threshold to fall. The value of deferred action 
is diminished whilst the value of immediate action is enhanced. Since time 
preference has altered to favour current outcomes the second influence dominates 
causing an aggregate fall in the optimal removal threshold. 
Changing the exercise price similarly has a significant impact. A patient entering 
coma following acute trauma may have more value as an organ donor than a 
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patient suffering long-term degenerative effects. In some cases net costs may be 
incurred in the process of removing support detracting from the put option 
analogy (potentiallywhere a patient has no value as a donor). Reducing the value 
of any benefit to removing support reduces the optimal decision threshold. 
Where a patient presents less value or creates a cost when removal of support 
occurs, this action is deferred for longer. A patient who has a high value of 
transplantable organs perhaps because they can save another patients life may 
therefore face a more stringent decision criterion. Taking the irreversible action 
to remove future life options for the current patient generates future options for 
alternative patients. This lowers the value of flexibility for the current patient. 
Individual patient characteristics have an impact on the value of deferring 
removal of life support, and so influence the timing of treatment withdrawal. 
Where maintaining future choices for the current patient is not valued highly 
relative to immediate actions that reduce or create flexibility elsewhere, the 
removal threshold is high, encouraging removal to occur more readily. 
5.5. Conchisions 
5.5.1 Applying real options analysis: the option to remove support 
The termination of life support is viewed here as a current action that 
significantly affects the availability and desirability of future choices accessible 
to the clinician. Removal of life support efforts is a decision influenced by 
uncertainty, and extensive irreversibility. Since the action can be deferred, the 
removal opportunity becomes an option to defer removal and can be analysed 
using financial option pricing techniques. Real options analysis places emphasis 
on the ability to defer taking the irreversible removal decision, in a situation 
where deferral is inherent yet not usually considered. Explicit appraisal of 
deferral allows a value to be placed on future flexibility. Although valuing 
deferral is in principle possible using current decision theory, the discipline of 
real options addresses this issue explicitly. This enhances transparency in the 
approach to valuing flexibility. 
109 
This application has shown that the ability to defer removal is valuable and 
sensitive to patient characteristics. As a result characteristics affect the real 
options decision threshold and directly influence decisions governing treatment; 
in theory each patient would have a unique treatment removal trigger and 
homogenous treatment recommendations are ruled out. Real options analysis has 
shown that capturing the effects of creating and destroying future flexibility is 
important. Failing to account for this source of costs and benefits may lead to a 
misstatement of the value of an action, and misguided decision making. In 
particular, the value of preserving a life is understated; leading to fewer resources 
than optimal being allocated to this speciality. 
This case study centred on an example involving total irreversibility, this is 
unlikely to be the case for many real options. Usually investment and 
disinvestments opportunities have sunk costs that constitute irreversibility but the 
projects themselves and associated outcomes can be altered (although usually at 
some cost) once initiated. Degrees of irreversibility can be accounted for within 
the real options framework by redefining the value matching condition, and 
modelling multiple interacting options. 
Extensive data requirements make applying the model presented here difficult in 
practice. Making this operational requires an estimate of the expected drift and 
variance of monetary benefit gained by deferral. For this, Quality of Life scales 
are essential, although patient assessment tools such as the Glasgow Coma score 
or the APACHE III scale supply important well-being data, they do not provide 
sufficiently detailed information to develop the necessary picture of expected 
benefit over time. For instance, mortality prediction models usually provide one- 
off assessments whilst options analysis requires ongoing assessments at regular 
intervals. Data frequency such as that shown by Chang (Chang, 1988), who 
tracked daily Apache 11 scores and used trend analysis to predict probability of 
death, would be required on an extensive and ongoing basis. 
Data requirement issues exist in parallel with other barriers to implementation. 
Acceptance of net benefit arguments is a prerequisite that necessitates an explicit 
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statement of policy makers' willingness to pay for health outcomes. The trade-off 
between methodologically accurate valuation models and maintaining simplicity 
such that options can still be solved analytically is an additional consideration. 
Data issues however, require a change in current practice and so perhaps pose the 
greatest obstacle. 
5.5.2 Wider implications 
This chapter has applied the principles of financial put-option pricing theory to 
assess cost-effectiveness of treating coma patients. Both the real options theory 
of abandonment and the concept of explicitly valuing future opportunities have 
wider appeal within health care. 
The theory of abandonment options might be used by phannaceutical companies 
to assess timing of production downsizing in response to uncertain demand, or 
the optimal abandonment time of a novel compound for which a lack of efficacy 
has been demonstrated. Outputs from hospitals might be examined to 
recommend optimal closure of out-dated wards in favour of newer facilities. On 
a micro level patients consuming specific drugs might be monitored. Well-being 
reaching some lower threshold indicates the optimal timing to end the regime or 
switch (abandon and reinvest) to an alternative. Within each of these potential 
applications the presence of uncertainty, some degree of irreversibility, and an 
ability to defer, supports the use of financial techniques. 
The idea of valuing future opportunities is particularly useful to assess 
desirability of current investment opportunities. Purchase of life saving 
equipment and research into life saving techniques create options to initiate life 
support. When merging with another company, a pharmaceutical may be 
interested in future opportunities created by the merger in addition to current finn 
value. In other words, decision makers are just as interested in the option 
premium, the value of future flexibility, as in intrinsic value and option value. 
Research and development projects are especially important for their effects on 
future capabilities. These examples assume the perspective of creating rather 
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than destroying options but any decision that involves a resource commitment 
destroys options. 
This chapter has used a continuous diffusion process to model the evolution of 
patient well-being. This format could be used in many patient level decisions in 
addition to macro level choices. For instance, medical and surgical management 
may be compared by modelling well-being following each course of action. 
Continuous processes are also appropriate when the underlying source of 
uncertainty is a price or cost such as the price of a pharmaceutical or price 
charged for health related services (perhaps dental or chiropody services). 
The purpose of this chapter was to apply real options within an area where 
deferral is not explicitly considered. A Brownian motion continuous diffusion 
process was used to value the flexibility lost when the option to defer removal of 
life support technology is exercised. Such flexibility has been shown to be 
valuable and should be acknowledged when decisions are made, irrespective of 
whether a choice creates or destroys future opportunities. The specific research 
problem identified is to specify and estimate relevant parameters. With this 
achieved the real options model can become operational. 
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Chapter 6. Real options analysis and technology 
assessment within the NHS. 
61 Introduction 
In 1997 the UK government set up the National Institute of Clinical Excellent 
(NICE) to assess the desirability of health-care related technologies. NICE 
respond to requests by the Department of Health for guidance on the usage of a 
variety of new and established technologies. Current evidence, incorporating 
information on clinical effectiveness, cost effectiveness, and wider implications 
to the National Health Service (NHS), is assessed to generate recommendations 
for appropriate use. 
When perforining an appraisal, NICE face an option to approve the given 
technology. Granting approval creates an option to alter this decision at a later 
date (an alteration option). This is analogous to a compound financial option 
where exercise of an initial option confers the ability to exercise a second. Both 
decisions are characterised by uncertainty in cost-effectiveness estimates, an 
ability to defer and some degree of irreversibility, suggesting further similarities 
with the compound option. 
Analysing technology appraisal as a compound option to approve and later 
retract may have implications for the initial guidance recommendation, 
particularly when current evidence is lacking or inconclusive. Complementary 
decisions to reduce irreversibilities may also be promoted. This chapter explores 
the methodological reasoning underlying, and implications resulting from, the 
application of financial option pricing techniques to the appraisal of health 
technologies. Having examined the role and decision-making capabilities of 
NICE in section 2, section 3 considers financial compound options analysis and 
section 4 considers real compound options, drawing parallels to decision making 
within NICE. Section 5 develops a model for the option to approve and later 
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retract. This is evaluated in section 6 using a numerical example. Section 7 
concludes. 
6.2 The role ofNICE and current decision makin 
Since its creation in 1997, NICE has been involved in appraising numerous 
technologies for use within the NHS of England and Wales. A technology, for 
the purposes of NICE, has a broad interpretation including medical devices, 
procedures and medicines. Examples of appraisals include cartilage 
transplantation for defective knee joints (Guidance issue No. 16), wisdom teeth 
removal (No. 1), and prescription of pharmaceuticals for management of patients 
suffering from Motor Neuron Disease (No. 20). 
Within the process of appraisal, NICE explore current evidence on areas such as 
cost, clinical effectiveness, equity implications and budgetary impaCtS30. This 
involves taking account of submissions from manufacturers, literature reviews of 
published material, and consultation from medical experts and patient 
representation groups. Having synthesised relevant evidence, guidelines are 
formulated. For example, the process has resulted in guidance on the use of 
nicotine replacement therapy (NRT) for smoking cessation (No. 39). In this case 
guidance recommends medication be prescribed for patients with an expressed 
desire to quit. Guidelines sometimes specify patient groups for whom the advice 
is appropriate, such as those of a certain age or with particular risk factors. For 
instance, NRT should not normally be prescribed if a patient has received this 
therapy within the past 6 months and failed. 
The UK is not alone in attempts to introduce economic considerations into 
technology appraisal. Australia led the way in requesting economic evidence to 
support applications for reimbursement. The Australian Medical Services 
Advisory Committee (MSAC) invites applications for review and follows a 
structured process that results in a statement of recommendation presented to the 
30 Details of NICE, technologies currently under appraisal, previously appraised and issued 
guidance can be found on the website; http: //NvNvw. nice. org. uk. 
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health minister. Since this scheme, countries including Portugal, Finland and 
Denmark have created similar committees. NICE is one of the youngest bodies 
assessing economic evidence on health related technologies. 
Currently within the UK, NICE guidance is viewed as relatively irreversible. 
Irreversibility may encompass an inability to recuperate sunk cost, abandonment 
expenses required to alter the decision itself and avoid adverse repercussions, or 
a physical inability to alter the decision and repercussions. Despite the existence 
of review dates where previous recommendations are assessed in the light of new 
information, political pressures and physical costs generate considerable 
irreversibility for technology approval. As technologies increasingly come up for 
review and guidelines are altered, political resistance may fall reducing the 
degree of irreversibility. 
Australia assumes a more flexible approach in the adoption decision, 
acknowledging possible reversal in their initial recommendation statement. 
Where evidence is inconclusive or insufficient MSAC have recommended 
interim approval. In 1999 endoluminal grafting for abdominal aortic aneurysms 
was given approval although ongoing data collection was recommended with 
review as soon as possible due to insufficient evidence. Also in 1999 directional, 
vacuum assisted breast biopsy was granted interim funding with the condition 
that costs be continually investigated. Evaluation of near patient cholesterol 
testing using cholestech LDX, brachytherapy for treatment of prostate cancer, 
and deep brain stimulation for symptoms of Parkinson's disease have all received 
similar recommendations. For the latter two, review was required within three 
years of the initial approval date. 
Acknowledging potential for reversibility reveals a similarity between decisions 
facing NICE and decisions to exercise compound financial options. Appraisal of 
new and existing health technologies creates an option to defer approval. The 
decision to exercise is surrounded by uncertainty in cost-effectiveness estimates, 
and exercise can usually be deferred, and is partially irreversible. Importantly, 
exercise in principle creates an option to alter, or defer altering, the original 
recommendation. As a technology is subject to more research and is used in a 
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wider context, and on a prolonged basis, information may become available that 
either supports or contradicts the initial approval decision. When newly available 
information alters the desirability of the technology, NICE can exercise their 
option to alter the treatment guidance. This may take the form of extended or 
retracted coverage, or reversing their initial decision by withdrawing the 
technology altogether. 
NICE face two sequentially linked options; the option to approve, and the option 
to alter that decision. Both elements of the decision problem are characterised by 
uncertainty, some degree of irreversibility, and an ability to defer. The sequential 
interaction of these decisions resembles a compound financial option and 
supports the use of option pricing techniques to evaluate the initial approval 
decision. These techniques encourage the reversal decision to be discussed ex- 
ante. The following section examines the analogy more closely, looking at the 
theory surrounding compound options and how this relates to the current 
application. This section also highlights existing examples of real compound 
options analysis. 
63 The coinvound ontion 
Compound options consist of any combination and number of simple call and put 
options. A financier may own a call option on a call option. The first call is an 
option to defer purchasing the second. Exercise confers the second option, which 
in turn confers the opportunity to defer purchasing some underlying asset. 
Compound options analysis is not new in the real options arena. Dixit and 
Pindyck (Dixit, 1989) provide an early study modelling interrelated decisions, 
examining entry and exit decisions of a firm given uncertain prices. The authors 
treat idle and active firm status as call options on each other and identify a pair of 
trigger prices that induce entry and exit. Entry provides active status and confers 
the option to exit, whilst exit makes a firm idle and confers the option to enter. 
Noting that these thresholds differ from thresholds identified using standard 
techniques, Dixit and Pindyck use their solutions to explain hysteresis. 
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Sunnevag (Sunnevag, 1998) looks at exploration licensing strategy for non- 
renewable resources. Exploration is evaluated as a compound call option on a 
ftirther call option to develop the resource. In this case the options are owned by 
relevant licence granting authorities that respond to uncertainty in resource 
prices. Valuation is based on a binomial lattice with the development option 
expiring in 20 years (50 periods each of 0.4 years). Sunnevag investigates 
optimal timing of exploration and development. 
Work in this area has been furthered by Trigeorgis (Trigeorgis, 1996) who 
valued complex multi-option leases, accounting for a series of exercise prices, 
non-proportional dividends and interaction effects. In addition, Rose (Rose, 
1998) has presented a methodology specifically to value interaction effects 
between embedded options, examining a tollroad infrastructure project. 
Underlying risk factors were simulated using Monte Carlo methods leading to 
the conclusion that option value may account for more than half of market value 
for complex interacting real options. Pcnnings (Pcnnings and Lint, 2000) has 
considered market entry as a compound option on phased roll out of a product. 
Pennings examines the optimal rate and global position of the phased roll out as 
endogenous actions to reduce uncertainty. 
In addition to addressing compound options, real options analysis has been used 
to evaluate the impact of varying degrees of irreversibility; an integral part of the 
compound real option. Tegene (Tegene et al., 1999) and Hodge (Hodge, 1984) 
both study irreversible development of agricultural land. The former discusses 
future returns from agriculture and urban use as the dominant sources of 
uncertainty. The decision to sell the land for development is analysed as 
irreversible exercise of an option. Hodge focuses on the uncertain value of 
preservation and discusses irreversibility in the form of expected opportunity loss 
from a given choice. Degrees of irreversibility are examined by altering the time 
taken for information, necessary to identify and correct errors, to become 
available. 
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Zhao (Zhao and Zilberman, 1999) introduces an irreversibility cost. Within this 
paper, which considers natural resource development, the author distinguishes 
types of irreversibility, categorising technical and economic irreversibility. 
Finally Fanai, (Fanai and Bum, 1997) defining irreversibility as the "degree to 
which ... anticipated and unanticipated impacts on a project can be mitigated", 
explicitly adopts the degree of irreversibility as a selection criterion. 
6.4 The coinnound option to anDrove and later retract 
In the case of technology approval NICE have an option to approve which 
involves selecting one of three choices; reject the claim for approval 
immediately, approve immediately, or defer making the approval commitment 
until some future date. NICE observe expected benefit to inform the approval 
decision. Exercising the option to approve is akin to a compound American call 
option. On exercise (irreversible) upfront costs are incurred to approve a 
technology with uncertainty future health benefits. The option to alter the 
approval guidance, which includes the option to reverse the decision and 
withdraw approval, is also conferred. 
The reversal option is only conferred once the option to approve is exercised and 
is akin to an American put option. In finance, exercising a put means giving up 
dividends and price appreciation in return for some positive price. In the real 
sector exercise of a put or abandonment option is usually with the aim of 
preventing or ending a stream of negative payments and occurs at some cost. 
Exercising the opportunity to reverse the approval decision may involve 
incurring political costs in return for ending the stream of uncertain benefits. 
When appraising a new or existing technology NICE own an American call on 
an American put. Figure 6.1 illustrates this compound approval option in 
decision tree format. Although the tree is structured as a collection of 
sequentially faced decisions and events, observation of uncertain expected and 
realised benefit occurs continuously and underlies the entire tree. 
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- Observe Confront Immediate Confront 
Immediate expected option to reversal option 
to 
approval -4 0 and reverse 
+ 
approve 
realised decision Defer Confront 
benefit reversal option to 
reverse 
Immediate 
rejection 
I Immediate 
approval 
Observe 
expected Immediate 
- Defer -4 0 and rejection 
approval realised 
benefit Defer 
approval 
Figure 6.1. Decision tree illustrating the compound option to approve a 
technology. 
The two elements of the compound real option can be compared to the 
characteristics of financial options (table 6.1) to assess similarities in structure. 
Both options are owned by NICE. The opportunity to approve is conferred by the 
nature of NICE as a decision-making body and exogenous agents pursuing 
research and development activities that generate technologies. The alteration 
option is conferred only through exercise of the approval option. In both cases 
uncertainty surrounds expected cost-effectiveness of immediate exercise and 
deferred action. With reference to this, infori-nation on clinical benefit, cost, and 
cost-effectiveness becomes available over time. Both options have some degree 
of irreversibility in the form of upfront costs associated with exercise, and both 
decisions can be deferred. 
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Option to approve Option to alter decision 
Decision maker NICE NICE 
Source of option Conferred exogenously via Conferred endogenously via 
actions of firms (R&D), and decision to approve 
apprais* process 
Nature of option Call - Investment Put - Abandonment 
Dominant source Expected cost-effectiveness Realised health gain and 
of uncertainty future expected cost- 
effectiveness 
Information gained Information on cost and Information on cost and 
through deferral effect from ongoing effect from ongoing 
randomised controlled and randomised controlled and 
pragmatic trials, and case pragmatic trials, and case 
study observations from study observations from 
increased use increased use 
Source of Cost of issuing guidance, Political and physical costs of 
irreversibility training practitioners in use altering adoption decision 
of technology 
Ability to defer Limited by NICE, arrival of Limited by NICE, arrival of 
new technologies, or public new technologies, or public 
pressure. pressure. 
May be known with May be known with certainty, 
certainty, entirely stochastic, entirely stochastic, or 
or dependant on arrival of dependant on arrival of 
additional information additional information 
Table 6.1. Characteristics describing the compound option. 
The parameters required to value the compound option are identical to those 
required for stand alone options because the structure and underlying source of 
uncertainty are the same (table 6.2). For the compound case two exercise prices 
(investment and abandonment costs) and, if applicable, two maturity dates are 
required. The exercise cost of adopting comprises the expense of appraising, 
creating, and disseminating guidelines as well as technological set up costs and 
associated training requirements. The exercise cost of altering is likely to be 
political. Although unique exercise dates may exist for each option, determined 
by both endogenous and exogenous factors, formal deadlines may not exist. 
Periodic benefit lost before the technology is adopted or received once approval 
has occurred represents the dividend found in financial models. 
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Parameters Compound option to approve a technology 
Current value of Expected benefit of approving (V) 
source of uncertainty 
Estimate of Uncertainty surrounding expected benefit. 
uncertainty (a 2) 
Cost of exercising call Cost incurred in development, dissemination 
and adoptio of guidelines (1) 
Cost of exercising put Costs incurred in reversing decision (E) 
option 
Dates before which Date before which NICE must make 
options must be decisions (TI, T2). Formal deadlines may not 
exerc se exist 
Benefits of exercising Periodic benefits received once approval 
/ costs of deferral occurs (8) 
Table 6.2. Parameters used to value the compound option to approve a health 
technology. 
Given the wider appeal of compound options methodology, and the similarities 
between the underlying financial problem and the compound option to approve 
new and existing technologies, the application of financial techniques to this area 
seems appropriate. The following section develops a model and numerical 
example to develop this analogy further. 
6.5 Ae model 
Many real options valuation techniques, including multinomial lattice methods, 
make the assumption of complete irreversibility. This usually takes two fonns. 
Firstly, projects have large up front costs that cannot be recuperated. Secondly, 
provision to end projects that have turned out less effective than anticipated is 
not often incorporated into modelling. Complete, or perfect, irreversibility rarely 
exists in practice so real option models must be adapted to account for differing 
degrees of irreversibility. Compound options analysis provides a way to achieve 
this through incorporating the opportunity to change decisions, and the costs of 
doing so. 
The compound option to approve and later reverse approval consists of two 
elements; an investment type option and an abandonment type option. The 
underlying source of uncertainty, expected benefit, is assumed to follow a 
geometric Brownian motion diffusion process (equation 6.1). 
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dV=a Vdt+aVdz (EQN. 6.1) 
Current expected benefit is known with certainty. Future values change each 
period dt with some drift a subject to a known and constant variance 0-2 . 
dz is the increment on the Weiner process 3 1. This fon-nulation assumes the 
option is available infinitely and once investment occurs benefits accrue in 
perpetuity. 
The components of the compound option are considered in turn. For the first 
element of the compound option NICE must decide, given the evolution of 
expected benefit, when (if ever) to exercise their option to approve. This amounts 
to choosing when to incur an irreversible sunk cost I, to approve, generate, and 
disseminate guidelines in order to benefit from the technology. The optimal 
action and timing is found by maximising the value of the investment 
opportunity Fo(V). This comprises a continuation value (value from maintaining 
the option) and a stopping value (value from immediate investment). 
The optimal stopping problem is solved using dynamic programming techniques 
to maximise the sum of the components of the optimal stopping problem. The 
valuation model follows methods used by Dixit and Pindyck (Dixit and Pindyck, 
1994) who show that the investment opportunity, Fo(V), must satisfy a second 
order partial differential equation (PDE): 
1a 2v2 Fo " (V) +a VFO'(V) - pFo (V) =0 (EQN. 6.2) T 
Fo'(V) and Fo"(V) represent first and second derivatives of Fo(V) with respect to 
V, and the subscript '0' refers to the fact that investment is yet to occur. The risk 
free discount rate is given by p. By satisfying the PDE, the value of the 
investment opportunity F(V), is always equal to the maximum of the 
continuation or stopping value. The solution has a functional form: 
31 Chapter 2 discusses the Weiner process in more detail. 
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Fo (V) = Ao VO'60 (EQN. 6.3) 
where AO is a constant yet to be determined and PO is the known constant: 
aap I (EQN. 6.4) flo 22222 
This solution is valid only over the interval during which investment has yet to 
occur, and the project remains inactive. If investment is found to become optimal 
at some upper threshold VH, FO(V) will be valid in the range (0, VH )- 
Whilst expected benefits are received each period they arrive at a constant cost C 
per period. Whilst continuing to hold the option to alter their approval decision, 
NICE hold an active project with operating benefits (V-C) accruing each period 
for which approval remains optimal. In the complete irreversibility case an 
investment threshold 32 can be obtained analyticall Y33 that relates to the cost per 
period (C) incurred once approval is given: 
fi 
fi-I (EQN. 6.5) 
Completely irreversible models usually contrast expected discounted operating 
benefits with upfront investment costs. Comparing marginal cost to marginal 
benefit (expected benefit per period) is more appropriate when a project can later 
be reversed and continual monitoring is required 34 . The optimal threshold can be 
used with the ftinctional form (equation 6.3) and a smooth pasting boundary 
condition to determine A: 
32 To distinguish the complete and partial irreversibility models the approval threshold in the 
complete irreversibility model is referred to as V*, and in the partial irreversibility model as VH- 
33 Given an absorbing barrier and appropriate value matching and smooth pasting boundary 
conditions (see Chapter 2 section 2.2; equations 2.19-2.24). 
34 When a project is fully irreversible an investment threshold is more likely to be obtained that 
relates expected discounted operating benefits to upfront sunk cost. Actual operating revenues are 
effectively irrelevant once the project is initiated since the project is ftilly irreversible. Here, for 
comparability with the reversible scenario, a threshold is generated that relates periodic expected 
benefits to periodic costs. 
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A=V*-c (A, -I)"'-' 
V *, 60 
'flo, 
00 C'60 -1 
(EQN. 6.6) 
The solution for the simple option, for a given set of parameter values, may be 
compared against the solution for the compound option in order to assess the 
impact of accounting for degrees of irreversibility. When there is incomplete 
irreversibility the adoption option must be solved simultaneously with the 
reversal option. 
To introduce the compound element of the option, the value of the active project 
must be considered. Having granted approval expected benefits of the technology 
(V-C) continue forever or until the decision is altered. The value of the alteration 
opportunity associated with the active project must satisfy a second order partial 
differential equation, which closely reflects that facing the inactive project: 
Ia 2V2FI" (V)+ a VFI'(V)-pF, (V)+V- C= 0 (EQN. 6.7) 2 
The subscript 'I' indicates that investment has occurred. The additional term (V- 
representing periodic operating profits of the active project, leads to a 
difference in functional fann for the solution: 
F, (V)=A, Vlßl + 
v-c) (8 
r 
(EQN. 6.8) 
The tenns 5 and r are the discount rates applied to benefits and costs 
respectively. As before A, is a parameter yet to be determined. P, is given by: 
2 
2p 
2 a2 a2-1. 
+ 
er 
2 <0 (EQN. 6.9) 
The first term of equation 6.8 values the abandonment option whilst the second 
two terms provide the discounted value of the live project if the firm must 
continue to operate forever. The reversal threshold is valid only once initial 
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investment has occurred, and whilst the project remains active. If reversal 
becomes optimal at a lower abandonment threshold VL, the solution will be valid 
for benefits above this threshold; FI(V) will be valid in the range (VL, 00)- 
The thresholds, VH and VU together form part of the solution to the compound 
adoption decision faced by NICE. As with simple options, at the thresholds, 
value matching and smooth pasting boundary conditions link the values and 
derivatives of the two opportunities, enabling the complete solution to be 
derived. 
The approval opportunity is given up at a cost of I in order to obtain the reversal 
opportunity. Therefore, at VH the value of the approval opportunity must be 
equal to the value of the reversal opportunity less the cost (1) of creating that 
opportunity (equation 6.10). This gives the value matching condition for 
investment. In addition the incremental values of both opportunities for a small 
change in expected benefits must be equal (equation 6.11), the smooth pasting 
condition. 
Fo (VH) = F, WH) -I (EQN. 6.10) 
Fo' (VH )=F, ' (VH ) (EQN. 6.11) 
On altering the adoption decision, NICE regain the initial option to adopt the 
technology of interest, at a cost of E. At VL the value of the reversal opportunity 
must equal the value of the approval opportunity less this cost (E) associated 
with reversing the decision (equation 6.12). Again the derivatives of the two 
functions must equate (the smooth pasting condition (equation 6.13)). 
F, (VL) = Fo (VL) -E 
F, (VL Fo (VL 
(EQN. 6.12) 
(EQN. 6.13) 
Rewriting the four boundary conditions using the values for the two options, FO 
(V) and FI(V), yields 4 equations in 4 unknowns; VL, VII, AO and A,. 
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PO A ViL c=I Aovjj + Ajvý + ý, 5 '. (EQN. 
6.14) 
fl, -l 91-1 1 - floAOVýj +fl, A, Vil +7=0 (EQN. 6.15) 
+ A, 
6. 
+ 
vi c= -E (EQN. 6.16) - AoVill. vi S-r 
'00-1 fli-I I -floAOVL +fl, AIVL +-y=O (EQN. 6.17) 
The simplicity of the basic model does not transfer due to the highly non-linear 
nature of the equations, and a closed form analytic solution is not possible. 
Numerical methods must be employed to simultaneously solve the four equations 
to obtain values for the 4 unknowns. 
Dixit (Dixit, 1989) uses this formulation to evaluate a proposed investment in a 
mine. He shows that a unique solution exists that is economically intuitive 
because the thresholds satisfy the natural progression O< VL<VH"ý"00. In the 
following section numerical methods are employed to solve the adoption and 
reversal decisions for a hypothetical technology assessment. 
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6.6.1 Numerical example 
In October 2003 NICE anticipates publication of their guidance from the wave 
six appraisal of newer drugs for epilepsy in adults and children. Assume that 
until approval is granted the drugs are not supplied by the health service. NICE 
have an option to approve which involves selecting one of three choices; reject 
the claim for approval inu-nediately, approve immediately, or defer making the 
approval commitment until some future date. The reversal option is conferred 
when the option to approve is exercised. NICE can explicitly identify the pair of 
transitional approval and reversal decision thresholds referring to expected 
benefit per treatment, V. 
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Suppose current expected benefit per treatment is E8 evolving through time 
according to patients' capacity to benefit at 3% (oý--0.03) with 10% volatility 
((3---0.1). Discount rates of 2% for benefits and 6% for costs are applied, 
consistent with existing economic evaluation practice. The costs of granting 
approval and generating guidelines are initially set to E200 (1) with reversal costs 
at 50% of this (E =ElOO), the constant costs (C) borne by the health service per 
treatment are V (table 6.3). The values have been scaled downwards from likely 
true values in order to maintain ease of identifying a solution. With this in mind 
approval and reversal costs might be interpreted as average costs per patient 
treated. 
Parameter Base case 
parameter values 
Drift in expected benefit (cc) 0.03 
Variance in expected benefit ((Y) 0.1 
Discount rate for costs (r) 0.06 
Discount rate for benefits (5) 0.02 
A2proval costs (I) E200 
Periodic costs of technology (C) V 
Reversal costs (E) Eloo 
Risk neutral discount rate 0.05 
Table 6.3. Base case parameter values for the compound option to approve and 
later reverse approval of a technology. 
UTS Software, TK Solver release 4 is used to calculate the constants (po, P I) and 
simultaneously solve the 4 equations (6.14 - 6.17) for the functional form 
parameters (Ao, A, ), and optimal thresholds (VL, V10- The package employs a 
modified Newton-Raphson iterative procedure to converge on the four solutions. 
For each iteration TK Solver uses either initial guesses (for the first iteration 
only) or previous solutions as inputs into the model. The problem is solved 
repeatedly until error tenns are reduced below a given tolerance. Manually 
substituting the final solutions into the four equations confiniis that an accurate 
solution has been identified. While accurate for parameter values within given 
ranges, the model is not sufficiently robust to solve for all combinations of 
inputs, particularly where high investment costs are required. 
For the parameter estimates summarised in table 6.3 the approval (Vfj) and 
alteration (VL) thresholds were found to be El 8.28 and EO. 31 respectively (table 
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6.4). These values satisfy the intuitive constraint 0`ý VL <Vll<oo. The epilepsy 
drugs should be approved when expected benefit reaches El 8.28. NICE would 
then exercise the option to reverse their decision only once expected benefit falls 
to EO. 3 1. Although a seemingly large differential exists between the thresholds 
they should be interpreted with reference to current expected benefit (H) and 
cost (0) per treatment. Palmer and Smith (Palmer and Smith, 2000b) have 
previously shown that for reasonable parameter values an investment threshold 
can exceed investment cost by a factor of 3.7. The current example suggests 
periodic benefits should exceed periodic costs by a factor of 2.6 for approval to 
occur. 
Variable Estimate 
po 1.53 
PI -6.53 
Ao 7.004 
A, 0.001 
VII E18.28 
VL EO. 31 
Table 6.4. Solutions for the compound option to approve and later reverse 
approval of a technology. 
Given current expected benefit of E8, if NICE were considering the problem for 
the first time they would not approve the drugs. If the drugs had previously been 
approved, NICE would not reverse this decision. 
The thresholds differ in structure and value to those derived under conventional 
investment theory. Equating marginal revenue with marginal cost suggests 
approval and reversal as expected benefits respectively rise above and fall below 
the 0 periodic cost. This leads to a single decision rule triggering exercise of 
both options, rather than the pair identified by real options analysis. The single 
decision rule introduces the potential for oscillation between approval and 
withdrawal decisions with very small changes in expected benefit or parameter 
estimates. This means possibly unnecessary investment and abandonment costs 
might be repeatedly incurred. 
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The real options approval threshold is significantly higher, and the reversal 
threshold significantly lower, than the E7 periodic cost of maintaining the option. 
This analysis therefore generates more conservative decision criterion for both 
types of option, reducing the possibility for oscillation in the optimal decision. 
The conservatism reflects the explicit handling of irreversibilities with real 
options modelling. 
The result that thresholds are more conservative is not specific to the numerical 
example demonstrated here. Examining the investment threshold in the presence 
of perfect irreversibility (equation 6.5) helps illustrate the generality of the 
conservative criterion. V* is related to costs and P. Equation 6.4 shows that 
exceeds one; it follows that P/(P-I) also exceeds one resulting in a decision rule 
V* that necessarily exceeds costs. V* exceeds C because immediate investment 
kills the option to invest at a later date. This is an implicit opportunity cost to 
investment, which is incorporated into real options analysis. When varying 
degrees of irreversibility are introduced, although the option to approve is lost, it 
can be regained later at some cost; the reversal cost. The implications of the 
degree of irreversibility are considered in the following section. 
Parallel arguments are true for an abandonment option considered in isolation. 
When simple options are combined to form a compound option the respective 
decision thresholds become connected. The result is two conservative decision 
criteria. 
The high value Of VH, more than twice the periodic cost, indicates reluctance of 
the decision maker to commit to an expensive and partially irreversible venture. 
Similarly the low value Of VL represents the decision maker's reluctance to incur 
expenses to abandon a venture that may later prove beneficial, especially when 
re-approval at a later date is also costly. Maintaining the status quo keeps future 
opportunities alive without having to incur sunk costs. Continuing to supply a 
drug even when it has been shown not to be cost-effective keeps open the option 
of later withdrawal or alteration to usage guidance without incurring large costs. 
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The boundaries (VU VH) define a region of inertia within which current expected 
(; E8) benefit falls. Within this area, if approval has previously been granted the 
drugs will continue in circulation, but if approval has not yet occurred, or has 
been withdrawn, the drugs shall remain unapproved. This provides an intuitively 
reasonable explanation for observed behaviours. For instance decision makers 
may not react immediately with changes in decisions following new information 
on expected benefit. This may indicate that expected bencfit has not altered 
sufficiently to reach a decision threshold. 
Given knowledge of whether approval has yet been given, current expected 
benefit, and the direction and extent of change over time, NICE can assess the 
likelihood of future approve or retraction, and anticipate future need for 
announcements, guidance, and improved information. For instance, suppose 
epilepsy drugs have not yet been approved, expected benefit is E14, and analysts 
anticipate a rise over time due to more accurate drug targeting. NICE should 
defer approval, but predicting an improvement in cost-effectiveness, should plan 
to review evidence after some period of time. Larger values of cc indicate quicker 
arrival at the required threshold and suggest the need for earlier review. 
When evaluating multiple technologies whose evidence is insufficient, 
expectations for the future can be used to prioritise the timing of reviews and 
appeals. Real options analysis can be used to justify the timing of re- 
examinations of current evidence, reducing the likelihood of ad hoc reviews set 
at ftiture dates with no apparent explanation. 
NICE may be concerned about differentiation among patient groups with 
contrasting characteristics and risk factors. Existing guidance has frequently 
made such distinctions. For instance, April 2001 guidance for treatment of 
patients who have experienced a myocardial infarction (MI) identifies three 
groups of patients; those with prior MI who do not have heart failure, those with 
prior MI who have diabetes, and those with prior MI who do have heart failure. 
The precise guidance depends on which group an individual falls in to. 
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Within the real options model individual characteristics may cause patient groups 
to differ with respect to their current expected benefit, drift and volatility over 
time. Guidance issue may even be more irreversible for some groups than others. 
A group of patients who, in the public perception, are believed to benefit greatly 
are likely to have greater political irreversibility costs (E). Due to interactions 
within the model this raises the initial investment threshold. Such differences 
generate contrasting decision thresholds between groups, allowing guidance to be 
tailored to a sub-group of interest. 
Similarly, every technology considered will have unique characteristics. 
Differences may exist in current expected benefits that evolve through time, with 
their associated drift and volatility, as information on disease incidence, 
prevalence and cost-effectiveness becomes available. Irreversibility in the form 
of sunk costs of approval and withdrawal may vary between technologies, in 
addition to ongoing treatment costs. Each technology will, therefore, have 
exclusive approval and reversal threshold that depend on the characteristics of 
the technology and the patients receiving treatment. 
Finally NICE may be interested in the arrival of trial based data that could impact 
on current expected benefit or its evolution. If a trial is known to be reporting 
soon and the release of data is anticipated to reduce uncertainty, these effects can 
be incorporated into the model and their effect on the decision thresholds 
observed. Alternatively NICE may choose to defer the approval decision pending 
release of additional information. 
Through this variety of mechanisms real options analysis can contribute to 
understanding and evaluating decisions faced by NICE with respect to new and 
existing health care technologies. 
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6.6.2 Assessing the impact of irreversibility 
Existing economic evaluation techniques make implicit assumptions with regards 
to the irreversibility of decisions. Actions are usually considered irreversible in 
the sense that upfront costs are sunk, and actions to alter or reverse decisions are 
rarely considered. Real options analysis highlights irreversibility and makes 
assumptions explicit, opening them to academic debate. Analysis of simple 
investment and abandonment options assume perfect irreversibility. Analysis of 
compound options, which examine interrelated sequential actions, allows varying 
degrees of irreversibility to be considered. In the current example, irreversibility 
enters the analysis through three factors; the existence of the reversal option, 
which allows the initial decision to be reversed, sunk costs of making the initial 
decision, and sunk costs incurred when the reversal option is exercised. 
To examine the impact of being able to reverse a decision, the investment 
threshold given partial irreversibility, VH can be compared to the threshold 
generated in a model of complete irreversibility V* (equation 6.5)35. 
ß-1 
(EQN. 6.5) 
From table 6.4, the P applying to the simple adoption option, Po, is 1.53. P/(P-I) 
is therefore given by 2.89 suggesting the perfectly irreversible approval threshold 
is reached when expected benefits exceed costs by a factor of 2.89. Given a cost 
level of V, approval is not announced until expected benefits reach E20.23, 
fl. 95 greater than the partial irreversibility model (VH =E 18.28). When 
analysing technologies with greater irreversibility NICE are therefore advised to 
be more conservative in their initial approval recommendation. 
35 Comparison of option values under complete and partial irreversibility may also seem 
appealing. However, this comparison requires using only a subset of the partial irreversibility 
model because option value depends the active/idle status of the firm. This is inappropriate due to 
synergies existing between the components. Since the approval threshold for the partial 
irreversibility model incorporates influences from the reversal decision, this latter comparison is 
valid. 
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Extensive irreversibility may surround the approval decisions of national 
programmes that have high public profiles such as issuing free contraceptives or 
advising regular cervical smear testing; approval or even the existence of either 
programme might be seen as irreversible. The higher approval threshold causes 
NICE to be more cautious, deferring for longer periods of time when analysing 
such programmes. When prioritising potential treatments, real options analysis 
lends greater support to investments with potential for reversibility. 
The sunk cost irreversibility metrics, I and E, also affect the decision-making 
thresholds. Increases in E and I amplify irreversibility, creating inertia against 
exercise. Dixit and Pindyck (Dixit and Pindyck, 1994) illustrate how this raises 
the investment, and reduces the reversal thresholds, widening the region of 
inertia. In the numerical example presented here doubling the approval cost from 
flOO to E200 increases the approval threshold from E12.51 to E18.28, and 
reduces the reversal threshold from EO. 32 to EO. 3 1. An effect is felt on the 
reversal threshold since exercising the option to reverse recreates the initial 
approval option and so allows the possibility of re-approval. This requires 
incurring I for a second time. Altering reversal costs has significantly less impact 
on both thresholds. This is predominantly because, if incurred at all, E is faced in 
the future. Discounting effects within the model cause the two types of cost to 
affect their 'own' threshold more strongly, and cause more immediate effects to 
be greater. Table 6.5 surnmarises influences on the thresholds. 
Influence Effect on VH Effect On VL 
Ability to reverse Negative 
I Positive Negative 
E Positive Negative 
C Positive Positive 
Cr Positive Positive 
Table 6.5. Factors influencing the decision thresholds for the compound option 
to approve and later reverse approval of a technology. 
Explicitly recognising and analysing the effects of irreversibility can contribute 
to decision making within NICE. Suppose NICE is considering approving one of 
two substitute drugs. Having been prescribed, withdrawal of compound A is 
associated with extensive side effects that make reversing the approval decision 
costly, both on an individual level and politically. Compound B is initially more 
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expensive to approve and prescribe due to training costs required by staff 
providing the medication. The relative attractiveness of the two compounds is not 
immediately apparent. Real options analysis can be used to assess relevant 
sources of irreversibility; informing immediate adoption decisions as well as 
longer run strategies for technology adoption, collection of additional 
information, and prioritising areas where actions to reduce irreversibility might 
be useful. 
6.7 Conchisions 
This chapter has structured technology approval decisions by NICE as exercise 
of a set of compound options, analogous to a portfolio of financial call and put 
options. For contingent choices to be analysed in this way exercise of one option 
must automatically confer a related choice. In this case technology approval 
confers an option to renege, altering the initial guidance. Both the approval and 
reversal decisions are characterised by the same underlying sources of 
uncertainty, some degree of irreversibility, and an ability to be deferred. 
The focus of this application has been the implications for health care decision 
making of incorporating option pricing techniques, specifically attitudes towards 
and methods for incorporating, partial irreversibility. This chapter has used 
dynamic programming and numerical techniques to solve the approval problem 
for two distinct, yet complementary, decision criteria. Although successful for 
the range of base case parameter values used, the iterative solver employed is not 
robust to large changes in these values. Further work is required to improve the 
power of the solution procedure and mathematical tractability. 
Conventional investment theory has a single investment / disinvestment 
threshold identified by marginal revenue equating to marginal cost. Within a 
volatile economy this can lead to successive and potentially unnecessary 
investment and disinvestment decisions. Real options analysis recognises 
sequentially linked investment and disinvestment decisions and identifies two 
complimentary decision thresholds generating a region of inertia that reduces the 
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potential for oscillating decision making. The criteria are unique to the 
technology of interest for the patient group under consideration. Within the 
bounds of this region inactive projects remain silent and active projects continue 
in operation. Dixit (Dixit, 1989) has argued that such inertia, which might be 
viewed as a cause of hysteresis and evidence of a sluggish economy, is actually 
the result of fin-ns' dynamic and strategic thinking. 
Applying real options analysis has emphasised the need for explicit discussion of 
irreversibility. In practice health care projects display varying different forms and 
degrees of irreversibility. NHS infrastructure projects involve heavy up front 
sunk expenditures and research efforts require initial spending in addition to 
prolonged commitment. Surgical operations often cannot be reversed at all and 
political costs may prove an important consideration in many strategy decisions. 
Outside of the NHS pharmaceutical companies may face irreversibilities linked 
to development and clinical testing of new drugs, and private health insurance 
companies face difficulty reversing previous commitments to finance certain 
treatments. Irreversibility has not yet received attention within health economics 
literature in proportion to its importance in decision making. Real options 
analysis may help to redress this problem. 
The understanding of irreversibility provided by real options analysis can be used 
to influence current actions, not only with respect to the decision of interest but 
also with respect to influencing future iffeversibilities. Actions might be taken 
today on the basis that they reduce future costs of reversing decisions, rather than 
because of high expected returns. For instance, the political costs of reversing an 
approval decision might be reduced by action taken now to promote the idea of 
temporary approval pending additional infon-nation. In the case of insufficient 
information, contracts might be drawn up such that the company submitting a 
drug for approval agrees to incur reversal costs should temporary approval be 
granted, and this turns out to be a poor decision 36 . 
36 NICE have, in essence, embraced this idea in their guidance for treatment of patients with 
Multiple Sclerosis. An evaluation of current treatments did not demonstrate cost-effectiveness. 
NICE/Department of Health have therefore approved the drugs but have set up a risk sharing 
scheme. This scheme aims to reduce the costs to the NES should treatments fail to be sufficiently 
cost-effective. Payments to the pharmaceutical companies are reduced if realised average cost per 
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On a broader perspective, advocating temporary and flexible nursing contracts 
may reduce the irreversibility of increasing staffing during winter months when 
pressure is greatest. Upfront thought about the sources and impact of 
irreversibility can help avoid irreversible situations being encountered, promote 
action to reduce irreversibilities, and shape longer run decision strategies. 
Additional work is needed in this area to assess the suitability of applying 
compound options analysis in practice. Whilst every effort has been made to 
create an intuitive example that encompasses real world effects, bringing 
empirical data into such a theoretical model will inevitably create difficulties. 
Perhaps the greatest challenge is to collect sufficient data at regular intervals to 
provide reliable estimates for the mean and variance of expected benefit and its 
progression through time. 
Compound options analysis has been applied here to address partial 
irreversibility within the health care arena. There are many broader issues for 
which this theory may be relevant. In essence compound option analysis is 
applicable to any situation in which multiple decisions interact sequentially. This 
is the case for staged development of new hospitals or where building a general 
ward creates an option to treat increasing numbers of patients. Adoption of new 
technologies, which require specialist training, may create options to switch 
between similar technologies requiring comparable skills, or upgrade to newer 
technologies as they become available. 
To conclude, this chapter has considered the application of compound options 
analysis to the health care sector to address partial irreversibility. This has 
required an amalgamation of the underlying principles of previous chapters that 
have considered call and put options independently. In this case study the 
compound option to approval and later reverse approval of health technologies 
has been analysed and decision criteria for the two complementary exercise 
Qaly exceeds some pre-agreed level. This measure acknowledges and takes account of 
irreversibilities potentially faced by NICE in their decision to approve. Details of the guidance 
and the risk sharing scheme are available on the NICE website: 
ht! p: //www. nice. org. uk/article. asp? a=27673 
136 
decisions generated. 
137 
Chapter 7. The option to wait for more information: 
option value and the value of information. 
7.1 Introduction 
Methods of incorporating uncertainty into economic evaluation of health 
technologies have been debated for some time. Techniques to help understand, 
present and evaluate uncertainty have included single, multi-way and 
probabilistic sensitivity analysis, scenario and threshold analysis, and the use of 
confidence intervals and cost-effectiveness acceptability curves (Briggs and 
Gray, 1999). Value of information analysis has developed as a tool that places a 
value on uncertainties within a model and has been proposed as a way to 
prioritise efforts to reduce uncertainty. The expected value of perfect information 
(EVPI) defines a maximum willingness to pay for research efforts that provide 
information relevant to the decision. 
Real option theories consider decisions under uncertainty and are relevant when 
choices can be deferred, and deferral is associated with learning more about 
uncertain variables. Analysing the opportunity to wait for information as an 
option to defer, allows option premium (difference between option value and 
intrinsic value) or the incremental value of deferral, to be estimated. This places 
a numerical estimate on the value of waiting for additional information. Option 
premium is therefore a form of value of information that can be compared to the 
expected value of perfect infon-nation. This may have implications both for the 
way uncertainty is perceived and the way research budgets, aimed at reducing 
uncertainty, are allocated. 
This chapter explores the relationship between these two measures of value of 
information. Section 2 considers existing work on value of information in 
economic evaluation and develops a stylised example concerning information 
gained from a clinical trial to illustrate relevant concepts. Section 3 discusses 
deferral as a way of gaining information, and estimates the incremental value of 
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deferral. Section 4 makes the distinction between actively seeking and 
independently observing information and identifies a relationship between option 
premium and the expected value of perfect information. The analogy between 
real and financial options is reiterated in section 5 where a combined Brownian 
motion / Poisson information arrival function is created to model the option to 
wait for additional information. Applications to health care and implications for 
decision making are examined. Section 6 concludes. 
7.2 Value of information in economic evahtation 
When a decision is made in the presence of uncertainty there is some possibility 
that an alternative, other than that with the greatest expected net benefit, offers a 
greater payoff retrospectively. Information collected prior to the decision being 
made can improve the probability of making an ex-post optimal decision. 
Uncertainty is therefore costly, and infon-nation is valuable for this reason. In the 
extreme, perfect information on parameters of interest may be sought. 
The expected value of perfect information (EVPI) 37 , measures the value of 
infonnation by considering the probability of making a sub-optimal decision 
(based on prior information) and the implications of doing so. EVPI is estimated 
by calculating the difference in expected payoff between a decision made with 
perfect information and one made in the presence of uncertainty. Discussion of 
the concept of EVPI and its usefulness within health care have developed from 
statistical decision theory (Raiffia and Schlaifer, 1959; Pratt et al., 1995). Lapin 
(Lapin, 1994) gives a non-technical introduction both to the idea and calculation 
of EVPI. In practice, value of information analysis has been applied to a variety 
of areas including engineering (Howard, 1966) and food safety (Hammitt and 
Cave, 1991). 
Clinical trials are designed to improve current evidence concerning effectiveness, 
providing greater information for clinicians, GP's and policy makers faced with 
37 EVPI is mathematically equivalent to, and is sometimes referred to, as expected opportunity 
loss. 
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choosing between competing technologies. Whilst gathering information is 
beneficial, it is also costly; trials and research and development consume large 
proportions of research budgets. EVPI defines the maximum potential 
improvement in payoff available as a result of improved information and, 
therefore, places a bound on the achievable benefit from collecting evidence. As 
a result EVPI has been used to identify an upper boundary on the willingness to 
pay for research activities within health care (Claxton and Posnett, 1996). EVSI 
(expected value of sample infon-nation) has likewise been used to define the 
potential benefits from clinical trials that sample effectiveness for a subset of the 
population (Claxton and Posnett, 1996). 
The EVPI concept has been increasingly applied to methodological work within 
health care, both as a form of sensitivity analysis and as a way of prioritising 
research proposals. Felli (Felli and Hazen, 1998) discusses the relative merits of 
various measures of decision sensitivity including probabilistic sensitivity 
analysis, and introduces EVPI as a possible alternative. Three case studies were 
used to show that EVPI supersedes the other measures for suitability in assessing 
the impact of uncertainty, and tractability when multiple sources of uncertainty 
exist. The author also mentions EVPI as an upper limit on the value of 
infon-nation gained from sampling or diagnostic testing. 
Claxton (Claxton, 1999) argues the irrelevance of sensitivity analysis for current 
decision making favouring comparison of expected values based on prior 
information. EVPI and EVSI are then reserved for the complementary decision 
of whether additional information is required. From a policy point of view the 
value of additional information becomes an aid to prioritising future research 
agendas. 
In addition to these predominantly theoretical papers, an increasing number of 
authors have estimated value of information 38 (VOI) in practice. Bartell (Bartell 
et al., 2000) examined specific risk management applications of genetic 
biomarkers for patients with occupational Chronic Beryllium Disease (CBD), 
38 Since EVPI is considered an unattainable theoretical construct, work has developed around 
'value of information'. This considers variables on which information might feasibly be gathered. 
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and Dakins (Dakins et al., 1996), has estimated EVPI and EVSI for 
environmental remediation efforts to reduce polychlorinated biPhenyl sediment 
contamination. 
Within the health care sector Meltzer (Meltzer, 2001) considers the decision to 
treat prostate cancer comparing three strategies; watchful waiting, radical 
prostatectomy and the optimal decision with perfect infon-nation on the average 
rate of progression. Melzer calculates that perfect information improves the 
expected value of treating each patient by US $6400 compared to making an 
optimal decision with prior information. Aggregating to estimate population 
EVPI yielded an estimate of US $21 billion, which far exceeds the cost of a 
proposed experiment that provides information on the likelihood that cancer is 
aggressive. Value of information analysis has also been used in other areas 
including the decision to adopt a new pharmaceutical for the treatment of 
Alzheimer's disease (Claxton et al., 2001). 
The classical concept of EVPI can be illustrated through a hypothetical example. 
The National Institute for Clinical Excellence (NICE) may find it useful to 
estimate value of information when assessing new and existing technologies for 
use within the NHS. Suppose a new technology has been submitted for 
assessment and NICE must make an approval or rejection decision. The decision 
is assumed to be fully irreversible. Once approved the technology confers 
uncertain monetary benefits each period in perpetuity. For simplicity the decision 
is characterised only by first order uncertainty, which is resolved by a trial that 
reports towards the end of the current period. If an improvement in cost- 
effectiveness is demonstrated expected benefits per period are f 1000. If a 
reduction is shown, benefits per period are f: 40. The prior belief is a 0.5 
probability that the trial will improve (or deteriorate) periodic monetary benefit. 
Upfront irreversible costs of approval are assumed to be; E2000 (figure 7.1) 
encompassing the costs of generating and disseminating guidelines. 
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Figure 7.1. The decision to approve a technology 
With a discount rate of 6% the optimal decision is to adopt the technology with a 
net benefit of E7187 (equation 7.1). 
.c 
Net benefit -2000+E 
0.5*1000+0-5*40 (EQN. 7.1) 
1=0 (1.06)' 
-2000+9187 
7187 
EVPI is calculated by considering immediately, the best retrospective decision. 
In this case approval should only be granted in the event that an improvement in 
cost-effectiveness occurs. The difference in payment between this and expected 
net benefit is EVPI. The classical approach to value of information assumes no 
delay in receiving information, and in this example additional information 
provided by the trial would improve expected payoff by E646 (equation 7.2). 
This represents the decision-makers maximum willingness to pay to obtain the 
research results immediately. 
EVPI Payoff under certainty - Payoff under uncertainty 
0E 
1000 
- 200 2000+z 
05*1000+0.5*40 (EQN. 7.2) 
'0 
(1.06)' 
I'=0 
(1.06)' 
01 
1 j0 
1=0 
7833-7187 
646 
Although simple, using a single source of first order uncertainty, this stylised 
example illustrates relevant concepts for comparison with a real options model. 
The approval decision is characterised by uncertainty and irreversibility and can 
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be considered an option if immediate action can be deferred. The option to defer 
approval is considered below. 
7.3 Option vahte as a vahte of information 
Exercising the option to approve a technology is akin to an American call option 
on a dividend paying stock. Taking advantage of the ability to defer allows 
information on sources of uncertainty to be gained during the waiting period. 
This can be incorporated into assessments about whether irreversible decisions 
with uncertain outcomes should be pursued. In that VOI and option pricing both 
examine the impact and value of improved information on current decision 
making, they are alike. 
Intrinsic value is the benefit associated with immediate action under an option 
pricing approach. Option value is the benefit associated with a deferred decision 
made in light of new information available during the period of deferral. The 
difference, option premium, is the incremental value of being able to defer and 
gather information, and equates to a value of deferred information. 
Suppose the National Institute for Clinical Excellence (NICE) face an option to 
defer approval for one year. In the intervening period the trial discussed 
previously will publicly report additional cost-effectiveness evidence revealing 
all information relevant to the decision. The probability and absolute payoff 
associated with improved or deteriorated cost-effectiveness remain the same. 
NICE must estimate intrinsic value and option value in order to make a decision 
(figure 7.2). 
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Figure 7.2. The decision to approve or defer approval of a technology 
If immediate approval occurs the irreversible costs are incurred upfront. 
Combining this with the 0.5 probability of receiving beneficial or detrimental 
cost-effectiveness evidence gives an intrinsic value estimate equal to net benefit 
under a traditional approach 39 . 
m 
Intrinsic value = -2000+X 
0-5*1000+0.5*40 (EQN. 7.3) 
1=0 (1.06)' 
-2000+9187 
7187 
If deferral is chosen, the trial reports prior to the decision being made. In this 
case irreversible costs and potential benefits are both delayed for one period. 
Real options analysis must weigh the relative gain from information against the 
gains and losses from delayed action. Once the trial has reported the decision 
maker can assess the relative desirability of approving given the additional trial 
39 Intrinsic value = max(net benefit, 0). If net benefit is negative no action would be taken and 
intrinsic value would be 0. Net benefit and intrinsic value only equate when net benefit is 
positive. 
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based information. On the exercise date the option to approve is exercised only if 
intrinsic value is positive. If the trial reports improved cost-effectiveness the 
optimal action is to approve (E14,780). Conversely, if the trial reports poor cost- 
effectiveness the optimal action is not to approve (0) (see figure 7.2). Following 
deferral, approval will only be granted if the trial demonstrates positive results. 
Current option value providing the expected value of deferral is given by: 
ov= 0x 1000 2000] (EQN. 7.4) 
(1.06)' 1.06 
0.5[16667-1886.8] 
7390 
The difference between option value and intrinsic value, option premium, gives 
the incremental value of deferral, and places a value on the information revealed 
during the waiting period; 
Option premium = Option value - Intrinsic value 
0 
1000 2000] 
2000 +E 
0-5*1000+0.5*40 i 
I'=, (1.06)' 
1.06 
1=0 (1.06)' 
(EQN. 7.5) 
7390-7187 
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Option premium may be interpreted as the maximum willingness to pay to gain 
information available during deferral. In this case deferral is optimal while the 
cost of observing information remains less than E203. When waiting provides 
perfect infon-nation on all sources of uncertainty relevant to the decision, as in 
this instance, EVPI and option premium both value obtaining perfect 
information. Since the two VOI estimates are based on the same underlying 
principles, intuition suggests they should equate. This example demonstrates a 
situation inwhich a difference exists. Deeper consideration reveals the reasons 
for this difference. 
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EVPI is the value associated with having perfect information available 
instantaneously (at t=O). Option premium differs from EVPI due to timing effects 
introduced into the decision tree by considering deferral. The real options 
framework ensures that option premium accounts for both the way in which, and 
time at which, information becomes available. In addition, the effects of delayed 
receipt of benefits and spending on sunk costs are incorporated. Since the 
negative influence (deferred benefits) dominates, and receipt of perfect 
information is delayed, option premium (; E203) is less than EVPI (E646). Without 
deferral and discounting influences in the calculation of option premium, the two 
estimates of value of infori-nation coincide. (The same is true if EVPI is adjusted 
for delayed arrival of infonnation)40. 
Some authors, outside of the health economics arena, have discussed theoretical 
circumstances and identified examples where option premium is equivalent to 
EVPI. This occurs particularly within 'consumption type options' where a 
consumer has an option to visit a site of outstanding natural beauty. In such 
examples the key sources of uncertainty are usually the individual's own 
preferences and whether the site still exists on the exercise date. For an 
individual with an option to visit a threatened natural park, deferral reveals both 
whether the park still exists, and whether the individual prefers to visit on the day 
of decision making. Information on the two sources of uncertainty is fully 
revealed, leading EVPI and option premium to equate if timing effects are 
accounted for. Smith (Smith et al., 1983) and Greenley (Greenley et al., 1981) 
have independently estimated option value for water quality improvements. 
Within a similar context Conrad (Conrad, 1980) has claimed that quasi-option 
value is equivalent to the expected value of infonnation and that option value 
40 Ile difference between EVPI and OP resulting from timing effects raises questions concerning 
the validity of using EVPI, which assumes infon-nation is instantaneously available, to assess the 
relative benefits of competing research proposals. Evidence from research is often not available 
for some time. When EVPI or EVSI is used as a willingness to pay for information and there are 
competing projects that might provide relevant evidence but at different times, presumably our 
willingness to pay for evidence should be adjusted for the expected timing of information arrival? 
Whilst relevant to the research priorities debate, and raising serious issues concerning the 
methodological interpretation and usefulness of VOI, this is a topic for future study and such 
questions are not the primary concern here. 
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equates to the expected value ofperfect information4l. This is intuitively sound 
in the consumer framework where deferral reveals complete information about 
preferences and future supply. Conclusions with respect to the relation between 
EVPI and option premium hinge on beliefs about sources of uncertainty and 
assumptions regarding resolution of information through time. 
Although EVPI and option premium can coincide this is not necessarily, or even 
usually, the case. The example considered above of NICE approving health 
related technologies defines a special case in which deferral provides perfect 
information about all sources of uncertainty relevant to the decision. The 
following section explores the more general case in which deferral provides only 
partial information, calculating the expected value of improved, rather than 
perfect information. 
7.4 Activel 
.y seekinz and 
independently observing information 
Deferral may reveal information on factors such as disease incidence and 
prevalence, whether competing drugs become available, or on an individual 
basis, disease progression. Cost-effectiveness analyses include variables such as 
efficacy, and trial based cost information for which data might only be obtained 
through positive actions. For instance, NICE may have felt there was insufficient 
information to make an immediate decision and may not have expected a trial to 
report further evidence in the near future. In this case deferral alone may not 
confer sufficient information for a decision to be made. Rather than simply 
deferring to benefit from exogenously available information revealed over time, 
NICE may consider taking positive steps to actively improve information. For 
instance, they may think about commissioning a trial to improve evidence. 
The extent of information revealed over time in practice will depend on the 
nature of uncertainty impacting on the decision and costs associated with 
collecting information. Prices of drugs, interest rates, actions of competitors 
introducing substitute technologies, some costs, and disease progression can be 
41 Chapter 2 examines the difference between these interpretations of option value. 
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reasonably well observed through time as they are revealed independently of any 
actions regarding the decision of interest. Evidence on factors such as 
effectiveness within a given population subset, or side-effects of a novel drug can 
only be discovered through specific, and usually costly, activities that are 
cndogenous to the decision of interest. 
Whilst EVPI refers to complete information on both types of variable, option 
premium is relevant for valuing information on variables that evolve 
stochastically through time. Uncertain variables may be categorised according to 
whether infon-nation must be actively sought, or simply observed. Where at least 
some variables are active, deferral cannot reveal complete information. In these 
cases option premium is necessarily less than EVP142. More accurately option 
premium (OP) becomes a subset of EVP1 (figure 7.3). This distinction creates 
cause to clearly define willingness to pay for information gained from different 
sources: option premium defines a maximum willingness to pay to observe 
exogenous information sources such as literature reviews, meta-analyses, or 
patient observations and tes 03. 
42 This distinction of value of information for different types of variable is similar to calculating 
partial EVPI of variables of interest (see (Fenwick et al., 2000)), although -with option premium 
variables are purposefidly categorised according to whether information on them becomes 
available though time. 
43 When there are no synergies or correlations between active and passive variables, the 
difference EVPI-OP, or active value of information (AVOI), gives a willingness to pay for 
positive actions including commissioning generic research, specific safety and efficacy trials, and 
cost-effectiveness analyses. 
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Figure 7.3. Distinguishing actively sought and exogenously observed 
infonnation 
Similar observations with regard to value of information and option value have 
been made previously outside of the health economics arena. Hanemann 
(Hanemann, 1989) has talked about option premium being "distinct from but 
bounded by value of infon-nation in the overall problem". Fisher and Hanemann 
(Fisher and Hanemann, 1990) consider option value as a conditional value of 
information (conditional on retaining an option to preserve or develop) and view 
expected value of perfect information as an unconditional value of information, 
and Gersbach (Gershbach, 1997) makes the distinction between actively sought 
information and uncertainty that is resolved only by the passage of time, using 
passive versus active terminology. 
For any given decision, if immediate action is optimal option premium will equal 
zero and EVPI will comprise active value of information only; there is no 
incentive to wait. When waiting is preferable, option premium affects our 
attitudes towards data collection and should be explicitly estimated to help 
inform both the initial adoption decision and the complementary decision of 
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whether to gain additional information. The following section derives a model of 
stochastic infonnation arrival. 
7.5 A model of information arrival 
7.5.1 The model 
Uncertainty plays an important role in the decision concerning when, and indeed 
whether, to approve the drug, and whether to commission research that improves 
information. Irreversibility also surrounds the approval decision: approval is a 
costly activity requiring dedicated time, and costs of generating and 
disseminating guidance. Potential political ramifications, especially if the 
approval decision is against popular opinion, or turns out to be poor in the light 
of mounting evidence, provide further sources of irreversibility. The ability to 
defer is inherent in any decision to approve a new or existing technology. The 
presence of these characteristics confirms the appropriateness of modelling the 
opportunity to defer approval as a real option. 
Whilst information on uncertain variables may evolve continuously, such as with 
prices or disease progression, sporadic events may occur that generate one off, 
discrete shocks in the information set. These events result in discontinuous 
changes in expected payoff. Shocks may include interim results of a trial 
becoming available, a patient becoming unfit for surgery, infections following 
surgery, or launch of a novel drug that affects cost-effectiveness of an existing 
compound. Combining a Brownian motion process with a Poisson arrival process 
enables information to evolve in this manner. 
Suppose NICE is considering approval of a new drug used to treat a specific 
disease. Expected benefit evolves continuously due to changing incidence and 
prevalence with drift (x and variance a2. The possibility of a trial reporting means 
there is some probability Xdt each period that V will change as a result of the 
Poisson arrival, causing an increment of dq. Expected benefit from immediate 
treatment (V) follows a combined evolutionary process. 
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dV 
= adt+adz+dq v (EQN. 7.6) 
The mean arrival rate, X, varies between 0, representing no event or trial, and I 
representing a trial reporting each time period. 1/k indicates the mean time 
between arrivals 44 . If a trial is expected once every three years (1/2, = 3) the mean 
arrival rate is 1/3. When an event occurs q changes by some proportion ý45 
(equation 7.7). If ý>O stochastically arriving trial results have a positive 
influence on V, the opposite occurs if ý<O. If ý=O events have no impact and the 
combined process reverts to Brownian motion. Following an event, V resumes 
the Brownian motion evolutionary process, until another occurs. 
dq = 
ýO with probability. (I -A )dt 
ý with probability. Adt 
(EQN. 7.7) 
Given this specification the average rate of change in expected benefit over any 
time period is Increasing either the likelihood or impact of an event alters 
the rate of change in V. Incorporating the Poisson element also has an impact on 
the variance of V. Although variation is mostly due to the continuous evolution, 
when an event occurs, it has a large impact. Dixit and Pindyck (Dixit and 
Pindyck, 1994) show that variance consists of two parts; one resulting from the 
Brownian motion influence when no event occurs, and the other from the 
Poisson influence. 
Variance(V)= a 
2V2 dt +Aý2V2 dt 
When considering this fon-nulation Dixit and Pindyck (Dixit and Pindyck, 1994) 
used a version of Ito's lemma specifically for finding the differential of the 
44 X is assumed fixed reflecting the idea that NICE would have some expectation governing the 
arrival time of information although 2, may be incorporated as a stochastic variable if there is no 
evidence concerning information arrival. 
45 In the following model ý is assumed to be a fixed proportion of expected benefit although in 
reality ý may be a random variable. 
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combined evolutionary process to identify a partial differential equation that 
must be satisfied by the value of the investment opportunity, F(V)46: 
YU2V2 I F"V+(r-i5)VF'(V)-(r+A)F(V)+AF[(I-ý)V] =0 
For action to occur at a finite point in time the growth rate of uncertain benefits 
cc, must be less than the rate r at which they are discounted. The difference r-a is 
given by 5 and represents dividend type payments. F'(V) and F"(V) represent 
the first and second derivatives of F(V) with respect to V. By satisfying the PDE, 
F(V) conforms to the intuitive constraint that the value of the investment 
opportunity must equal the maximum of the continuation (value from deferring) 
or stopping value (value from exercising). The partial differential equation is 
subject to an absorbing barrier, value matching condition and smooth pasting 
condition 47 . Finding F(V) requires solving the PDE subject to the boundary 
conditions. To comply with the absorbing barrier F(V) takes the form 
F(V) =A VIO where 0 is the solution to a non-linear equation: 
2fi(p 
+ (r - (r + A) +A 
(I - ý)16 =0 (EQN. 7.8) 
Numerical methods are required to find P but once achieved, the parameter A can 
be estimated and the immediate action threshold, V*, identified. Option value 
and option premium, both at the critical threshold and the current value of V, can 
also be determined. Vonnegut (Vormegut, 2000) has used similar combined 
evolutionary methods to assess investment in emerging economies. This study 
used Poisson events to reflect structural economic changes, allowing events to 
impact both positively and negatively on expected value. 
46 This is the stochastic equivalent (accounting for the Poisson event) to the deterministic case 
presented in chapter two (equation 2.15) where the value of the investment opportunity is 
maximised over time. 
47 The boundary conditions are the same as those of the stand-alone Brownian motion model 
(equation 2.20). 
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7.5.2 Numerical example 
The key uncertainties within the model are whether and/or when a trial reports 
evidence and the effect this has on cost-effectiveness. Assume that the trial, on 
publication of results, demonstrates a fall in the cost-effectiveness of the 
compound under consideration by NICE, causing a doivnivardjump in payoff. 
The Poisson event then has a negative impact on the evolutionary process 
defining cost-effectiveness. 
dV 
= adt + udz - dq v 
(EQN. 7.9) 
In particular, assume the abrupt Poisson jump causes expected benefit to fall to 
zero, reducing payoff by 100% (ý-- 1). Due to zero being an absorbing state in the 
Brownian motion process expected benefit remains at zer048 . This renders the 
option worthless. In this case 2, defines a maximum ability to defer before the 
option becomes worthless49. In reality the effects from the trial would not be 
known and there would also be uncertainty on prior parameter estimates and 
implications for posterior estimates where Bayesian analysis is used. 
The assumptions serve to simplify the analysis allowing analytic solutions to be 
obtained, and although seemly restrictive, numerous health economic 
applications confann to such a specification. Patients participating in a watchful 
waiting regime usually have some disease whose progression evolves 
continuously. Adverse events may occur that render immediate treatment less 
effective. For instance, the patient may experience some co-morbidity. In the 
extreme a patient may become unfit for surgery, making the value of immediate 
treatment, and thus the option, zero. 
Further examples include a firm with an option to market a drug whose price will 
evolve continuously. The Poisson event 'a competitor releases a dominant drug' 
48 This is would not necessarily be the case for alternative evolutionary processes. 
49This formulation effectively allows an exercise date to be incorporated in to the perpetual 
Brownian motion diffusion process. 
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may make the payoff from marketing the current drug fall to zero. Coma patients 
also conform to this model. The uncertain events that a patient either dies 
naturally or regains consciousness render the option to defer removal of support 
worthless because this is no longer a relevant alternative. 
In the case where ý=I Dixit and Pindyck show that equation 7.8 simplifies to a 
quadratic, from which 0 can be determined; 
fl =-! -(r-g)lu 
2+r- 9)/u 2_ 1]2 +2(r+A)lu 
2 (EQN. 7.10) T 
This differs from models without the combined Poisson element in the addition 
of), which serves as a positive influence on P. V* and A are then given by; 
v*=-p---I fl-i 
V*-I 
V*fl 
and option value can the be obtained from the functional form; 
F(V) =A V6 
(EQN. 7.11) 
(EQN. 7.12) 
(EQN. 7.13) 
Assume that the expected benefit from approval is currently 1.150 and improves 
at a rate of I% per period with associated volatility of 20%. Suppose also that 
one period is equal to one year, and that on average a trial will report after 6 
years (X=O. 167). If these estimates are combined with a discount rate (6%), and 
an investment cost normalised to I for illustrative purposes, option value can be 
estimated. A summary of these base case estimates is given in table 7.1. 
50 Chosen to be 10% larger than the cost of approval for illustrative purposes. 
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Parameter Base case 
parameter value 
V 1.1 
Cc 0.01 
0.2 
I 
I 
r 
r 
0.06 
0.167 
Table 7.1. Base case parameter values for the option to deferral approval in order 
to improve information 
Option premium at the optimal investment threshold V*, at the current level of 
expected benefit, and at the point where traditional techniques advocate approval 
(V=I) can then be obtained to illustrate the value of observed infonnation. 
7.5.3 Results 
Given the base case parameter estimates (table 7.1) the net benefit of immediate 
approval is 0.1 (1.1 -1 = 0.1), while the option to defer approval is worth 0.1668 
(table 7.2). 
Parameter Calculation Base case result 
13 Equation 13 3.628 
A Equation 15 0.118 
Option value F(V) Equation 10 0.1668 
_ Net benefit V-1 0.1 
Option premium F(V)-max[(V-1), Ol 0.0668 
V* Equation 14 1.38 
Table 7.2. Base case solutions for the option to defer approval in order to 
improve infon-nation 
When traditional techniques overlook deferral they suggest approval should be 
granted immediately (NB>O). Real options theory recommends deferral in order 
to gain observable information on evolving expected benefit (OV>NB). This 
ability to wait adds 0.0668, or 67% to the value of the approval opportunity, 
suggesting additional information is worth this amount. Figure 7.4 shows option 
value and net benefit for a range of expected benefits. 
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Figure 7.4. Intrinsic value and option value for a range of net benefits for the 
option to defer approval in order to improve inforination. 
Option value assumes a minimum of zero when net benefit from immediate 
action is very negative. Consequently real options analysis would suggest that 
approval neither be given now nor deferred. Although net benefit does not 
become positive until expected benefit exceeds the investment cost (V=I), option 
value becomes positive at approximately V=0.4. This indicates positive gains 
from additional information. Option value becomes equal to net benefit at the 
real options investment threshold V*=1.38, indicating immediate action should 
be pursued. In this case the gains from deferral and information gathering no 
longer exceed the gains from immediate action. 
From the real options analysis perspective, a new drug or technology is rejected 
outright if expected benefits are less than 0.4. Deferral is recommended once 
expected benefits exceed this level (but remain less than V*), and immediate 
approval is given when expected benefit exceeds 1.38. Within this range of 
expected benefit, deferral is optimal suggesting that observable information is 
valuable. 
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Under traditional techniques a technology is approved when expected benefit 
equates to the irreversible investment cost (V=I). This threshold is appropriate if 
deferral is not feasible. A technology with net benefits just smaller would be 
rejected whilst one with net benefit just greater would be approved; opposing 
decision rules despite the potentially very small actual difference between 
technologies". Real options analysis circumvents the perversely polarised 
treatment of relatively similar projects by placing a high value on observable 
information, and recommends that the adoption decisions for both technologies 
be deferred. Waiting may reveal differences in cost or effect that enable 
technologies to be distinguished methodically on cost-effectiveness grounds. 
The incremental value of deferral (option premium) can also be used to identify 
the decision threshold and estimate a maximum willingness to pay for observable 
information. Option premium is plotted for a range of expected benefits (figure 
7.5). Until option value becomes first becomes positive option premium remains 
at zero. Net benefit here is so poor that even positive additional information is 
unlikely to influence the rejection conclusion. This makes exogenously observed 
inforination effectively worthless and immediate rejection optimal. At V=V* 
option value becomes equal to intrinsic value and option premium is again zero. 
The decision is undertaken immediate precisely because the action is sufficiently 
desirable that additional information holds no further benefits. 
Between the two limits (V=0.4 and V=V*=1.38) option premium assumes 
positive values. In this region observing exogenous information relevant to the 
decision of interest has some benefit, and so waiting becomes optimal. If current 
expected benefit is 1.2, option value is 0.23 and option premium is 0.03. The 
willingness to pay to observe information amounts to 13% (0.03/0.23) of the 
value of the option. While the costs of observing infonnation do not exceed this 
level, observational research including literature reviews and meta-analyses, is 
efficient. 
51 Confidence intervals surrounding the point estimate may well include 0, suggesting no 
significant difference between technologies. 
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Figure 7.5. Option premium for a range of expected benefits for the option to 
defer approval in order to improve information. 
At V=I=l the difference between option value and intrinsic value is greatest and 
so option premium is at a maximum (0.118), observational data is at its most 
valuable and deferral is most strongly supported. This point coincides with the 
decision-making threshold adopted by traditional methodology so that at the 
exact value of expected benefit where standard techniques change from rejection 
to approval, real options analysis most strongly advocates waiting. This 
represents a significant change in decision making. If confidence intervals are 
used to supplement expected values, when expected benefit is I (V=I) a 90% 
confidence interval may well include 0 suggesting no significant positive benefit 
to immediate approval. This knowledge helps support the recommendation of 
deferral. Once V* is reached a confidence interval is less likely to include the 
possibility of no significant difference. 
The shape of the option premium curve emphasises the similarities between 
option premium and EVPL Both represent a maximum value to collecting 
specific types of information. They are based on the same underlying principles 
and when graphed over a range of expected benefits both assume the same shape. 
Consistent with classical value of information, observable information is most 
valuable when the immediate decision is marginal. In both cases information 
becomes less valuable as the difference in payoff between the optimal decision 
and the next best alternative increases. Traditional and real options techniques 
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therefore agree that additional information is most valuable when a close call 
exists between alternatives, although real options analysis then recommends 
deferral, enabling collection and incorporation of additional evidence. 
7.5.4 Sensitivity analysis 
Whilst real options analysis is useful for analysing the approval decision of a 
single technology in isolation, sensitivity analysis helps examine the impact of 
different characteristics belonging to multiple technologies. Option premium is 
responsive to the expected arrival rate of the Poisson event X. If a trial is 
expected to report in 20 years (perhaps referring to a cancer technology currently 
undergoing initial research and development) the rate of arrival is 0.05. An 
increased rate suggests trials are expected to report more frequently (perhaps 
representing technologies undergoing phase one and two testing). Figure 7.6 
plots the effect on option premium of three arrival rates; 0.05,0.1,0.2 equivalent 
to trials reporting every 20,10 and 5 years. 
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Figure 7.6. The effect of different Poisson arrival rates over a range of expected 
benefits. 
Increasing the expected arrival rate of information reduces option premium for 
each level of expected benefit. As infon-nation arrives more frequently 
uncertainty is resolved quicker reducing the benefit to further deferral. With 
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respect to decision making, option premium first becomes positive at a higher 
expected benefit, and returns to zero (identifying V*) at a lower expected benefit 
reducing the range of benefits for which deferral is optimal. 
Comparing two technologies requesting approval with the same underlying 
characteristics but differing in the expected arrival of information, the technology 
with a trial reporting sooner will have a lower V* threshold. If the expected 
benefit of the two technologies starts from the same level and continues to 
increase at the same rate, approval will occur sooner. This generates a preference 
towards technologies with results reporting sooner. The alternative technology 
however, has greater value of observational data suggesting more extensive 
efforts may be pursued to obtain further information. This may encourage efforts 
to speed information arrival such as commissioning reviews, or encouraging 
interim results. 
Uncertainty also enters the model through variance in the continuous element of 
the information evolution function, a. Greater uncertainty is associated with 
larger option premium (figure 7.7) for all values of expected benefit. If changes 
in disease incidence and prevalence or the costs of using a technology cause 
increased uncertainty, the value of observing exogenously available information 
will increase. This reduces the threshold that recommends deferral in preference 
to rejection and increases the immediate approval threshold. Deferral is therefore 
optimal over a greater range of expected benefits. 
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Figure 7.7. The effect of different sigma over a range of expected benefits 
When competing technologies are being assessed, if neither is suitable for 
immediate approval NICE can consider the benefits from gathering additional 
information to help inform a future decision. More importantly, NICE can 
combine analysis on continuous and one off sources of uncertainty and 
information arrival to compare the relative merits of waiting to observe evidence 
on each of the technologies. This may be useful when one technology is 
surrounded by greater uncertainty but additional evidence is expected sooner. 
This example has assumed a single source of first order uncertainty that is 
resolved with the passing of time. It is rare that time alone will provide all the 
information relevant to a decision of interest and often specially commissioned 
trials are necessary. Suppose EVPI for this decision problem was 0.55, half the 
value of expected benefit. For the prior level of expected benefit (V=I. 1) deferral 
was recommended and option premium was 0.067. Willingness to pay for a new 
trial providing further evidence is 0.483 (0.55-0.067) 52 , 12% less than the 
willingness to pay for complete information on all variables. In addition if this 
estimate is used to determine whether a particular research proposal should be 
carried out, the expected timing of information arrival from that proposal should 
be acknowledged. 
52 This assumes there are no interactions between exogenously observed information and actively 
sought information 
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Although option premium and EVPI are based on the same underlying principles 
they refer to opposing types of variable; those revealing information over time 
and those on which evidence must be actively sought. If the value of observing 
information is ignored in this example, EVPI overstates the maximum 
willingness to pay for research activities by 13.9% (0.067/0.483)53. When 
thinking in practice about population EVPI and commissioning of trials to 
improve evidence, 13% represents a large difference in funding. The greater is 
option premium as a proportion of EVP1 the more EVPI potentially 
overestimates the maximum willingness to pay for active research. If EVPI is 
used as a means of allocating budgets without accounting for option premium, a 
misallocation of resources may result, with less money than optimal going 
towards observational efforts. 
7.6 Conclusions 
This chapter has developed the breadth of real options applications in health care 
moving from the individual decision-making perspective concerning patients or 
technologies, towards implications for collecting future evidence and associated 
budgetary implications. This has been achieved by reconsidering value of 
infonnation theory from a real options perspective. The application has lead to 
three important developments; enabled improved modelling of information 
arrival, provided an insight into the implications of the timing of information 
arrival, and demonstrated the benefits of valuing information available 
exogenously to the decision of interest. 
Brownian motion and Poisson arrival processes were combined to create a 
dynamic evolution of information function. Combining the processes improves 
the modelling capabilities of real options. Specifically, Brownian motion, which 
assumes variables evolve continuously in perpetuity allowing options to be 
infinitely deferred, is adjusted to account for sporadic one-off events. This allows 
53 This assumes that EVPI is calculated using perfect information on all variables. In practice 
EVPI has usually been estimated on variables for which information can feasibly be sought. 
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models to account for numerous events including competitor actions, infection 
following surgery, and death. Whilst used here to describe continuous disease 
and discrete exogenous trial influences on expected cost-effectiveness, this 
model is likely to describe many decision-making problems within the field of 
economic evaluation in health care. Some alternative applications have been 
discussed. 
Furthennore, introducing a Poisson event that reduces the value of the option to 
zero at a stochastic time point creates an exercise date by effectively defining a 
maximum deferral period. The option must be exercised prior to this date else it 
becomes worthless. Decay of machinery, competitive forces, and the finite nature 
of life similarly impose flexible timing constraints on actions and their payoffs. 
Adjusting the expected arrival rate of the first event allows the average time 
horizon to be altered to reflect the deadline of the project under analysis. This 
allows a broader range of projects, those with prominent but uncertain exercise 
dates, to be modelled using a continuous diffusion process rather than a 
multinomial approximation. 
This chapter has also sought to contribute to value of information literature in 
health care. In particular the timing of information arrival has been considered. 
EVPI estimates the value of perfect information available instantaneously. When 
comparing potential research projects it is important to acknowledge that 
information received in five or ten years time is not as valuable as information 
received instantaneously. This should be reflected in our willingness to pay for a 
given project. 
In addition, a methodological distinction has been made between option premium 
and the expected value of perfect infonnation. Where perfect information can be 
observed over time, and adjustments are made for timing, the two are equal. In 
the general case where deferral reveals information on a subset of variables 
option premium is less than EVPI. The distinct yet complementary elements of 
EVPI leads to a categorisation of variables as being observational or active in 
nature, depending on how evidence concerning the variable must be sought. 
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Deferral is useful if variables on which information is naturally revealed over 
time are present within a decision problem. 
Variables may at times create conflict in their classification; in particular 
classification may change over time. Cost-effectiveness estimates may be 
improved through initiating a trial or by waiting for existing trials to report. The 
former constitutes positive actions and forms part of active value of information 
while the latter demonstrates information gained from deferral. When NICE 
commission a trial to improve evidence they are taking actions motivated by 
active variables. As the trial begins to report the same uncertainty is revealed by 
observation. Decision makers must decide whether active resolution is necessary; 
this is determined by their assessment of exactly how much, and what quality of 
evidence may be gained by deferral. 
Using a combined infon-nation ftinction absolute and relative option premium 
have been estimated for a hypothetical example. The absolute value gives the 
maximum willingness to pay for observational evidence. This includes allocating 
funds to reviewing existing medical evidence such as literature reviews and 
meta-analyses, and at a patient level, observing progress through means such as 
clinical observation, MRI, CT and biopsy. Option premium relative to EVPI has 
broader, policy level implications. In particular relative option premium should 
be used in conjunction with EVPI to ensure efficient allocation of resources 
dedicated to reducing uncertainties. 
The model used to illustrate these concepts has required some assumptions, 
particularly those facilitating an analytic solution. This limitation is 
acknowledged, and can be overcome with the use of numerical techniques and 
detailed computer programming. Here the emphasis has remained firmly on 
illustrating the principles behind, and implications of, using real options theory to 
value observable information. There are several developments that naturally 
follow from this work. Perhaps the most important is calculating option premium 
in practice. Although fraught with difficulties including estimating volatilities 
through time, once achieved, observational research efforts can be subject to the 
same theoretical economic assessment as positive research efforts. Further work 
164 
may also be carried out on the extent of interaction between observable and 
actively sought information so that infort-nation might be obtained in the most 
efficient manner. 
This chapter has reconsidered value of information literature from a real options 
analysis perspective. Through taking a dynamic view of uncertainty, and 
modelling information evolving during a period of deferral this application has 
highlighted the importance of the timing of information arrival and the 
distinction between observational and active variables. These insights may have 
implications both for the current decision of whether to pursue a given project 
and the complementary decision of whether to collect additional evidence. This 
chapter has therefore shown that real options analysis may have an influence 
beyond current decision making. 
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Chapter 8. Conclusions: real options analysis, a 
useful tool? 
8.1 Introduction 
Real options analysis has become increasing well established since the 
development of financial option pricing in the 1960s, and its application to real 
investment projects beginning in the 1970s. The tool has brought innovative 
ways to evaluate the uncertainty, irreversibility and timing flexibility that 
characterise many decision problems. Developments in financial valuation and 
growing awareness of the limitations of traditional techniques have encouraged 
hypothetical real options applications to become detailed analyses of topical 
decision problems. In addition, greater use of computer programmes to calculate 
option values has made the tool increasingly accessible. To this end authors from 
varied backgrounds have begun using real options theory. 
This thesis has built on hvo stands of growing literature; the broadening real 
options literature, and health economic evaluation methodology. This is achieved 
by establishing a motivation for, and assessing the suitability of, applying 
financial option pricing techniques to the evaluation of health care related 
projects. Several case studies, encompassing a range of decision-making 
scenarios faced by health care professionals have been analysed using real 
options methodology. For each study the theoretical and practical justification for 
employing options analysis has been assessed, and the implications of doing so 
discussed. 
Chapter one identified a set of research aims to provide a logical, coherent 
structure from which to approach the case studies. In the process of exploring the 
research aims this thesis has made three significant contributions to existing 
literature. Firstly, the reasons for proposing the use of real options analysis, and 
the methods for doing so are established. Secondly, the implications with respect 
to decision making are shown. Thirdly, underlying these two contributions, real 
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options theory is used to identify and make explicit, assumptions that are 
currently made implicitly within traditional techniques. Real options analysis 
demonstrates the importance of these assumptions and opens them to critical 
review. Section 2 considers these contributions in greater detail. Section 3 
outlines areas for future research. Concluding thoughts are presented in section 4. 
8.2 Research contributions 
8.2.1 Motivations and methodsfor the application of real options analysis 
Financial options provide an opportunity with no associated obligation to 
perform a prespecified action subject to agreed conditions. The first set of 
research questions explore the extent to which health care decisions fit within 
this framework. The questions emphasise the structure of decision making in real 
and financial environments and assumptions underlying option valuation. The 
review in chapter 2 showed that exercise of a financial option is a choice made 
under conditions of uncertainty, irreversibility, and timing flexibility. Examples 
presented throughout this thesis demonstrate that these characteristics feature in 
many health care decisions. The four studies identified sources of uncertainty, 
types and degrees of irreversibility, and factors enhancing and limiting the ability 
to defer. 
Uncertainty has received considerable attention in economic evaluation 
literature. Discussions encompass estimation, presentation, and methods for 
dealing with uncertainty, as well as allocating resources to resolve uncertainty. 
Irreversibility and the ability to defer have received considerably less attention. 
Real options analysis highlights the characteristics as three equally significant 
interacting forces, encouraging detailed consideration of each. This makes the 
analogy between real and financial options explicit. The fundamental role of 
these characteristics makes them central to many conclusions and implications, 
and it is assumptions with respect to these factors that are sometimes made 
implicitly within existing evaluative frameworks. 
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The case studies also examined and confirmed that the variables required for 
option pricing are present in health care options. Usually variables transfer 
readily between financial and real models. Where differences occur these have 
been dealt with on an individual basis. For instance, chapter four noted the 
existence of observation costs that are assumed non-existent in financial 
modelling, and treated these as implicit dividends. 
Part of the motivation for using real options theory has come from recognised 
limitations in existing methodology. Real options analysis has been used to 
highlight some of these. While problems cannot necessarily be solved, 
recognition and discussion through the application of option pricing techniques is 
an important process towards understanding and addressing these limitations. 
Several areas have been discussed: 
* Now or never decision-making dominating the practice of economic 
evaluation 
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. 
" Lack of clarity over assumptions governing irreversibility. 
" Ad hoc discounting. 
" Ignoring strategic reasons for investment. 
" Inability to value active management. 
Deferral can be addressed by current techniques: the now or never tendency is a 
problem of practice rather than methodology with deferral often receiving 
insufficient attention to assess whether it is appropriate. Real options analysis 
focuses on whether waiting is relevant, and what may be gained during a period 
of waiting, explicitly challenging the now or never tendency. Information on 
disease progression, incidence, prevalence, efficacy and cost-effectiveness, 
prices, and actions of competitors may be revealed over time. Highlighting 
variables that reveal information illustrates potentially unforeseen gains and 
losses exposing important influences on the decision of interest 
54 Except in areas where deferral is the key decision of interest such as watchftil waiting. 
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Within the case studies, different timing horizons and information arrival 
processes have been illustrated. The American formulation of health care options 
was recognised and applied throughout. The binomial was used to provide an 
exact deadline for the option to defer treatment in a discrete framework whilst 
Brownian motion examples modelled infinite time horizons in a continuous 
framework. Taking a restricted version of the combined Brownian motion / 
Poisson model allowed a compromise between the extremes. Covering these 
possibilities gives confidence that real options analysis can be applied to model 
deferral in many health care decision problems. 
Irreversibility has particularly been over looked in economic evaluation. Real 
options analysis raises the issue and presents ways in which to identify and 
integrate it into decision making. Degrees of irreversibility are incorporated 
partly via sunk costs and scrap values but more importantly by the structure of 
the model itself. Developing a simple option generates perfectly irreversible 
decisions. Degrees of reversibility are modelled when compound options, that 
allow choices to reverse decisions or mitigate outcomes, are built in. Chapter six 
emphasised the ability to model irreversibility within a real options framework 
by analysing the option to approve and later retract approval of health 
technologies. 
Within economic evaluation discount rates are applied and justified with appeal 
to NICE guidelines where a difference between rates applied to costs and 
benefits is advocated. The lack of methodological reasoning underpinning either 
the choice of, or distinction between, rates generates an area of debate. Within an 
options problem events are described by their risk neutral, rather than actual 
probability of occurrence, allowing the entire decision problem to be discounted 
by the risk-free rate. This provides an alternative to arbitrary section of rates. 
Discounted cash flow techniques have been criticised for failing to recognise 
strategic reasons for investment by rejecting projects whose net present value 
falls below zero. Strategic value includes benefit derived from creating future 
choices, such as development of novel compounds by pharmaceutical companies 
that create opportunities to market and later expand production. Research and 
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development efforts are pursued predominantly for strategic reasons. Applying 
real options analysis to decision making in health care requires a dynamic 
specification for uncertainty. This raises the possibility that although not 
immediately attractive, projects may be sufficiently profitable at a later date, and 
allows strategic value to be recognised through deferral rather than rejection of 
projects that initially seem unattractive. This idea has been embraced throughout 
this thesis by use of the trichotomous decision rule in each case study. 
Real options analysis offers improved assessment of the value of active 
management. Decision trees enable some reaction to anticipated events yet a full 
description of actions covering the entire length of a project generates a complex 
tree whose analysis borders on impossible. Unanticipated events that affect 
project value, by their very nature, cannot be incorporated. Real options analysis 
provides a flexible approach to uncertainty. Decisions and events are combined 
in a similar manner but dynamic uncertainty is incorporated that allows expected 
benefit to diverge from its predicted path. This formulation permits influences 
from both anticipated and unanticipated sources of uncertainty and reactions to 
these from management. 
Within each case study multiple sources of dynamic uncertainty and structures 
for the resolution of information over time were combined to influence option 
payoffs. A discrete trinomial lattice allowing well-being to improve, deteriorate, 
or remain unchanged was illustrated for the option to postpone treatment. 
Continuous Brownian motion models were presented to assess the options to 
remove life support and approve new technologies, and a combined Brownian 
motion / Poisson jump structure was used to assess value of infonnation in a 
health economics framework. The breadth of applications considered, joined 
with the coverage of uncertainty formulations demonstrates the versatility of real 
options concepts. 
Real options analysis addresses some of these limitations by combining the rule 
of maximising immediate payoff with particular explicit attitudes and 
assumptions towards dealing with uncertainty, irreversibility and the ability to 
defer. 
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The methods for applying option techniques have been presented in some detail 
within the case studies and have shown how specific ideas about these factors 
can be integrated into analysis of health care related options. Decisions normally 
undertaken on a now/never basis have been challenged and deferral proposed, 
sources of irreversibility highlighted and incorporated, and volatility estimated to 
reflect multiple sources of both static and dynamic uncertainty. 
By identifying weaknesses of existing techniques and addressing these with the 
strengths of option pricing methodology, this thesis has shown how real options 
analysis can create a coherent framework within which to evaluate health care 
decision problems. 
8. Z2 Implications of applying real options analysis 
The second set of research questions examines the implications of broadening 
real options applications to health care and includes the extent to which new 
conclusions are offered. The central role of uncertainty, irreversibility and timing 
flexibility means real options analysis contributes most to decision making where 
these characteristics have not previously been fully considered. 
The most prominent difference between results from real options and traditional 
evaluation is the trichotomous decision structure incorporating deferral. The 
ability to defer decisions thus provides great potential for altered decisions. Any 
proposed action can be accepted immediately, rejected immediately, or deferred 
either indefinitely or for a specific period of time. The case study on watchful 
waiting illustrated instances where a patient recommended for immediate 
curative treatment by traditional decision techniques would be placed on a formal 
watchful waiting programme given real options analysis. Likewise, when NICE 
is making approval decisions, options analysis emphasises the possibility of 
delaying approval or recommending temporary approval. 
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The absolute attractiveness of deferral and range of expected benefits for which 
deferral is optimal is influence by uncertainty. The watchful waiting study 
demonstrated the increased range of benefits for which deferral is chosen when 
uncertainty increases and the corresponding decrease in attractiveness of 
immediate action. Low deferral costs, including costs of observing information, 
and greater growth in expected benefits have a similar impact. For any set of 
parameter estimates, option premium is necessarily greatest when net present 
value is zero. Analysing the option to wait for additional information 
demonstrated that the value of infon-nation gained from observational efforts is 
largest, and waiting therefore most valuable, when current decision techniques 
first advocate immediate action. Real options analysis is more likely to provide 
contrasting results and conclusions when uncertainty is high, observation costs 
are low, and the immediate decision is marginal. 
The approach to handling uncertainty makes two further contributions to decision 
analysis; allowing for anticipated and unanticipated uncertain events and 
encouraging dynamic rather than static formulations. Both these influences can 
alter the optimal decision by changing the absolute attractiveness of deferral and 
incremental value relative to immediate action. The latter observation enables 
real options analysis to contribute to value of information literature. Chapter 
seven discussed how deferral reveals exogenously available information and why 
option premium can be interpreted as a partial value of information. In addition 
to having implications for the attractiveness of immediate action, option 
premium was shown to have potential ramifications for the complementary 
decision of whether to collect further information. This in turn can affect the way 
research budgets are allocated. 
The option owned by NICE to approve and later retract approval of a health 
technology illustrated how varying degrees of irreversibility can be incorporated 
into decision making. Modelling an option to reverse decisions at some cost, 
reduced the threshold which triggered technology approval, making immediate 
action more likely, and deferral optimal over a smaller range of benefits. This 
conclusion can have implications for patient prioritisation. Patients with lesser 
irreversibility, perhaps whose potential side effects from surgery are easier or 
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cheaper to correct, may receive treatment sooner. Through effects such as these, 
real options analysis also emphasises that actions to improve flexibility can be as 
important as immediate value maximisation strategies. 
The combined impact of these aspects and most striking result of real options 
analysis is the creation of the threefold decision structure and associated effect on 
the threshold triggering immediate action. These effects potentially lead to 
significant differences between recommendations made by tradition forms of 
analysis and those provided under real options analysis. 
8. Z3 Highlighting assumptions made implicitly within e-risting evaluation 
techniques 
The previous two sections have shown how uncertainty, irreversibility and an 
ability to defer can have a significant impact on how a decision problem is 
modelled and the results of an analysis, leading to implications for decision 
making. When assumptions with respect to these factors are made implicitly, 
inaccurate modelling and biased conclusions can result. Moreover, assumptions 
should be open to critical review and debate, something that is not possible when 
they are made implicitly with little thought or attention given to their significance 
for decision making. 
Few economic evaluations explicitly recognise and discuss the extent to which 
any decision is already reversible, or could be made reversible by future 
coordinated activities. Employing real options analysis to promote explicit 
discussion is an important step towards clarifying the role of irreversibility. 
Value of infon-nation used to set future research priorities suggests information 
gained will be incorporated into the decision strategy at a later date. Aspects of 
irreversibility may prevent this altogether or, more likely, generate costs of doing 
so. Upfront, explicit discussion of irreversibility can help recognition of such 
issues before an initial decision is made. Previous sections have shown this can 
have serious implications for if, and when, actions are pursued. 
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In contrast much focus has been placed on uncertainty. In particular distinctions 
have been made between first order and second order uncertainty. Although 
probability distributions arc used to describe second order uncertainty these 
distributions, which usually consist of current mean and variance estimates, are 
static. Real options analysis has promoted a dynamic view of uncertainty by 
asking how event probabilities change through time, making evident the static 
assumption of tradition analyses. This has implications for immediate decision 
making as well as value of infon-nation and future decision making. 
The ability to defer is generally only examined if deferral is the key decision of 
interest, otherwise an implicit assumption is made either that waiting is not 
possible or that this alternative holds no benefit (or cost). Again there are 
potential implications for decision making. 
Using real options analysis to assess decision problems in which these factors are 
present has highlighted areas where assumptions are made implicitly within 
existing techniques and encouraged explicit critical discussion of these factors. 
Only through fon-nally identifying such assumptions and considering them 
openly can their applicability and relevance to a decision problem be assessed. 
More importantly where explicit consideration concludes that an assumption is 
inappropriate, discussion can be initiated to adjust for this. Real options analysis 
has been used here to challenge existing assumptions particularly those 
concerning uncertainty, irreversibility and the ability to defer, and in some cases 
propose alternatives. 
8.3 Further work 
Whilst much has been achieved within this thesis, the application of an existing 
technique to a new area inevitably creates extensive areas for future research. 
These include examining a broader range of health related projects developing 
valuation methods to account for the increasingly diverse characteristics of these 
projects. Primarily due to data collection issues and timing constraints, analysis 
here has been theoretical in nature. A key development is, therefore, analysis of 
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an empirical decision problem. The decision of interest would need to be 
confirmed as an options problem and well specified with ample data to support 
the application. Variables relevant to real options analysis would have to be 
identified perhaps using formats suggested within this thesis. Once appropriate 
models are identified they could be populated using information available from 
published literature or observed sources such as population incidence and 
prevalence or disease progression. 
Creating an empirical example poses many problems for analysts. Lander 1998 
(Lander and Pinches, 1998) details some of the issues faced when using real 
options analysis in practice. Chapter 4 examined an option to defer therapeutic 
treatment and found that many factors influence well-being including disease 
progression, ability to cope with effects of disease, confounding factors and 
subjective quality of life. Each factor must be observed through time at regular 
intervals to provide data to estimate a volatility parameter. This may imply 
changes in the current practice of data collection. Data is usually collected at 
strategic time points, perhaps I week, I month and 3 months following start of 
the trial. For drift and variance parameters to have a meaningful role within the 
model periods must be of equal length implying observations on a weekly or 
monthly basis for the duration of observation. Alternative specifications for the 
resolution of information may not have such extensive requirements. 
When there are multiple sources of uncertainty Monte Carlo simulation can be 
used to combine these sources into a single monetary value required for input 
into the real options model. This requires estimating those sources of uncertainty 
that will dominate, driving the evolution of uncertainty and resolution of 
information through time. Observations can be used as a basis to estimate and 
extrapolate expected growth in net benefit due to immediate and deferred action, 
and generate estimates of volatility through time. 
Such an example would demonstrate both the positive aspects and problems 
encountered when applying real options analysis in practice. In particular if 
immediate and deferred action were compared, the potential impact on decision 
making could be irrevocably displayed. 
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Further research includes extending the breadth of applications within health 
care. This thesis has detailed four applications yet a far wider area might benefit 
from real options thinking. Chapter four examined a decision problem in which 
deferral is already considered relevant. Similar deferral analysis might be applied 
to assess different timings between preventative screening sessions for patients 
with contrasting risk factors. For example real options analysis might be used to 
analyse whether women who become sexually active at a younger age, or who 
have had numerous partners should be encouraged receive cervical smear tests 
on a more frequent basis. 
Chapter 5 discussed the option to defer removal of life support efforts 
emphasising the role of irreversibility. Options analysis may be particularly 
relevant for assessing the merits of genetic screening (and disclosing genetic 
information) where there is perfect irreversibility of information disclosure. All 
surgery potentially involves irreversibility; transplant and amputation present 
poignant examples. Where one treatment precludes the use of another, such as 
drugs that should not be used in conjunction, irreversibility is present and a real 
options approach can be considered. 
The option to approve and later retract approval of a technology for use within 
the NHS (the subject of chapter 6) assumed a policy level perspective. In other 
domains options analysis has been used to retrospectively assess the success of 
policy decisions such as the impact of subsidies. In a similar way payment 
mechanisms for GP's or incentive compatible reimbursement might be 
considered. 
In addition to broadening applications within health care, as the theory of real 
options develops and use becomes more widespread there will need to be 
empirical tests assessing option valuation. For instance, once created, evolution 
of information functions will need to be verified perhaps using regression 
analysis. Chapter 7, for instance, thought about the use of a combined Brownian 
motion and Poisson evolutionary process. The ability of this function to describe 
the events of interest would need to be assessed. In addition, the way in which 
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new information is incorporated in to decision models should be explored. In 
particular the use of Bayesian analysis that assesses the relative importance of 
prior and newly available information and combines them to generate posterior 
estimates should be investigated as a tool to enhance real options analysis. 
Future research also includes ways to make real options techniques more 
accessible. Traditionally options analysis has involved cumbersome dynamic 
equations or mathematically challenging finite difference methods. 
Improvements in computing techniques are making this easier but can lead to 
confusion and the creation of a black box of understanding around the methods. 
Wider use of spreadsheets and Monte Carlo simulation techniques to model and 
combine uncertainties improves the openness of real options analysis in a way 
that is increasingly acceptable to health services researchers. Improved 
accessibility will also prove important for dissemination; an issue that must be 
confronted if real options techniques are to be incorporated into decision making 
as standard practice. 
8.4 Concludim- thotte-hts 
This thesis has applied real options analysis to decision making within health 
care. Case studies on options to defer therapeutic treatment, defer removal of life 
support, approve new and existing health technologies, and gather information 
have been considered. Comparing the structure of decision making between 
financial options and the health care examples provided theoretical justification 
for the application of real options analysis. Within the studies this thesis has 
established that options are valuable and should be included in decision analytic 
modelling when uncertainty, irreversibility and an ability to defer characterise 
the decision. 
A variety of types and combinations of options and their potential contributions 
to decision making have been considered. This includes both call and put 
options, which are the core building blocks of financial decision making; all 
portfolios of financial options consist of some combination of these two blocks. 
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The real equivalents; investment and abandonment opportunities, are the building 
blocks of real options analysis. Within the first two case studies these types of 
option were considered in turn, and their applicability within health care 
examined. The third case study combined the blocks to build a portfolio. From 
this basis theoretically any portfolio of investment and disinvestments decisions 
within the health care context, that are characterised by uncertainty, 
irreversibility and an ability to defer, can be examined. The final case study 
demonstrated that real options theories maybe used to analyse and reinterpret 
important issues within the domain of health economics. The foundations for 
wider application of financial option pricing techniques within health care have 
been established. 
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Appendix: trinomial option pricing program 
This program is written in Fortran. 
c 
c Trinomial Tree 
c 
2 
c 
c 
IMPLICIT REAL*8 (A-H, O-Z) 
DIMENSION OVALUE(2000) 
LOGICAL CALLFLAG, american 
CHARACTER*16 NAME 
T=1.5 
N= 18 
R=0.06 
B=0.06 
S= 20000 
X= 24020 
V=0.2 
F= 261 
Callflag = true. 
American = true. 
c 
c 
C 
c 
c 
Z= -1 
If(callflag) z=I 
DT = T/N 
U= exp(v*dsqrt(2*dt)) 
D= exp(-v*dsqrt(2*dt)) 
UX = exp(v*dsqrt(dt/2)) 
DX = exp(-v*dsqrt(dt/2)) 
AX = exp(b*dt/2) 
PU = ((ax-dx)/(ux-dx))**2 
PD = ((ux-ax)/(ux-dx))**2 
PM =1- PU - PD 
Df = exp(-r*dt) 
P= PM+PU+PD 
Do 3 ITER = 1,31 
S= ITER*1000+14000 
Do 10 i=0,2*n 
ovalue(i) 0 
mn = n*2 n-i 
if(mn. 1t. 0) mn =0 
in =i-n 
if(in. 1t. 0) in =0 
ovalue(i) = z*((s-f)*u**in*d**mn-x) 
if(ovalue(i). lt. 0) ovalue(i) =0 
10 continue 
C Line 50 
C 
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Do 20 j= n-1,0, -l 
Do 30 i=O, j*2 
If(american) goto 25 
c 
c European 
c 
ovalue(i) = (pu*ovalue(i+2)+pm*ovalue(i+l) 
+pd*ovalue(i))*df 
goto 30 
C 
C American 
C 
25 mn = j*2 -j-i 
if(mn. 1t. 0) mn =0 
in =i-j 
if(in. 1t. 0) in =0 
ttl = z*((s-f)*u**in*d**mn-x) 
tt2 = (pu*ovalue(i+2)+pm*ovalue(i+l) 
+pd*ovalue(i))*df 
ovalue(i) = ttl 
if(tt2. gt. ttl) ovalue(i) = tt2 
30 continue 
20 continue 
C 
Write(6, *) IS=', S 
Write(6, *) 'option value=', ovalue(O) 
If(iter. gt. 1) goto 3 
Write(6, *) IT=', T 
Write(6, *) IN=', N 
Write(6, *) 'R=I, R 
Write(6, *) 'B=', B 
Write(6, *) IX=I, X 
Write(6, *) IV=,, V 
Write(6, *) IU=I, U 
Write(6, *) ID=I, D 
Write(6, *) IPU=I, PU 
Write(6, *) IPD=I, PD 
Write(6, *) IPM=I, Pm 
Write(6, *) IP=I, P 
Write(6, *) IF=', F 
Write(6, *) I --------- 
C 
3 continue 
Stop 
End 
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